

# Prof. MUHİT ÖZCAN

## Personal Information

Web: <https://avesis.ankara.edu.tr/ozcan>

## International Researcher IDs

ORCID: 0000-0002-1326-1918

Publons / Web Of Science ResearcherID: AAG-2251-2021

ScopusID: 57199400915

Yoksis Researcher ID: 105207

## Education Information

Post Doctorate of Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1994 - 1996

Expertise In Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1987 - 1992

Undergraduate, Ankara University, Tıp Fakültesi, Tıp Pr., Turkey 1979 - 1985

## Foreign Languages

English, C1 Advanced

## Research Areas

Hematology

## Academic Titles / Tasks

Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2003 - Continues

Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2003 - 2014

Associate Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1996 - 2003

Assistant Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1996 - 1996

Expert, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1994 - 1996

Expert, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1987 - 1992

## Academic and Administrative Experience

Ankara University, 2004 - 2007

## Advising Theses

ÖZCAN M., Otolog Kök Hücre Mobilizasyonu Yapılan Hastalarda Pleriksafor Kullanımının Hemostatik Sistem Üzerine Etkilerinin Araştırılması, Expertise In Medicine, Ö.KOÇ(Student), 2021

ÖZCAN M., Hematolojik kanserler nedeniyle kemoterapi alan hastalarda egzersizin yaşam kalitesi, tedavi süreci ve

laboratuvar bulgularına etkilerinin değerlendirildiği prospektif bir araştırma, Expertise In Medicine, E.İSMET(Student), 2014

ÖZCAN M., Multiple miyelom hastalarında mikropartikül prokoagulan aktivitenin (MP:PKA) tedavilerle ve trombotik komplikasyonlar ile ilişkisi, Postgraduate, S.GUNALTAY(Student), 2008

ÖZCAN M., Allojeneik hematopoetik kök hücre nakli sonrası görülen mukozitle HLA tipleri ilişkisi, Expertise In Medicine, G.KABAÇAM(Student), 2006

ÖZCAN M., Allojeneik kök hücre nakli yapılan akut myeloblastik ve kronik myelsiter lösemi hastalarında haftalık ADAMTS13 enzim tayini ve komplikasyonlarla ilişkisi, Expertise In Medicine, S.CİVRİZ(Student), 2005

ÖZCAN M., Kronik lenfositler lösemi olgularında ZAP-70 ekspresyonunun akım sitometrik analizi, Expertise In Medicine, S.KOÇAK(Student), 2005

ÖZCAN M., Aktive protein C rezistansının ABO kan gruplarıyla ilişkisi, Postgraduate, A.DİLARA(Student), 2002

ÖZCAN M., Hematopoetik kök hücre transplantasyonu sonrası dolaşkan solubl adezyon molekülleri ve sitokinler, Expertise In Medicine, H.ÇELEBİ(Student), 2000

ÖZCAN M., Granülosit koloni uyaran faktör kullanımının allojenik kök hücre vericilerinde doku faktörü ekspresyonu ve hemostaz üzerine etkileri, Expertise In Medicine, P.TOPÇUOĞLU(Student), 2000

ÖZCAN M., Akut lösemide doku faktörü: Plazma aktivitesinin ve akım sitometrisi ile yüzey ekspresyonunun incelenmesi, Expertise In Medicine, S.GÖKREM(Student), 1999

ÖZCAN M., Orak hücreli anemisi olan hastaların plazmalarında doku faktörü (TF) aktivitesi, Postgraduate, A.BENGÜ(Student), 1999

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The effects of substituting cladribine for fludarabine on outcomes of a reduced intensity conditioning regimen**  
Sahin U., Uurlu S. M., Gokmen A., Arslan O., Ozcan M.  
JOURNAL OF CLINICAL ONCOLOGY, no.16, 2024 (SCI-Expanded)
- II. **BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).**  
Ozcan M., Lavie D., Chaudhry A., Zhou X., Paydar I., Farooqui M. Z. H., Ghia P.  
JOURNAL OF CLINICAL ONCOLOGY, no.16, 2024 (SCI-Expanded)
- III. **Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study**  
Pabst T., Papayannidis C., DEMİRKAN F., Doronin V., Fogliatto L. M., Guttke C., Gyan E., Hamad N., Herrera P., Hultberg A., et al.  
The Lancet Haematology, vol.10, no.11, 2023 (SCI-Expanded)
- IV. **Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data**  
Ateoglu E. B., Gulbas Z., Uzay A., ÖZCAN M., ÖZKALEMKAŞ F., Dal M. S., Kalyon H., Akay O. M., Devenci B., Bekoz H., et al.  
HEMATOLOGICAL ONCOLOGY, vol.41, no.4, pp.663-673, 2023 (SCI-Expanded)
- V. **Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study**  
Zinzani P. L., Mayer J., Benjamini O., Berkovits A., Glimelius I., Stevens D., Chaudhry A., DEMİR A. M., Garcia Sanz R., Kim W. S., et al.  
AMERICAN JOURNAL OF HEMATOLOGY, 2023 (SCI-Expanded)
- VI. **Dose-Escalation, Dose-Confirmation, and CohortExpansion Study of Nemtabrutinib in Patients With Hematologic Malignancies: Multicohort, Open label, Phase 2BELLWAVE-003Study**  
Jurczak W., Perini G. F., Owen C., ÖZCAN M., Gonzalez Barca E., Wrobel T., Lavie D., Chaudhry A., Ghia P., Xu Yan X. Y., et al.  
AMERICAN JOURNAL OF HEMATOLOGY, 2023 (SCI-Expanded)

- VII. **Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.**  
Ozcan M., Lee S. T., Mensah F., Modi D., Fossa A., Kim W. S., Paszkiewicz-Kozik E., Sawalha Y., Sevindik O. G., Norasetthada L., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- VIII. **Association of FLT3 and NPM1 mutations in patients with acute myeloid leukemia with metabolomic patterns determined by mass spectrometry**  
Toprak S. K., Yesilyurt S. G., Koyun D., Ozcan M., Ozen C.  
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- IX. **KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.**  
Lavie D., Timmerman J., Sanz R. G., Kim W. S., Kim T. M., Avigdor A., Dierickx D., Jagadeesh D., Molin D., Ozcan M., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- X. **waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.**  
Zinzani P. L., Mayer J., Benjamini O., Berkovits A., Glimelius I., Stevens D. A., Chaudhry A., Demir A. M., Sanz R. G., Kim W. S., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- XI. **BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.**  
Perini G. F., Owen C., Ozcan M., Jurczak W., Barca E. G., Wrobel T., Lavie D., Chaudhry A., Ghia P., Xu Y., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- XII. **Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.**  
McDonald A. B., Verburgh E., Gotti M., Pinto A., Zaucha J., Ivanov V., Melnichenko V., Mocikova H., Ozcan M., Patti C., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- XIII. **waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).**  
Lavie D., Ozcan M., Paszkiewicz-Kozik E., Barca E. G., Kim T. M., Puccini B., Wang S., Yusuf R., Marinello P., Kim W. S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- XIV. **Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center**  
CENGİZ SEVAL G., Civriz Bozdog S., TOPRAK S. K., Kurt Yuksel M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., Gurman G., BEKSAÇ M., İlhan O., et al.  
Balkan medical journal, vol.40, no.3, pp.197-204, 2023 (SCI-Expanded)
- XV. **Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.**  
Zinzani P. L., Thieblemont C., Melnichenko V., Bouabdallah K., Walewski J., Majlis A., Fogliatto L. M., Martin Garcia-Sancho A., Christian B., Gulbas Z., et al.  
Blood, 2023 (SCI-Expanded)
- XVI. **Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma**  
Nastoupil L. J., Hess G., Pavlovsky M. A., Danielewicz I., Freeman J., García-Sancho A. M., Glazunova V., Grigg A., Hou J., Janssens A., et al.  
Blood Advances, vol.7, no.22, pp.7141-7150, 2023 (SCI-Expanded)
- XVII. **Picturing asthma in Turkey: results from the Turkish adult asthma registry**  
ÇELİK G. E., AYDIN Ö., GÖKMEN D., Buhari G. K., Sozener Z., GEMİCİOĞLU B., Bulut I., Beyaz S., Orcen C., Ozdemir S. K., et al.

JOURNAL OF ASTHMA, vol.60, no.11, pp.1973-1986, 2023 (SCI-Expanded)

- XVIII. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data**  
Kircali E., Cengiz Seval G., Öztürk C., Yılmaz H., Koyun D., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Arslan Ö., Özcan M., et al.  
BALKAN MEDICAL JOURNAL, vol.40, no.1, pp.51-56, 2023 (SCI-Expanded)
- XIX. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas**  
Sahin U., Gokmen A., Soydan E., Urlu S. M., Merter M., Gokgoz Z., ARSLAN Ö., ÖZCAN M.  
Clinical Lymphoma, Myeloma and Leukemia, vol.23, 2023 (SCI-Expanded)
- XX. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients**  
Gokmen A., Sahin U., Soydan E., Gokgoz Z., Okcu M. K., Ozan U., ARSLAN Ö., İLHAN O., ÖZCAN M.  
Clinical Lymphoma, Myeloma and Leukemia, vol.22, no.10, 2022 (SCI-Expanded)
- XXI. Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia**  
Ozdemir Z. N., Kircali E., Şahin U., Seval G., Bozdağ S. C., Toprak S. K., Yuksel M., Topcuoglu P., Arslan Ö., Demirer T., et al.  
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.22, no.8, pp.596-600, 2022 (SCI-Expanded)
- XXII. Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease**  
KOYUN D., CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., DEMİRER T., İLHAN O., et al.  
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.38, no.3, pp.601-605, 2022 (SCI-Expanded)
- XXIII. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.**  
Wang M. L., Jurczak W., Jerkeman M., Trotman J., Zinzani P. L., Belada D., Boccomini C., Flinn I. W., Giri P., Goy A., et al.  
The New England journal of medicine, vol.386, pp.2482-2494, 2022 (SCI-Expanded)
- XXIV. The efficacy and safety of second allogeneic hematopoietic stem cell transplantation.**  
Toprak S. K., Korcalo E., Seval G. C., Bozdağ S. C., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Gurman G., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- XXV. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome**  
CENGİZ SEVAL G., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAY B. N., Sanlı H. E., GÜRMAN G., TOPRAK S. K., ÖZCAN M.  
Dermatologic Therapy, vol.35, no.5, 2022 (SCI-Expanded)
- XXVI. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine**  
Pratz K. W., Jonas B. A., Pullarkat V., Recher C., Schuh A. C., Thirman M. J., Garcia J. S., DiNardo C. D., Vorobyev V., Fracchiolla N. S., et al.  
Journal of Clinical Oncology, vol.40, no.8, pp.855-865, 2022 (SCI-Expanded)
- XXVII. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma**  
Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., de Oliveira J. S., Buccheri V., Perini G. F., Dickinson M., et al.  
Blood Advances, vol.6, no.2, pp.590-599, 2022 (SCI-Expanded)
- XXVIII. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data**  
Sehn L. H., Hertzberg M., Opat S., Herrera A. F., Assouline S., Flowers C. R., Kim T. M., McMillan A., ÖZCAN M., Safar V., et al.

- Blood Advances, vol.6, no.2, pp.533-543, 2022 (SCI-Expanded)
- XXIX. **Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies**  
Civriz Bozdağ S., Cengiz Seval G., Yönel Hindilerden İ., Hindilerden F., Andıç N., Baydar M., Aydın Kaynar L., Toprak S. K., Göksoy H. S., Balık Aydın B., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.39, no.1, pp.43-54, 2022 (SCI-Expanded)
- XXX. **Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study Küçük B-Hücreli Lenfomalarda Ek İmmünohistokimyasal Belirteçlerin Ayırıcı Tanıdaki Yeri: Bir Olgu-Kontrol Çalışması**  
Kıvrak H., Yüksel S., Ateş C., Merter M., Kaygusuz G., Özcan M., Kuzu I.  
Turkish Journal of Hematology, vol.39, no.3, pp.178-187, 2022 (SCI-Expanded)
- XXXI. **The Effects of Exercise Prescription on Aerobic Performance and Quality of Life During the Course of Lymphoma Chemotherapy: Results of a Prospective Controlled Study**  
Sahin U., Dundar I., ÇELEBİ M. M., Merter M., Oktay E. I., ZERGEROĞLU A. M., ÖZCAN M.  
Clinical Lymphoma, Myeloma and Leukemia, vol.22, 2022 (SCI-Expanded)
- XXXII. **The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma**  
Ilhan O., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., Arslan O., Özcan M., Demirer T., Gurman G., et al.  
BLOOD, vol.138, 2021 (SCI-Expanded)
- XXXIII. **Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)**  
Zinzani P. L. L., Thieblemont C., Melnichenko V., Bouabdallah K., Waleswski J., Majlis A., Fogliatto L., Martin Garcia-Sancho A., Christian B., Gulbas Z., et al.  
BLOOD, vol.138, no.Supplement 1, pp.306, 2021 (SCI-Expanded)
- XXXIV. **Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab**  
Matasar M. J., Capra M., Özcan M., Lv F., Li W., Yañez E., Sapunarova K., Lin T., Jin J., Jurczak W., et al.  
BLOOD, vol.138, no.Supplement 1, pp.3538, 2021 (SCI-Expanded)
- XXXV. **The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study**  
Özcan M., Cassaday R. D., Singh P., Zarzycka E., Zhang X., Nègre E., Vandendries E., Altuntas F.  
BLOOD, vol.138, no.Supplement 1, pp.1208-1210, 2021 (SCI-Expanded)
- XXXVI. **CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).**  
Matasar M. J., Capra M., ÖZCAN M., Lv F., Li W., Yanez E., Sapunarova K., Lin T., Jin J., Jurczak W., et al.  
CANCER RESEARCH, vol.81, no.13, 2021 (SCI-Expanded)
- XXXVII. **Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial**  
Matasar M. J., Capra M., ÖZCAN M., Lv F., Li W., Yanez E., Sapunarova K., Lin T., Jin J., Jurczak W., et al.  
LANCET ONCOLOGY, vol.22, no.5, pp.678-689, 2021 (SCI-Expanded)
- XXXVIII. **Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.**  
Pratz K., Jonas B. A., Pullarkat V., Recher C., Schuh A. C., Thirman M. J., Garcia J. S., Dinardo C. D., Vorobyev V., Fracchiolla N., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15\_suppl, pp.7018, 2021 (SCI-Expanded)
- XXXIX. **ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma**  
Nowakowski G. S., Chiappella A., Gascoyne R. D., Scott D. W., Zhang Q., Jurczak W., ÖZCAN M., Hong X., Zhu J., Jin J., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.12, pp.1317-1340, 2021 (SCI-Expanded)

- XL. **Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study**  
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson N. A., Fogliatto L. M., Goncalves I, de Oliveira J. S. R., Buccheri V., et al.  
The Lancet Oncology, vol.22, no.4, pp.512-524, 2021 (SCI-Expanded)
- XLl. **Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis**  
Akbulut D., Yüksel S., Kircali E., Aktaş B. Y., Kaygusuz G., Saglam A., Soylemezoglu F., Üner A., Özcan M., Turker A., et al.  
MODERN PATHOLOGY, vol.34, no.SUPPL 2, pp.796-797, 2021 (SCI-Expanded)
- XLII. **Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis**  
Akbulut D., YÜKSEL S., Kircali E., AKTAŞ B. Y., KAYGUSUZ G., Saglam A., Soylemezoglu F., ÜNER A., ÖZCAN M., Turker A., et al.  
LABORATORY INVESTIGATION, vol.101, no.SUPPL 1, pp.796-797, 2021 (SCI-Expanded)
- XLIII. **Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma**  
Panayiotidis P., Follows G. A., Mollica L., Nagler A., ÖZCAN M., Santoro A., Stevens D., Trevarthen D., Hiemeyer F., Garcia-Vargas J., et al.  
Blood Advances, vol.5, no.3, pp.823-828, 2021 (SCI-Expanded)
- XLIV. **Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors**  
Ozdemir Z. N., Sahin U., DALVA K., BALTACI M. A., Uslu A., Ozturk C., CENGİZ SEVAL G., TOPRAK S. K., Yuksel M., TOPÇUOĞLU P., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.2, pp.111-118, 2021 (SCI-Expanded)
- XLV. **Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation**  
Hodkinson B. P., Schaffer M., Brody J. D., Jurczak W., Carpio C., Ben-Yehuda D., Avivi I., Forslund A., ÖZCAN M., Alvarez J., et al.  
TRANSLATIONAL ONCOLOGY, vol.14, no.1, 2021 (SCI-Expanded)
- XLVI. **Melphalan pharmacokinetics and transplant related toxicity during autologous stem cell transplantation**  
Sahin U., Soydan E., Gokmen A., ÖZCAN M., ARSLAN Ö.  
BONE MARROW TRANSPLANTATION, vol.56, no.1, pp.7-8, 2021 (SCI-Expanded)
- XLVII. **Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy**  
Ozdemir Z. N., CENGİZ SEVAL G., Sahin U., Uslu A., Gunduz M., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., TOPÇUOĞLU P., KUZU I., et al.  
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.37, no.1, pp.67-75, 2021 (SCI-Expanded)
- XLVIII. **REPLY FROM THE AUTHORS**  
Bozdog S. C., Seval G. C., Hindilerden I. Y., Hindilerden F., Andic N., Baydar M., Kaynar L. A., Toprak S. K., Goksoy H. S., Aydin B. B., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.4, pp.332, 2021 (SCI-Expanded)
- XLIX. **Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag**  
Kircali E., CENGİZ SEVAL G., KOYUN D., Ozturk C., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.410-411, 2020 (SCI-Expanded)
- L. **The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation**

CENGİZ SEVAL G., Kircali E., BALTACI M. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.204, 2020 (SCI-Expanded)

- LI. **Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?**  
CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.  
BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.305-306, 2020 (SCI-Expanded)
- LII. **Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)**  
CENGİZ SEVAL G., Ulas E. B., TOPRAK S. K., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.192-193, 2020 (SCI-Expanded)
- LIII. **Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience**  
Bekoz H., Ozbalak M., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F., Altuntas F., Cakar M. K., Sonmez M., et al.  
Annals of Hematology, vol.99, no.11, pp.2565-2576, 2020 (SCI-Expanded)
- LIV. **Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent**  
Kircali E., Cengiz G., Çolak S., Gunduz M., Ataca Atilla P., Atilla E., Özen M., Özcan M., Beksac M.  
BLOOD, vol.136, no.Supplement 1, pp.13-14, 2020 (SCI-Expanded)
- LV. **Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study**  
Zinzani P. L., Melnichenko V., Bouabdallah K., Walewski J., Majlis A., Fogliatto L., Caballero D., Christian B. A., Gulbas Z., Özcan M., et al.  
BLOOD, vol.136, no.Supplement 1, pp.42-43, 2020 (SCI-Expanded)
- LVI. **Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension**  
Sehn L. H., Hertzberg M., Opat S., Herrera A. F., Assouline S. E., Flowers C., Kim T. M., Mcmillan A., Özcan M., Safar V., et al.  
BLOOD, vol.136, no.Supplement 1, pp.17-19, 2020 (SCI-Expanded)
- LVII. **Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation**  
Atilla P. A., AKKUŞ E., Atilla E., Gökmen İnan N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPRAK S. K., Baskal N., Akan H., DEMİRER T., et al.  
CLINICAL TRANSPLANTATION, vol.34, no.10, 2020 (SCI-Expanded)
- LVIII. **AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A**  
Dinardo C. D., Jonas B. A., Pullarkat V., Thirman M. J., Garcia J. S., Wei A. H., Döhner H., Fenaux P., Recher C., Konopleva M., et al.  
CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA, vol.20, pp.179, 2020 (SCI-Expanded)
- LIX. **A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A**  
DiNardo C. D., Jonas B. A., Pullarkat V., Thirman M. J., Garcia J. S., Wei A. H., Doehner H., Fenaux P., Recher C., Konopleva M., et al.  
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.20, 2020 (SCI-Expanded)
- LX. **A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-**

**2a in patients with myeloproliferative neoplasm.**

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kircali E., Ozturk C., Civriz Bozdag S., Toprak S. K., Topcuoglu P., Arslan O., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15\_suppl, pp.19536, 2020 (SCI-Expanded)

- LXI. **Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.**  
Demirer T., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., Gurman G., Ilhan O., Beksac M., Özcan M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15\_suppl, pp.19522, 2020 (SCI-Expanded)
- LXII. **Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.**  
Toprak S. K., Cengiz Seval G., Atilla E., Civriz Bozdag S., Kurt Yuksel M., Topcuoglu P., Akay B. N., Sanli H., Gurman G., Ozcan M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15\_suppl, pp.20038, 2020 (SCI-Expanded)
- LXIII. **A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma**  
Hajek R., Pour L., ÖZCAN M., Sanchez J. M., Sanz R. G., Anagnostopoulos A., Oriol A., Cascavilla N., Terjung A., Lee Y., et al.  
EUROPEAN JOURNAL OF HAEMATOLOGY, vol.104, no.5, pp.435-442, 2020 (SCI-Expanded)
- LXIV. **Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.**  
Dreyling M., Santoro A., Mollica L., Leppae S., Follows G., Lenz G., Kim W. S., Nagler A., Dimou M., Demeter J., et al.  
American journal of hematology, vol.95, no.4, pp.362-371, 2020 (SCI-Expanded)
- LXV. **Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data**  
Seval G. C., Uslu A., Kircali E., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Dalva K., Arslan O., Ozcan M., et al.  
Transplantation and Cellular Therapy, vol.26, no.3, pp.305-306, 2020 (SCI-Expanded)
- LXVI. **Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**  
Seval G. C., Ozturk N., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Gurman G., Ilhan O., et al.  
Transplantation and Cellular Therapy, vol.26, no.3, pp.109-110, 2020 (SCI-Expanded)
- LXVII. **Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience**  
Ozbalak M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., Yildiz B., Karadurmus N., Kaynar L., Yagci M., et al.  
ANNALS OF HEMATOLOGY, vol.99, no.2, pp.301-307, 2020 (SCI-Expanded)
- LXVIII. **Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma**  
Sehn L. H., Herrera A. F., Flowers C. R., Kamdar M. K., McMillan A., Hertzberg M., Assouline S., Kim T. M., Kim W. S., ÖZCAN M., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.2, pp.155-176, 2020 (SCI-Expanded)
- LXIX. **Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma**  
Armand P., Rodig S., Melnichenko V., Thieblemont C., Bouabdallah K., Tumyan G., ÖZCAN M., Portino S., Fogliatto L., Caballero M. D., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.37, no.34, pp.3291-3301, 2019 (SCI-Expanded)
- LXX. **IS AGE AN IMPORTANT FACTOR FOR AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH NON-HODGKIN LYMPHOMA?**  
Ilhan O., Seval G., Uslu A., Bozdag S., Toprak S., Yuksel M., Topcuoglu P., Arslan O., Ozcan M., Demirer T., et al.  
JOURNAL OF GERIATRIC ONCOLOGY, vol.10, no.6, pp.46-47, 2019 (SCI-Expanded)
- LXXI. **Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem**



## Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (SCI-Expanded)

- LXXII. **Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 52 patients**  
Cengiz Seval G., Topcuoglu P., Arslan O., Gurman G., Demirer T., Kuzu I., Ozcan M.  
ANNALS OF ONCOLOGY, vol.30, pp.441, 2019 (SCI-Expanded)
- LXXIII. **Neutropenic fever and stem cell mobilization**  
TOPÇUOĞLU P., ÖZCAN M.  
JOURNAL OF CLINICAL APHERESIS, vol.34, no.4, pp.517-518, 2019 (SCI-Expanded)
- LXXIV. **AGE IS NOT IMPORTANT IN FIT ELDERLY PATIENTS WITH AGGRESSIVE LYMPHOMA**  
Ilhan O., Uslu A., Cengiz Seval G., Tap E., Basarir U., Civriz Bozdag S., Toprak S., Kurt Yuksel M., Topcuoglu P., Arslan O., et al.  
HEMATOLOGICAL ONCOLOGY, vol.37, pp.418, 2019 (SCI-Expanded)
- LXXV. **Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.**  
Demirer T., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., Arslan O., Özcan M., Akan H., Ilhan O., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.37, no.15\_suppl, pp.19532, 2019 (SCI-Expanded)
- LXXVI. **Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?**  
Ilhan O., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., Arslan O., Özcan M., Demirer T., Akan H., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.37, no.15\_suppl, pp.19524, 2019 (SCI-Expanded)
- LXXVII. **Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients**  
Atilla E., Topcuoglu P., Akkus E., Atilla P. A., Bozdag S. C., Yuksel M. K., Demirer T., Arslan O., Ozcan M., Ilhan O., et al.  
Transplantation and Cellular Therapy, vol.25, no.3, pp.322, 2019 (SCI-Expanded)
- LXXVIII. **Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)**  
Seval G. C., Atilla E., Ulas B., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., et al.  
Transplantation and Cellular Therapy, vol.25, no.3, pp.176-177, 2019 (SCI-Expanded)
- LXXIX. **Does Level of Vitamin D Prior to Allogeneic Stem Cell Transplantation Affect the Transplant Outcomes?**  
Soydan E., Gokmen A., Gökgöz Z., Şen Ş., Özkumur K. O., Okcu M. K., Arslan O., Ozcan M.  
Transplantation and Cellular Therapy, vol.25, no.3, pp.110, 2019 (SCI-Expanded)
- LXXX. **Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma**  
O'Connor O. A., ÖZCAN M., Jacobsen E. D., Roncero J. M., Trotman J., Demeter J., Masszi T., Pereira J., Ramchandren R., Beaven A., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.37, no.8, pp.613-624, 2019 (SCI-Expanded)
- LXXXI. **Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study**  
Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu B., Nagler A., ÖZCAN M., Avivi I., Bosch F., et al.  
LANCET HAEMATOLOGY, vol.6, no.2, 2019 (SCI-Expanded)
- LXXXII. **Severe Bone Marrow Hypoplasia with Black Cumin (Nigella sativa) Ingestion in a Patient with T-ALL in First Complete Remission**  
Ozdemir Z. N., Ozturk C., KUZU I., ÖZCAN M.

- TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.3, pp.215-217, 2019 (SCI-Expanded)
- LXXXIII. **A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience**  
Cekdemir D., Guvenc S., Ozdemirkiran F., Eser A., Topts T., ÖZKOCAMAN V., ŞAHİN H. H., Turak E. E., Esen R., Comert M., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.4, pp.230-237, 2019 (SCI-Expanded)
- LXXXIV. **Comparison of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience**  
Topcuoglu P., Cengiz Seval G., Civriz Bozdog S., Toprak S. K., Kurt Yuksel M., Dalva K., Arslan O., Özcan M., Demirer T., Ilhan O., et al.  
BLOOD, vol.132, no.Supplement 1, pp.5776, 2018 (SCI-Expanded)
- LXXXV. **Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy**  
Walewski J., Hellmann A., Siritanaratkul N., ÖZSAN G. H., ÖZCAN M., Chuncharunee S., Goh A. S., Jurczak W., Koren J., Paszkiewicz-Kozik E., et al.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.183, no.3, pp.400-410, 2018 (SCI-Expanded)
- LXXXVI. **Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients**  
CENGİZ SEVAL G., Sahin D. G., Soydan E. A., Ozcelik T., Gokmen A., Gokgoz Z., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., Arat M.  
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.18, 2018 (SCI-Expanded)
- LXXXVII. **Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.**  
CENGİZ SEVAL G., Bulat B., Ozel F., Tasci O., KUZU I., CİVRİZ BOZDAĞ S., Toprak S. K., YÜKSEL M., Topcuoglu P., Ozcan M., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- LXXXVIII. **Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.**  
Sehn L. H., Kamdar M., Herrera A. F., McMillan A., Flowers C., Kim W. S., Kim T. M., Ozcan M., Demeter J., Hertzberg M., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- LXXXIX. **Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.**  
Gokmen A., Soydan E., Gokgoz Z., Kurdal M., Tek I., Ilhan O., Arslan O., Ozcan M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XC. **Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma**  
Ilhan O., Seval G. C., Toprak S. K., Bozdog S. C., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Akan H., et al.  
Transplantation and Cellular Therapy, vol.24, no.3, pp.142, 2018 (SCI-Expanded)
- XCI. **Retrospective Analysis Leam Conditioning for Autologous Stem Cell Transplantation**  
Soydan E., Gokmen A., Gökğöz Z., Ilhan O., Arslan O., Ozcan M.  
Transplantation and Cellular Therapy, vol.24, no.3, pp.144, 2018 (SCI-Expanded)
- XCII. **Upper respiratory viral infections in patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation: a retrospective study**  
Atilla E., ŞAHİN EROĞLU D., Atilla P. A., Dolapci I., TEKELİ F. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., İLHAN O., ARSLAN Ö., et al.  
ANTIVIRAL THERAPY, vol.23, no.6, pp.523-527, 2018 (SCI-Expanded)
- XCIII. **Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?**  
Atilla E., Yalciner M., Ailla P. A., Ates C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., Gunduz M., Ozen M., Akan H., et al.

ANTIVIRAL THERAPY, vol.23, no.8, pp.647-653, 2018 (SCI-Expanded)

- XCIV. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma**  
Dreyling M., Santoro A., Mollica L., Leppa S., Follows G. A., Lenz G., Kim W. S., Nagler A., Panayiotidis P., Demeter J., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.35, no.35, pp.3898-3909, 2017 (SCI-Expanded)
- XCV. Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia**  
Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu A. B., Nagler A., Ozcan M., Avivi I., Bosch Albareda F., et al.  
BLOOD, vol.130, no.Suppl\_1, pp.833, 2017 (SCI-Expanded)
- XCVI. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)**  
Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., AKAY B. N., ŞANLI H., GÜRMAN G., ÖZCAN M.  
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.106, no.3, pp.426-430, 2017 (SCI-Expanded)
- XCVII. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation**  
Gunduz M., Ozen M., Sahin U., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., BEKSAÇ M., et al.  
CLINICAL TRANSPLANTATION, vol.31, no.7, 2017 (SCI-Expanded)
- XCVIII. Proper diagnosis of antithrombin III deficiency**  
Ozdemir Z. N., ÖZCAN M.  
ANATOLIAN JOURNAL OF CARDIOLOGY, vol.17, no.4, 2017 (SCI-Expanded)
- XCIX. Allogeneic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia**  
Atilla E., Atilla P. A., Pekcan G., İLHAN O., GÜRMAN G., ÖZCAN M., ARSLAN Ö.  
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol.23, no.3, 2017 (SCI-Expanded)
- C. Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients**  
GÜRMAN G., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol.23, no.3, 2017 (SCI-Expanded)
- CI. Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL)**  
Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., Akan H., BEKSAÇ M., İLHAN O., GÜRMAN G., et al.  
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol.23, no.3, 2017 (SCI-Expanded)
- CII. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study**  
Ozen M., Ustun C., Ozturk B., TOPÇUOĞLU P., Arat M., Gunduz M., Atilla E., Bolat G., ARSLAN Ö., DEMİRER T., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.16-26, 2017 (SCI-Expanded)
- CIII. Therapeutic Plasma Exchange for Thrombotic Microangiopathy**  
Ilhan O., Atilla E., Ataca Atilla P., Civriz Bozdag S., Kurt Yuksel M., Toprak S. K., Topcuoglu P., Akan H., Demirer T., Beksac M., et al.  
BLOOD, vol.128, no.22, pp.4939, 2016 (SCI-Expanded)
- CIV. A rare complication after allogeneic stem cell transplantation: post-transplant erythrocytosis**  
Atilla E., TOPÇUOĞLU P., Ataca P., Pekcan G., CİVRİZ BOZDAĞ S., YÜKSEL M., ÖZCAN M., GÜRMAN G., TOPRAK S. K.  
CLINICAL TRANSPLANTATION, vol.30, no.6, pp.669-672, 2016 (SCI-Expanded)
- CV. A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during Construction**  
Ozen M., Yilmaz G., Coskun B., TOPÇUOĞLU P., Ozturk B., Gunduz M., Atilla E., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.1, pp.41-47, 2016 (SCI-Expanded)

- CVI. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study**  
TOMBAK A., Ucar M. A., AKDENİZ A., TİFTİK E. N., Sahin D. G., Akay O. M., Yildirim M., Nevruz O., Kis C., GÜRKAN E., et al.  
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.4, pp.273-280, 2016 (SCI-Expanded)
- CVII. Fertility After Allogeneic Hematopoietic Stem Cell Transplantation: A 23-Year Review From A Tertiary Hospital**  
Atilla P. A., Atilla E., Ediboglu E., CİVRİZ BOZDAĞ S., To-Prak S. K., ARSLAN Ö., ÖZCAN M., GÜRMAN G., TOPÇUOĞLU P.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.145-152, 2016 (SCI-Expanded)
- CVIII. First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)**  
O'connor O. A., Özcan M., Jacobsen E. D., Roncero Vidal J. M., Trotman J., Demeter J., Masszi T., Pereira J., Ramchandren R., D'amore F. A., et al.  
BLOOD, vol.126, no.23, pp.341, 2015 (SCI-Expanded)
- CIX. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients**  
Gurman G., Ataca P., Atilla E., Civriz Bozdog S., Toprak S. K., Yuksel M. K., Demirer T., Akan H., Arslan O., Topcuoglu P., et al.  
BLOOD, vol.126, no.23, pp.1952, 2015 (SCI-Expanded)
- CX. Upper and Lower Respiratory Tract Infections By Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)**  
Atilla E., Ataca P., Sahin D., Topcuoglu P., Dolapci I., Tekeli A., Toprak S. K., Civriz Bozdog S., Yuksel M. K., Ozcan M., et al.  
BLOOD, vol.126, no.23, pp.5479, 2015 (SCI-Expanded)
- CXI. Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides**  
Atilla E., Ataca P., Civriz Bozdog S., Toprak S. K., Yuksel M. K., Akay B. N., Sanli H., Topcuoglu P., Ozcan M., Gurman G., et al.  
BLOOD, vol.126, no.23, pp.5062, 2015 (SCI-Expanded)
- CXII. Is Initial CD3+ T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?**  
Atilla E., Ataca P., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Ilhan O., Beksac M., et al.  
BLOOD, vol.126, no.23, pp.5483, 2015 (SCI-Expanded)
- CXIII. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation**  
Merter M., Atilla E., Sahin U., Civriz Bozdog S., Kurt Yuksel M., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Gurman G., et al.  
BLOOD, vol.126, no.23, pp.5456, 2015 (SCI-Expanded)
- CXIV. Seroprevalence for Toxoplasma Gondii in Allogeneic Hematopoietic Stem Cell Transplantation Recipients**  
Atilla E., Ataca P., Balli S., Isikoglu B., Topcuoglu P., Ozcan M., Akan H.  
BLOOD, vol.126, no.23, pp.5459, 2015 (SCI-Expanded)
- CXV. Follow-up of del(5)q MDS patients with or without other chromosomal abnormalities**  
Turedi O., Ataca P., TUNCALI T., Atilla E., Vicdan A., Durmaz C. D., DALVA K., KUTLAY N., KARABULUT H. G., ILGIN RUHİ H., et al.  
CHROMOSOME RESEARCH, vol.23, 2015 (SCI-Expanded)
- CXVI. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey**  
Salihoglu A., ELVERDİ T., Karadogan I., Paydas S., Ozdemir E., Erdem G., Karadurmus N., Akyol G., Kaynar L., Yegin Z. A., et al.  
ANNALS OF HEMATOLOGY, vol.94, no.3, pp.415-420, 2015 (SCI-Expanded)
- CXVII. Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients**

CENGİZ SEVAL G., ÖZCAN M.

JOURNAL OF CLINICAL MEDICINE, vol.4, no.3, pp.441-459, 2015 (SCI-Expanded)

- CXVIII. **Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report**  
Ayh M., ÖZCAN M., CENGİZ SEVAL G.  
TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.2, pp.180-183, 2015 (SCI-Expanded)
- CXIX. **Antilymphocyte/Thymocyte Globulin for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: 20-Year Experience at a Single Center**  
Ozen M., CİVRİZ BOZDAĞ S., Cakmak G., TOPÇUOĞLU P., Eroglu A. H., Glunduz M., ARSLAN Ö., DEMİRER T., Akan H., İLHAN O., et al.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.25, no.4, pp.236-244, 2015 (SCI-Expanded)
- CXX. **Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?**  
Ilhan O., Ataca P., Atilla E., Toprak S. K., Kaygusuz G., Kuzu I., Bozdag S. C., Topcuoglu P., Arslan O., Ozcan M., et al.  
BLOOD, vol.124, no.21, pp.5555, 2014 (SCI-Expanded)
- CXXI. **Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy**  
Yuksel M. K., Gokmen A., Ozcan M., Arslan O., Ilhan O., Ozbek D., Okcu M. K., Koktas O.  
BLOOD, vol.124, no.21, pp.5925, 2014 (SCI-Expanded)
- CXXII. **Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside**  
Ataca P., Toprak S. K., Atilla E., Topcuoglu P., Kurt Yuksel M., Kaygusuz G., Kuzu I., Arslan O., Ozcan M., Ilhan O., et al.  
BLOOD, vol.124, no.21, pp.5462, 2014 (SCI-Expanded)
- CXXIII. **Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center**  
Sahin U., Merter M., Ataca P., Atilla E., Atesagaoglu B., Pekcan G., Civriz Bozdag S., Toprak S. K., Topcuoglu P., Arslan O., et al.  
BLOOD, vol.124, no.21, pp.5150, 2014 (SCI-Expanded)
- CXXIV. **The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model**  
Seval G., Ozkavukcu S., Seval M., Ayli M., Ozcan M.  
BLOOD, vol.124, no.21, pp.1799, 2014 (SCI-Expanded)
- CXXV. **Do FMS-like Tyrosine Kinase 3 and Nucleophosmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?**  
Gunduz M., Ataca P., Ozen M., Atilla E., Bozdag S. C., Toprak S. K., Topcuoglu P., Ozcan M., Demirer T., Beksac M., et al.  
BLOOD, vol.124, no.21, pp.5328, 2014 (SCI-Expanded)
- CXXVI. **Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients**  
Topcuoglu P., Ataca P., Bozdag S. C., Toprak S. K., Arslan O., Ozcan M., Demirer T., Konuk N., Akan H., Ilhan O., et al.  
BLOOD, vol.124, no.21, pp.5887, 2014 (SCI-Expanded)
- CXXVII. **The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph+ Acute Lymphoblastic Leukemia**  
Gurman G., Merter M., Ataca P., Ozen M., Atesagaoglu B., Gunduz M., Pekcan G., Sahin U., Toprak S. K., Topcuoglu P., et al.  
BLOOD, vol.124, no.21, pp.5281, 2014 (SCI-Expanded)
- CXXVIII. **Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation**  
Topcuoglu P., Gunduz M., Ozen M., Civriz Bozdag S., Kocak Toprak S., Arslan O., Ozcan M., Demirer T., Ilhan O., Akan H., et al.  
BLOOD, vol.124, no.21, pp.5891, 2014 (SCI-Expanded)
- CXXIX. **Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience**  
Atilla E., Sahin U., Ataca P., Uslu A., Kircali E., Atesagaoglu B., Pekcan G., Merter M., Gunduz M., Ozen M., et al.  
BLOOD, vol.124, no.21, pp.5448, 2014 (SCI-Expanded)
- CXXX. **The Treatment of Acquired Hemophilia with Combination Therapy of Immunosuppressives and**

## **Immunoabsorption**

Bilgin A. U., ÖZCAN M., Ayyildiz E., İLHAN O.

TURKISH JOURNAL OF HEMATOLOGY, vol.31, no.2, pp.194-196, 2014 (SCI-Expanded)

- CXXXI. **Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: A multicentre registry in Turkey**  
Kavaklı K., ZÜLFİKAR H., ZÜLFİKAR O. B., ZÜLFİKAR O. B., Aydoğan G., Aydoğan G., Salcıoğlu Z., Salcıoğlu Z., Oner A. F., Oner A. F., et al.  
Haemophilia, vol.18, no.3, pp.383-391, 2012 (SCI-Expanded)
- CXXXII. **Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients**  
TOPÇUOĞLU P., Arat M., ÖZCAN M., ARSLAN Ö., İLHAN O., BEKSAÇ M., GÜRMAN G.  
ANNALS OF HEMATOLOGY, vol.91, no.4, pp.577-586, 2012 (SCI-Expanded)
- CXXXIII. **How Does Influenza A (H1N1) Infection Proceed in Allogeneic Stem Cell Transplantation Recipients?**  
CİVRİZ BOZDAĞ S., Bozkurt G., Topcuoglu P., AZAP A., Ozcan M., Konuk N., Arslan O.  
TURKISH JOURNAL OF HEMATOLOGY, vol.29, no.1, pp.63-66, 2012 (SCI-Expanded)
- CXXXIV. **Immunophenotyping Features in Acute Myeloid Leukemia (AML) with NPM1+ and/or FLT3+**  
Topcuoglu P., Dalva K., Bozdog S. C., Arslan O., Ozcan M., Ilhan O., Akan H., Beksac M., Gurman G.  
BLOOD, vol.118, no.21, pp.4908, 2011 (SCI-Expanded)
- CXXXV. **First and Second High Dose Treatment Supported by Autologous Hematopoietic Cell Transplantation Rescue in Multiple Myeloma**  
Bozdog S. C., Topcuoglu P., Beksac M., Ilhan O., Ozcan M., Gurman G., Arslan O.  
BLOOD, vol.118, no.21, pp.4528, 2011 (SCI-Expanded)
- CXXXVI. **Aplastic anemia and clopidogrel/Nonfatal aplastic anemia associated with clopidogrel**  
CİVRİZ BOZDAĞ S., ÖZCAN M.  
ANADOLU KARDIOLOJİ DERGİSİ-THE ANATOLIAN JOURNAL OF CARDIOLOGY, vol.11, no.3, pp.276, 2011 (SCI-Expanded)
- CXXXVII. **The Efficacy of Vorinostat in Combination With Interferon Alpha and Extracorporeal Photopheresis in Late Stage Mycosis Fungoides and Sezary Syndrome**  
ŞANLI H., AKAY B. N., Anadolu R., ÖZCAN M., Saral S., Akyol A.  
JOURNAL OF DRUGS IN DERMATOLOGY, vol.10, no.4, pp.403-408, 2011 (SCI-Expanded)
- CXXXVIII. **Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial**  
BEKSAÇ M., ALİ R., Ozcelik T., ÖZCAN M., Ozcebe O., Bayik M., PAYDAŞ S., BÜYÜKAŞIK Y., İLHAN O., ÖZKALEMKAŞ F., et al.  
LEUKEMIA RESEARCH, vol.35, no.3, pp.340-345, 2011 (SCI-Expanded)
- CXXXIX. **The effect of CD34 count and clonogenic potential of hematopoietic stem cells on engraftment**  
Sari T., YÜKSEL M., TOPÇUOĞLU P., Tol M., Ayyildiz E., ÖZCAN M., İLHAN O.  
TRANSFUSION AND APHERESIS SCIENCE, vol.43, no.3, pp.315-320, 2010 (SCI-Expanded)
- CXL. **Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.**  
ŞANLI H., AKAY B. N., Ozcan M.  
Journal of drugs in dermatology : JDD, vol.9, no.8, pp.1014-6, 2010 (SCI-Expanded)
- CXLI. **Development of Hodgkin's Lymphoma Under Bexarotene Treatment for Sezary Syndrome and Review of the Literature**  
Sanli H., AKAY B. N., ÖZCAN M.  
JOURNAL OF DRUGS IN DERMATOLOGY, vol.9, no.8, pp.1014-1016, 2010 (SCI-Expanded)
- CXLII. **ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION IN PATIENTS POSITIVE FOR HEPATITIS B SURFACE ANTIGEN**  
Topcuoglu P., Soydan E., Idilman R., Arslan O., Ozcan M., Ilhan O., Beksac M., Arat M., Gurman G.  
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol.16, no.2, 2010 (SCI-Expanded)
- CXLIII. **Presence Of Abnormal Plasma Cells In Peripheral Stem Cell Harvest Products Predict Early Relapse**

**Following Autologous Stem Cell Transplantation In Patients With Multiple Myeloma**

Bakanay S., Dalva K., Koksoy B., Civriz S., Ayyildiz E., Arat M., Ozcan M., Ilhan O., Beksac M.  
Transplantation and Cellular Therapy, vol.16, no.2, pp.239, 2010 (SCI-Expanded)

- CXLIV. **Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF**  
Ozcelik T., Topcuoglu P., BEKSAÇ M., Ozcan M., Arat M., Biyikli Z., Bakanay S. M., Ilhan O., GÜRMAN G., Arslan O., et al.  
BONE MARROW TRANSPLANTATION, vol.44, no.12, pp.779-783, 2009 (SCI-Expanded)
- CXLV. **2nd international congress on leukemia, lymphoma and myeloma**  
Arat M., Özsan G. H., Yenerel M. N., Cetin M., ÖZCAN M.  
Expert Review of Hematology, vol.2, no.5, pp.509-512, 2009 (SCI-Expanded)
- CXLVI. **Simultaneous occurrence of Kaposi's sarcoma and nodular lymphocyte predominant subtype of Hodgkin's lymphoma in the same lymph node**  
Kankaya D., Kaygusuz G., KUZU I., SAVAŞ B., Bakanay S. M., ÖZCAN M.  
TURKISH JOURNAL OF HEMATOLOGY, no.4, pp.201-203, 2009 (SCI-Expanded)
- CXLVII. **Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.**  
Topcuoglu P., Dalva K., Bakanay S. M., Bozdag S. C., Arslan O., Ozcan M., Arat M., Beksac M., Gurman G.  
BLOOD, vol.114, no.22, pp.4846, 2009 (SCI-Expanded)
- CXLVIII. **Follow-up of ADAMTS13 enzyme and its relationship with clinical events after allogeneic hematopoietic stem cell transplantation**  
CİVRİZ BOZDAĞ S., Gunaltay S., DALVA K., ÖZCAN M.  
BLOOD COAGULATION & FIBRINOLYSIS, vol.20, no.3, pp.165-169, 2009 (SCI-Expanded)
- CXLIX. **Flow Cytometric Analysis of T Cell Functions in CML Patients Under Imatinib Therapy**  
Sahin D. G., Dalva K., Meric S., Gurman G., Ozcan M., Arslan O., Arat M.  
BLOOD, vol.112, no.11, pp.2633, 2008 (SCI-Expanded)
- CL. **Clonal evolution of monosomy 7 in acquired severe aplastic anemia: Two cases treated with allogeneic hematopoietic stem cell transplantation**  
Bakanay Ş. M., TOPÇUOĞLU P., Bilgin A. U., Yararbaş K., Karaüzüm S. B., ÖZCAN M., Arat M., ÜNDAR L., İLHAN O.  
Turkish Journal of Hematology, vol.25, no.2, pp.94-97, 2008 (SCI-Expanded)
- CLI. **Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center experience**  
İLHAN O., TOPÇUOĞLU P., Arat M., Soydan E. A., YÜKSEL M., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., Akan H., et al.  
Turkish Journal of Hematology, vol.25, no.2, pp.87-93, 2008 (SCI-Expanded)
- CLII. **T-helper-1 (Th1) and Th2 cytokines after allogeneic hematopoietic stem cell transplantation (allo-HSCT)**  
TOPÇUOĞLU P., Bakanay Ş. M., DALVA K., Arat M., BEKSAÇ M., ÖZCAN M.  
Turkish Journal of Hematology, vol.25, no.1, pp.24-35, 2008 (SCI-Expanded)
- CLIII. **A case report of the Modified Malmo Protocol: An alternative therapeutic approach to refractory chronic idiopathic thrombocytopenic purpura**  
Yazman D., Konuk N., ÖZCAN M., Arat M., Soydan E., ARSLAN Ö., İLHAN O.  
THERAPEUTIC APHERESIS AND DIALYSIS, vol.12, no.3, pp.255-258, 2008 (SCI-Expanded)
- CLIV. **The relevance of T cells and follicular dendritic reticulum cells on predicting the clinical behaviour of follicular lymphomas**  
Ozgun A., Kankaya D., Altas S., Kaygusuz G., Bakanay S. M., Ozcan M., KUZU I.  
VIRCHOWS ARCHIV, no.2, pp.446, 2007 (SCI-Expanded)
- CLV. **How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight**  
Topcuoglu P., Soydan E. A., Ekiz F., Ayyildiz E., Dalva K., Ozcan M., Arslan O., Arat M., Han O.  
TRANSFUSION AND APHERESIS SCIENCE, vol.36, no.3, pp.275-280, 2007 (SCI-Expanded)
- CLVI. **277: Allogeneic hematopoietic cell transplantation in imatinib era**

- Ugur Bilgin A., Soydan E., Topcuoglu P., Arslan O., Ozcan M., Gurman G., Demirer T., Akan H., Beksac M., Konuk N., et al.  
Transplantation and Cellular Therapy, vol.13, no.2, pp.100-101, 2007 (SCI-Expanded)
- CLVII. **Serum transforming growth factor beta 1 levels in multiple myeloma patients**  
Coşkun H. Ş., İlham O., ÖZCAN M., Ayaz S., DALVA K., Üstün C., Arat M.  
Turkish Journal of Hematology, vol.23, no.1, pp.47-52, 2006 (SCI-Expanded)
- CLVIII. **Granuloma annulare on herpes zoster scars in a Hodgkin's disease patient following autologous peripheral stem cell transplantation.**  
Sanli H., Kocyigit P., Arica E., Kurtyuksel M., Heper A., Ozcan M.  
Journal of the European Academy of Dermatology and Venereology : JEADV, vol.20, no.3, pp.314-7, 2006 (SCI-Expanded)
- CLIX. **The Impact of Methylenetetrahydrofolate Reductase C677T Gene Polymorphism on Engraftment after Allogeneic Hematopoietic Cell Transplantation.**  
Soydan E. A., Topcuoglu P., Ozcan M., Arslan O., Gurman G., Beksac M., Arat M., İlhan O.  
BLOOD, vol.106, no.11, pp.5318, 2005 (SCI-Expanded)
- CLX. **Expression of IFITM1 in chronic myeloid leukemia patients**  
AKYERLİ BOYLU C., BEKSAÇ M., Holko M., Frevel M., Dalva K., ÖZBEK U., Soydan E., Ozcan M., Ozet G., İlhan O., et al.  
LEUKEMIA RESEARCH, vol.29, no.3, pp.283-286, 2005 (SCI-Expanded)
- CLXI. **Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis.**  
Erkan O., Bozdayi A., DİŞİBEYAZ S., Oguz D., Ozcan M., Bahar K., Karayalcin S., Ozden A., Bozkaya H., Yurdaydin C., et al.  
European journal of gastroenterology & hepatology, vol.17, no.3, pp.339-43, 2005 (SCI-Expanded)
- CLXII. **Allogeneic Hemapoietic Progenitor Cell Collection Using Four Different Cell Separators: A Retrospective Comparative Analysis.**  
Arat M., Arslan O., Soydan E. A., Ayyildiz E., Dalva K., Tol M., Ozcan M., Gürman G., Demirer T., Akan H., et al.  
BLOOD, vol.104, no.11, pp.5009, 2004 (SCI-Expanded)
- CLXIII. **The Comparison of Myeloablative Versus Reduced Intensity Conditioning Regimen in ABO Mismatched Allogeneic Hematopoietic Cell Transplantation.**  
Topcuoglu P., Arat M., Bolukbasi T., Soydan E., Ozer Y., Ozcan M., Gurman G., Demirer T., Akan H., Beksac M., et al.  
BLOOD, vol.104, no.11, pp.5146, 2004 (SCI-Expanded)
- CLXIV. **Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.**  
Toprak S. K., Dalva K., Mizrak D., Arat M., Ozcan M., Gurman G., İlhan O., Beksac M.  
BLOOD, vol.104, no.11, pp.4671, 2004 (SCI-Expanded)
- CLXV. **High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - A retrospective evaluation**  
Demirer T., Ayli M., Fen T., Ozcan M., Arat M., Buyukberber S., Arslan O., GÜRMAN G., Akan H., İlhan O.  
Bone Marrow Transplantation, vol.34, no.9, pp.781-786, 2004 (SCI-Expanded)
- CLXVI. **Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.**  
İlhan O., Arat M., Arslan O., Ayyildiz E., Sanli H., BEKSAÇ M., Ozcan M., GÜRMAN G., Akan H.  
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, vol.30, no.3, pp.185-7, 2004 (SCI-Expanded)
- CLXVII. **Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies**  
İdilman R., Arat M., Soydan E., TÖRÜNER M., Soykan I., Akbulut H., Arslan O., Ozcan M., Turkyilmaz A., Bozdayi M., et al.  
JOURNAL OF VIRAL HEPATITIS, vol.11, no.2, pp.141-147, 2004 (SCI-Expanded)
- CLXVIII. **The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy**



- Arat M, Arslan O, GÜRMAN G., Dalva K, Ozcan M, Ugur A, Ilhan O.  
TRANSFUSION AND APHERESIS SCIENCE, vol.30, no.1, pp.9-15, 2004 (SCI-Expanded)
- CLXIX. **Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors**  
Topcuoglu P, Arat M, Dalva K, Ozcan M.  
BONE MARROW TRANSPLANTATION, vol.33, no.2, pp.171-176, 2004 (SCI-Expanded)
- CLXX. **Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation.**  
Idilman R, Ustun C, Karayaicin S, Aktemel A, Turkyilmaz A, Ozcan M., Arslan O, Bozdayi A, Van Thiel D., Akan H.  
Clinical transplantation, vol.17, no.5, pp.438-443, 2003 (SCI-Expanded)
- CLXXI. **Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation.**  
TUTAR D. E., Ozcan M., Kilickap M., GÜLEÇ H. S., Aras O., Pamir G., Oral D., Dandele L., Key N.  
Circulation, vol.108, no.13, pp.1581-4, 2003 (SCI-Expanded)
- CLXXII. **Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers**  
BEKSAÇ M., Celebi H., Sargin D., Yalcin A., Topcuoglu P., Kalayoglu-Besisik S., Beyan C., Arslan O., Ozcan M., GÜRMAN G., et al.  
BONE MARROW TRANSPLANTATION, vol.31, no.10, pp.897-904, 2003 (SCI-Expanded)
- CLXXIII. **Effects of replacement fluids on coagulation system used for therapeutic plasma exchange.**  
Tek I, Arslan O., Arat M., Ozcan M., Akdag B., Ilhan O.  
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, vol.28, no.1, pp.3-7, 2003 (SCI-Expanded)
- CLXXIV. **The detection of flow cytometric G-CSF receptor expression and its effect on therapy in acute myeloid leukemia**  
Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Koc H., Akan H., Ozcan M.  
LEUKEMIA & LYMPHOMA, vol.44, no.5, pp.791-795, 2003 (SCI-Expanded)
- CLXXV. **The role of ABO incompatibility in allogeneic peripheral blood stem cell transplantation**  
ARSLAN Ö., Coşkun H. Ş., Arat M., Soydan E., ÖZCAN M., GÜRMAN G., Çelebi H., DEMİRER T., Akan H., İLHAN O., et al.  
Turkish Journal of Haematology, vol.19, no.3, pp.401-409, 2002 (SCI-Expanded)
- CLXXVI. **Monitoring of peripheral blood CD34+cell counts on the first day of apheresis is highly predictive for efficient CD34+cell yield**  
Demirer T., Ilhan O., Ayli M., Arat M., Dagli M., Ozcan M., Haznedar R., Genc Y., Fen T., Ayyildiz E., et al.  
THERAPEUTIC APHERESIS, vol.6, no.5, pp.384-389, 2002 (SCI-Expanded)
- CLXXVII. **A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters vs 12 liters**  
Demirer T., Dagli M., Ilhan O., Ayli M., Haznedar R., Fen T., Gunel N., Genc Y., Arat M., Ozcan M., et al.  
BONE MARROW TRANSPLANTATION, vol.29, no.11, pp.893-897, 2002 (SCI-Expanded)
- CLXXVIII. **A retrospective comparison of oral versus intravenous administration of Busulfan: Preliminary results show similar toxicity but less relapse**  
Arat M., Topcuoglu P., Soydan E., GÜRMAN G., Ozcan M., Arslan O., Koc H., Ilhan O., Konuk N., Uysal A., et al.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)
- CLXXIX. **Presence of tissue factor (TF) antigen expressing cells within allogeneic peripheral blood progenitor cell (PBPC) harvest**  
Ozcan M., Topcuoglu P., Arat M., Dalva K., Soydan E., Arslan O., Ilhan O.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)
- CLXXX. **Is there a correlation between peripheral blood CD34+cells and peripheral blood erythrocyte precursors in healthy G-CSF stimulated donors and the effect of G-CSF and apheresis on complete blood count**  
Tavat C., Arslan O., Arat M., Ilhan O., Ozcan M., Topcuoglu P., BEKSAÇ M., Akan H.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)

- CLXXXI. **The role of busulfan at post transplant pulmonary complications in allogeneic hematopoietic cell transplantation**  
Soydan E, Arat M, Ozdemir Kumbasar O, Ozcan M, Arslan O, GÜRMAN G, Koc H, İlhan O, BEKSAÇ M, Alper D, et al.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)
- CLXXXII. **Does donor recipient ABO-incompatibility have any effect on the course and outcome of allogeneic hematopoietic cell transplantation?**  
Arslan O, Arat M, Soydan E, COŞKUN H. Ş., Topcuoglu P, Ozcan M, GÜRMAN G, Demirel T, İlhan O, Koc H, et al.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)
- CLXXXIII. **The profile of erythrocyte antigens after allogeneic hematopoietic stem cell transplantation**  
Yildirim I, Arsian O, Ozer Y, Arat M, Soydan E, Topcuoglu P, Ozcan M, GÜRMAN G, İlhan O, Koc H, et al.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)
- CLXXXIV. **Thromboembolic complications after allogeneic hematopoietic cell transplantation: the İbni Sina experience**  
Yazman D, Topcuoglu P, Arat M, Soydan E, Kurt M, Ozcan M.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)
- CLXXXV. **Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF**  
Demirel T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, Fen T, Genc Y, Dincer S, Arslan O, et al.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.116, no.2, pp.468-474, 2002 (SCI-Expanded)
- CLXXXVI. **In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia**  
Ustun C, BEKSAÇ M, Dalva K, Koc H, Konuk N, İlhan O, Ozcan M, Topcuoglu P, Sertkaya D, Hayran M.  
MEDICAL ONCOLOGY, vol.19, no.1, pp.59-67, 2002 (SCI-Expanded)
- CLXXXVII. **An atypical Juvenile Chronic Myelocytic Leukemia patient with skin rashes, vasculitis and arthritis**  
Cesur S, Çiftçi A, Kurt H, ÖZCAN M.  
Cancer Research, Therapy and Control, vol.11, no.3-4, pp.219-221, 2002 (SCI-Expanded)
- .LXXXVIII. **An unusual presentation of plasma cell dyscrasias: cardiac tamponade due to myelomatous infiltration.**  
Arat M, Ulusoy V, Demirel T, Uysal A, Ozcan M, Dincer S, İlhan O, Koc H.  
Leukemia & lymphoma, vol.43, no.1, pp.145-8, 2002 (SCI-Expanded)
- CLXXXIX. **Nephrotic syndrome after allogeneic peripheral blood stem cell transplantation.**  
Akar H, KEVEN K, Celebi H, Orhan D, Nergizoglu G, Erbay B, Tulunay O, Ozcan M, ERTÜRK Ş.  
Journal of nephrology, vol.15, no.1, pp.79-82, 2002 (SCI-Expanded)
- CXC. **A case of familial Mediterranean fever with amyloidosis as the first manifestation**  
Kutlay S, Yilmaz E, Koytak E, Tulunay O, KEVEN K, Ozcan M, ERTÜRK Ş.  
AMERICAN JOURNAL OF KIDNEY DISEASES, vol.38, no.6, 2001 (SCI-Expanded)
- CXCI. **A randomized trial of assessment of efficacy of leukapheresis volumes, 8 L versus 10L.**  
Demirel T, Ayli M, Arat M, Gunel N, Ozcan M, Haznedar R, Arslan O, GÜRMAN G, Dagli M, Fen T, et al.  
BLOOD, vol.98, no.11, 2001 (SCI-Expanded)
- CXCII. **Repopulation of liver endothelial cells, but not hepatocytes, by allogeneic hematopoietic cell transplants.**  
İdilman R, Tukan A, Erdem E, Arat M, TÖRÜNER M, Soykan I, KUZU I, Ozcan M, Topcuoglu P, Soydan E, et al.  
BLOOD, vol.98, no.11, 2001 (SCI-Expanded)
- CXCIII. **Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte-colony stimulating factor (rh-GSCF): A randomized evaluation of different doses of rh-G-CSF.**  
Demirel T, Ayli M, Arat M, Ozcan M, Gunel N, Haznedar R, Dagli M, Arslan O, GÜRMAN G, Demirel S, et al.  
BLOOD, vol.98, no.11, 2001 (SCI-Expanded)
- CXCIV. **Allogeneic hematopoietic stem cell transplantation using IV Busulfan.**  
Arat M, BEKSAÇ M, GÜRMAN G, Ozcan M, Arslan O, Soydan E, Yazman D, Topcuoglu P, İlhan O, Koc H, et al.  
BLOOD, vol.98, no.11, 2001 (SCI-Expanded)

- CXCV. **Thrombophilic gene mutations in cirrhosis with portal vein thrombosis**  
Erkan O, Bozdayi A, Bozbas A, Disibeyaz S, Ozcan M, Bozkaya H, Bahar K, Karayalcin S, Ozden A, Yurdaydin C, et al.  
JOURNAL OF HEPATOLOGY, vol.34, pp.68, 2001 (SCI-Expanded)
- CXCVI. **Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation**  
Ozcan M, Ustun C, Akcaglayan E, Akan H, Arslan O, Ilhan O, BEKSAÇ M, GÜRMAN G, Demirer T, Arat M, et al.  
BONE MARROW TRANSPLANTATION, vol.27, no.5, pp.499-505, 2001 (SCI-Expanded)
- CXCVII. **The long term follow-up of lymphoma patients conditioned with CBV regimen and autologous stem cell rescue: Ibni Sina experience**  
Arat M, Soydan E, Arslan O, Ozcan M, GÜRMAN G, Konuk N, Uysal A, BEKSAÇ M, Ylhan O, Koc H, et al.  
BONE MARROW TRANSPLANTATION, vol.27, 2001 (SCI-Expanded)
- CXCVIII. **High-dose Thiotepea, Melphalan and Carboplatin (TMCB) with autologous Peripheral Blood Stem Cell (PBSC) support in patients with hematologic malignancies and solid tumors**  
Demirer T, Ilhan O, Ayli M, Arat M, Fen T, Ozcan M, Arslan O, GÜRMAN G, Akan H, Konuk N, et al.  
BONE MARROW TRANSPLANTATION, vol.27, 2001 (SCI-Expanded)
- CXCIX. **Value of combined Ga-67 and Tc-99(m)-human immunoglobulin G whole-body scanning in malignant lymphoma**  
KÜÇÜK N. Ö, Aras G, Soylu A, Ozcan M, İBİŞ E, Dincol D.  
NUCLEAR MEDICINE COMMUNICATIONS, vol.22, no.3, pp.325-329, 2001 (SCI-Expanded)
- CC. **Treatment of steroid refractory GVHD with anti-thymocyte globulin**  
Ozcan M, Arat M, GÜRMAN G, Arslan O, Topcuoolu P, BEKSAÇ M, Ylhan O, Konuk N, Uysal A, Koc H, et al.  
BONE MARROW TRANSPLANTATION, vol.27, 2001 (SCI-Expanded)
- CCI. **Th1/Th2 cytokines and soluble adhesion molecules after allogeneic hematopoietic stem cell transplantation: influence of stem cell source and use of Dalteparin**  
Celebi H, Ozcan M, Arat M, Dalva K.  
BONE MARROW TRANSPLANTATION, vol.27, 2001 (SCI-Expanded)
- CCII. **Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia**  
GÜRMAN G, Celebi H, Ustun C, Arat M, Ilhan O, Ozcan M, Arslan O, Uysal A, Akan H, BEKSAÇ M, et al.  
THERAPEUTIC APHERESIS, vol.5, no.1, pp.54-57, 2001 (SCI-Expanded)
- CCIII. **The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation**  
GÜRMAN G, Dilek I, Arslan O, Arat M, BEKSAÇ M, Ilhan O, Ozcan M, Akan H, Dalva K, Konuk N, et al.  
TRANSFUSION AND APHERESIS SCIENCE, vol.24, no.1, pp.23-28, 2001 (SCI-Expanded)
- CCIV. **Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation**  
Ozcan M, Morton C, Solovey A, Dandeleit L, Bach R, Hebbel R, Slungaard A, Key N.  
THROMBOSIS AND HAEMOSTASIS, vol.85, no.2, pp.250-255, 2001 (SCI-Expanded)
- CCV. **Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies**  
GÜRMAN G, Arat M, Ilhan O, Konuk N, BEKSAÇ M, Celebi H, Ozcan M, Arslan O, Ustun C, Akan H, et al.  
CYTOTHERAPY, vol.3, no.4, pp.253-260, 2001 (SCI-Expanded)
- CCVI. **CD41+and CD42+hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation**  
Demirer T, Ilhan O, Arat M, Genc Y, Ozcan M, Dalva K, Celebi H, BEKSAÇ M, Akan H, GÜRMAN G, et al.  
JOURNAL OF CLINICAL APHERESIS, vol.16, no.2, pp.67-73, 2001 (SCI-Expanded)
- CCVII. **The value of peripheral blood CD34(+) cell quantification in autologous hematopoietic stem cell apheresis.**  
Ilhan O, Arslan O, Arat M, Ozcan M, GÜRMAN G, Dalva K, BEKSAÇ M, Demirer T, Konuk N, Uysal A, et al.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CCVIII. **The use of rhG-CSF for peripheral blood progenitor cell collection in healthy donors may induce the tissue factor dependent pathway.**

- Topcuoglu P., Ozcan M., Dalva K., Arat M.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CCIX. **Collection of donor lymphocytes for cellular immunotherapy.**  
Arat M., Ilhan O., Arslan O., GÜRMAN G., Ozcan M., Ciftci A., Ayyıldız E., Koc H.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CCX. **The influences of stem cell source and G-CSF administration on changes in naturally occurring anticoagulants after allogeneic hematopoietic stem cell transplantation.**  
Ozcan M.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CCXI. **Phase-II study of high-dose thiotepa, melphalan and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in patients with hematologic malignancies and solid tumors.**  
Demirer T., Ilhan O., Ayli M., Arat M., Fen T., Haznedar R., Ozcan M., Arslan O., GÜRMAN G., Akan H., et al.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CCXII. **Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment**  
BEKSAÇ M., Arat M., Akan H., Koc H., Ilhan O., Ozcan M.  
CANCER, vol.89, no.7, pp.1474-1481, 2000 (SCI-Expanded)
- CCXIII. **Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation: Risk and benefit ratio of HBV vaccination in recipients.**  
Idilman R., Ustun C., Akan H., Karayalcin S., Ozcan M., Arslan O., Ilhan O., Akyol G., Bozdayi M., Colantoni A., et al.  
HEPATOLOGY, vol.32, no.4, 2000 (SCI-Expanded)
- CCXIV. **Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: experience of İbni Sina Hospital**  
Arslan O., COŞKUN H. Ş., Arat M., Celebi H., Ozcan M., GÜRMAN G., Ustun C., Demirer T., Akan H., Ilhan O., et al.  
BONE MARROW TRANSPLANTATION, vol.25, no.12, pp.1229-1232, 2000 (SCI-Expanded)
- CCXV. **Uptake of Tc-99m human immunoglobulin in malignant abdominal lymphoma**  
KÜÇÜK N. Ö., Aras G., Soylu A., Ozcan M., İBİŞ E., Akin A., KIR K. M., Erbay G., Tokuz G.  
CLINICAL NUCLEAR MEDICINE, vol.25, no.3, pp.227-228, 2000 (SCI-Expanded)
- CCXVI. **Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogeneic peripheral stem-cell donors primed with recombinant C-CSF**  
Arslan O., Akan H., Arat M., Dalva K., Ozcan M., GÜRMAN G., Ilhan O., Konuk N., BEKSAÇ M., Uysal A., et al.  
CYTOTHERAPY, vol.2, no.4, pp.259-265, 2000 (SCI-Expanded)
- CCXVII. **Treatment of acute and chronic graft versus host disease with mycophenolate mofetil.**  
Ilhan O., Celebi H., Arat M., Arslan O., Akcaglayan E., Ustun C., Ozcan M., GÜRMAN G., Akan H., Konuk N., et al.  
BLOOD, vol.94, no.10, 1999 (SCI-Expanded)
- CCXVIII. **Adoptive immunity transfer in hepatitis B virus carriers with hematological malignancy who undergoing allogeneic hematopoietic stem cell transplantation**  
Idilman R., Ustun C., Turkyilmaz A., GÜRMAN G., Ozcan M., Karayalcin S., Akan H., Ilhan O., BEKSAÇ M., Bozdayi M., et al.  
HEPATOLOGY, vol.30, no.4, 1999 (SCI-Expanded)
- CCXIX. **The value of Tc-99m HIG scan in malignant lymphoma**  
KÜÇÜK N. Ö., Aras G., Soylu A., Ozcan M., İBİŞ E., Dincol D., Akin A., KIR K. M., Erbay G., Tokuz G.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, vol.26, no.9, pp.1149, 1999 (SCI-Expanded)
- CCXX. **Treatment of aregenerative anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: A case report**  
Üstün C., Çelebi H., Arat M., ÖZCAN M., Dilek I., GÜRMAN G., DEMİRER T., İLHAN O., Keskin R., Koç H.  
Therapeutic Apheresis, vol.3, no.3, pp.275-277, 1999 (SCI-Expanded)
- CCXXI. **Analysis of tissue factor (TF) expression on leukemic cells by flow cytometry: Correlation with tissue factor activity and clinical parameters**  
Kilic S., Ozcan M., Dalva K., BEKSAÇ M., Koc H.  
THROMBOSIS AND HAEMOSTASIS, pp.763, 1999 (SCI-Expanded)

- CCXXII. **Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation**  
Demirer T., Celebi H., Arat M., Ustun C., Demirer S., Dilek I., Ozcan M., Ilhan O., Akan H., GÜRMAN G., et al.  
BONE MARROW TRANSPLANTATION, vol.24, no.3, pp.335-337, 1999 (SCI-Expanded)
- CCXXIII. **Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe**  
Ustun C., Idilman R., GÜRMAN G., Ozcan M., Akyol G., Akan H., Ilhan O., BEKSAÇ M., Uysal A., Konuk N., et al.  
JOURNAL OF HEPATOLOGY, vol.31, no.2, pp.202-209, 1999 (SCI-Expanded)
- CCXXIV. **The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT.**  
Ilhan O., Demirer T., Arat M., Dalva K., COŞKUN H. Ş., BEKSAÇ M., Akan H., Ozcan M., Arslan O., GÜRMAN G., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CCXXV. **Allogeneic peripheral blood stem cell transplantation in patients with severe aplastic anemia.**  
Gurman G., Celebi H., Ustun C., Arat M., Ilhan O., Ozcan M., Arslan O., Uysal A., Akan H., Beksac M., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CCXXVI. **Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY) - Paclitaxel and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast cancer: Ibni Sina experience**  
Arat M., Demirer T., Ilhan O., Koc H., Ustun C., Celebi H., Ayyildiz E., Tuziin A., Gunman G., Ozcan M.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CCXXVII. **A protocol proposal comparing conventional approach with high-dose chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) in patients with small cell lung cancer limited to thorax.**  
Demirer T., Arat M., Koc H., Ilhan O., Celebi H., Ozcan M., Akan H., GÜRMAN G., Uysal A.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CCXXVIII. **The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.**  
Ozcan M., Ustun C., Ilhan O., Beksac M., Akcaglayan E., GÜRMAN G., Akan H., Demirer T., Arat M., Celebi H., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CCXXIX. **Allogeneic hematopoietic cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.**  
GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., Celebi H., Ozcan M., Ilhan O., Demirer T., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CCXXX. **Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.**  
Ustun C., Ozcan M., Beksac M., Ilhan O., Cakir M., GÜRMAN G., Arslan O., Akan H., Demirer T., Arat M., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CCXXXI. **The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation**  
Ilhan O., Arslan O., Arat M., BEKSAÇ M., Akan H., Ozcan M., GÜRMAN G., Konuk N., Uysal A., Koc H.  
TRANSFUSION SCIENCE, vol.20, no.1, pp.69-71, 1999 (SCI-Expanded)
- CCXXXII. **Differences in liver pathology and clinical outcome between two patients with Hepatitis B virus and graft versus host disease**  
Üstün C., ÖZCAN M., GÜRMAN G., Çakir M., Erekuş S., AKYOL G., Arat M., Çelebi H., İdlman R., İLHAN O., et al.  
Pathology and Oncology Research, vol.5, no.3, pp.229-232, 1999 (SCI-Expanded)
- CCXXXIII. **A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse**  
Üstün C., ARSLAN Ö., BEKSAÇ M., Koç H., GÜRMAN G., Özçelik T., Yılmaz B., İlhan O., Akan H., ÖZCAN M., et al.  
Biology of Blood and Marrow Transplantation, vol.5, no.1, pp.28-35, 1999 (SCI-Expanded)
- CCXXXIV. **Allogeneic peripheral blood stem cell transplantation in acute non-lymphoblastic leukemia**  
Arslan O., Ustun C., Arat M., Celebi H., Akan H., BEKSAÇ M., Ilhan O., GÜRMAN G., Ozcan M., Konuk N., et al.  
HEMATOLOGICAL ONCOLOGY, vol.16, no.4, pp.155-162, 1998 (SCI-Expanded)

- CCXXXV. **Allogeneic hematopoietic stem cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.**  
GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., Celebi H., Ozcan M., Ilhan O., Demirer T., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXXXVI. **Circulating CD44 and ICAM-1 levels in low grade non-Hodgkin's lymphoma and B-CLL patients during interferon alpha-2A treatment.**  
BEKSAÇ M., Arat M., Akan H., Koc H., Ilhan O., Ozcan M.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXXXVII. **The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.**  
Ozcan M., Ustun C., Ilhan O., BEKSAÇ M., Akcaglayan E., GÜRMAN G., Akan H., Demirer T., Arat M., Celebi H., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXXXVIII. **Allogeneic peripheral blood stem cell transplantation in patients with severe aplastic anemia.**  
GÜRMAN G., Celebi H., Ustun C., Arat M., Ilhan O., Ozcan M., Arslan O., Uysal A., Akan H., BEKSAÇ M., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXXXIX. **Increased CD38 expression on peripheral blood lymphocytes associate with more advanced disease and poor survival in multiple myeloma patients.**  
Ates A., Ilhan O., Ozcan M., Dalva K., Ugur N., BEKSAÇ M., Akan H., Koc H.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXL. **Interferon alpha 2a and low dose cytarabine in chronic myeloid leukemia: Second interim analysis of multicenter study.**  
Ilhan O., Ozcan M., Yalcin A., Koc H., BEKSAÇ M., Unal A., Tunali A., GÜRMAN G., Dunder S., Undar L., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXLI. **T-cell subsets in multiple myeloma: Relation to clinical phase and stage of disease and prognosis.**  
Ates A., Ilhan O., Ozcan M., Dalva K., Ugur N., BEKSAÇ M., Akan H., Koc H.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXLII. **Enhanced expression of tissue factor (TF) by circulating endothelial cells (CECs) following bone marrow transplantation (BMT).**  
Morton C., Solovey A., Dandele L., Ozcan M., Slungaard A., Hebbel R., Key N.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXLIII. **Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.**  
Ustun C., Ozcan M., BEKSAÇ M., Ilhan O., Cakir M., GÜRMAN G., Akan H., Demirer T., Arat M., Celebi H., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXLIV. **Serum transforming growth factor beta 1 levels in multiple myeloma.**  
COŞKUN H. Ş., Ilhan O., Ozcan M., Ayaz S., Dalva K., Ustun C., Arat M., BEKSAÇ M.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CCXLV. **Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.**  
Ustun C., Idilman R., Ozcan M., Akan H., Karayalcin S., GÜRMAN G., Ilhan O., BEKSAÇ M., Uysal A., Konuk N., et al.  
HEPATOLOGY, vol.28, no.4, 1998 (SCI-Expanded)
- CCXLVI. **Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia**  
BEKSAÇ M., Arslan O., Koc H., Akan H., Ilhan O., Arat M., Ozcan M., GÜRMAN G., Konuk N., Uysal A.  
MEDICAL ONCOLOGY, vol.15, no.3, pp.183-190, 1998 (SCI-Expanded)
- CCXLVII. **Acute myeloblastic leukemia associated with hyperleukocytosis and diabetes insipidus**  
Dilek I., Uysal A., Demirer T., Koc H., Ozcan M., Keles H., Numanoglu N., Ustun C., Ciftci E.  
LEUKEMIA & LYMPHOMA, vol.30, no.5-6, pp.657-660, 1998 (SCI-Expanded)
- CCXLVIII. **Cladribine therapy in chronic lymphoproliferative disorders: Single center experience**  
BEKSAÇ M., Ilhan O., Uysal A., Koc H., Idilman R., Arat M., Ustun C., Ozcan M.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.102, no.1, pp.244, 1998 (SCI-Expanded)
- CCXLIX. **Randomized unicenter trial for comparison of three regimens in de novo adult acute**

### **nonlymphoblastic leukemia**

BEKSAÇ M., Arslan O., Koc H., Akan H., Ilhan O., Arat M., Ozcan M., GÜRMAN G., Konuk N., Uysal A.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.102, no.1, pp.220, 1998 (SCI-Expanded)

- CCL. **Flow cytometric G-CSF receptor expression in acute myeloid leukemia and role in G-CSF use at induction chemotherapy**  
Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Koc H., Akan H., Ozcan M., Konuk N., Uysal A.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.102, no.1, pp.87, 1998 (SCI-Expanded)
- CCLI. **Allogeneic peripheral blood stem cell transplantation in leukemias: A single center results**  
Koc H., GÜRMAN G., Arslan O., Ustun C., Ozcan M., Dilek I., Akan H., Ilhan O., Konuk N., Uysal A., et al.  
BONE MARROW TRANSPLANTATION, vol.21, 1998 (SCI-Expanded)
- CCLII. **Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia**  
Dilek I., Demirer T., Ustun C., Arat M., Koc H., BEKSAÇ M., Erdi H., Anadolu R., Ozcan M., Ilhan O., et al.  
BONE MARROW TRANSPLANTATION, vol.21, no.11, pp.1159-1161, 1998 (SCI-Expanded)
- CCLIII. **Is there a relationship between G-CSF response to conditioning regimen and engraftment after bone marrow transplantation?**  
Ozcan M., BEKSAÇ M.  
BONE MARROW TRANSPLANTATION, vol.21, no.5, pp.533-534, 1998 (SCI-Expanded)
- CCLIV. **Allogeneic peripheral blood stem cell transplants cause more chronic graft versus host disease and less relapse compared to bone marrow transplants**  
BEKSAÇ M., Ustun C., Ozcan M., Koc H., Ilhan O., Ozcelik T., Dalva K., GÜRMAN G., Akan H., Arat M., et al.  
BONE MARROW TRANSPLANTATION, vol.21, 1998 (SCI-Expanded)
- CCLV. **Intravesical tranexamic acid instillations for the treatment of hemorrhagic cystitis**  
Ozcan M., Ustun C., Turan M., GÜRMAN G., BEKSAÇ M.  
BONE MARROW TRANSPLANTATION, vol.21, 1998 (SCI-Expanded)
- CCLVI. **Incidence of Tuberculosis after bone marrow transplantation in a single center from Turkey**  
Arslan O., GÜRMAN G., Dilek I., Ozcan M., Koc H., Ilhan O., Akan H., Konuk N., Uysal A., BEKSAÇ M.  
HAEMATOLOGIA, vol.29, no.1, pp.59-62, 1998 (SCI-Expanded)
- CCLVII. **Surface adhesion molecules in peripheral stem cells of healthy donors primed with G-CSF.**  
Akan H., Dalva K., Ustun C., Koc H., Ilhan O., Uysal A., Ozcan M., Beksac M.  
BLOOD, vol.90, no.10, pp.3487, 1997 (SCI-Expanded)
- CCLVIII. **A randomized single institutional study on comparison of idarubicin (I) versus daunorubicin (D) versus mitoxantrone (M) containing induction and consolidation regimens in acute myeloblastic leukemia (AML).**  
BEKSAÇ M., Arslan O., Koc H., Akan H., Ilhan O., Arat M., Ozcan M., GÜRMAN G., Konuk N., Uysal A.  
BLOOD, vol.90, no.10, pp.3806, 1997 (SCI-Expanded)
- CCLIX. **Hematological and cytogenetic efficiency of interferon alpha 2a plus low dose cytarabine in chronic myelogenous leukemia: An interim analysis of multicenter study.**  
Ilhan O., Ozcan M., Yalcin A., Koc H., BEKSAÇ M., Unal A., Tunali A., Gulbas Z., GÜRMAN G., Dundar S., et al.  
BLOOD, vol.90, no.10, pp.3999, 1997 (SCI-Expanded)
- CCLX. **A phase III, randomized multicenter study of induction with or without granulocyte colony stimulating factor (G-CSF) followed by intensive consolidation versus stem cell transplantation (PBSCT) in AML (preliminary results of Turkish Leukemia Study Group TLG95-002).**  
BEKSAÇ M., Tunali A., Akoglu T., Dundar S., Paydas S., Ilhan O., Koc H., Ozcan M., Ovali E., Uysal A., et al.  
BLOOD, vol.90, no.10, pp.3805, 1997 (SCI-Expanded)
- CCLXI. **Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic progenitor cell transplantation.**  
GÜRMAN G., Arslan O., Koc H., Dilek I., Ustun C., Ozcan M., Akan H., Ilhan O., SUNGUROĞLU A., Konuk N., et al.  
BLOOD, vol.90, no.10, pp.4452, 1997 (SCI-Expanded)
- CCLXII. **Serial change in circulating tissue factor procoagulant activity in bone marrow transplantation (BMT).**

- Ozcan M., Slungaard A., Dandelet L., Bach R., Key N.  
BLOOD, vol.90, no.10, pp.1883, 1997 (SCI-Expanded)
- CCLXIII. **Serial change in circulating tissue factor procoagulant activity (TF PCA) in bone marrow transplantation.**  
Ozcan M., Slungaard A., Dandelet L., Bach R., Key N.  
BLOOD, vol.90, no.10, pp.3157, 1997 (SCI-Expanded)
- CCLXIV. **Clinical relevance of flow cytometric BCL-2 and CD95 expression in acute myeloid leukemia.**  
Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Akan H., Koc H., Ozcan M., Konuk N., Uysal A.  
BLOOD, vol.90, no.10, pp.3709, 1997 (SCI-Expanded)
- CCLXV. **Allogeneic peripheral blood stem cell transplantation: Is there an increased risk of graft vs host disease in leukemia patients?**  
Koc H., GÜRMAN G., Arslan O., Ozcan M., Dilek I., Akan H., Ilhan O., Konuk N., BEKSAÇ M., Uysal A.  
JOURNAL OF CHEMOTHERAPY, vol.9, no.5, pp.371-376, 1997 (SCI-Expanded)
- CCLXVI. **HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia**  
Ilhan O., BEKSAÇ M., Arslan O., Ozcan M., Koc H., Akan H., GÜRMAN G., Konuk N., Uysal A.  
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.66, no.3, pp.291-295, 1997 (SCI-Expanded)
- CCLXVII. **Hepatitis B virus infection in allogeneic bone marrow transplantation**  
Ustun C., Koc H., Karayalcin S., Akyol G., GÜRMAN G., Ilhan O., Akan H., Ozcan M., Arslan O., Konuk N., et al.  
BONE MARROW TRANSPLANTATION, vol.20, no.4, pp.289-296, 1997 (SCI-Expanded)
- CCLXVIII. **Protein-C, protein-S, antithrombin-III levels after hematopoietic stem cell transplantation**  
Akar H., Ozcan M., Arslan O., Ilhan O., Koc H., Akan H., GÜRMAN G., Dalva K., Konuk N., Uysal A., et al.  
THROMBOSIS AND HAEMOSTASIS, 1997 (SCI-Expanded)
- CCLXIX. **Incidence of graft vs host disease in allogeneic bone marrow transplantation in a single center study from Turkey**  
Ilhan O., Akan H., Koc H., GÜRMAN G., Arslan O., Ozcan M., Erdi H., Erdem C., Konuk N., Uysal A., et al.  
HEMATOLOGY AND CELL THERAPY, vol.39, no.3, pp.133-136, 1997 (SCI-Expanded)
- CCLXX. **Hemorrhagic cystitis as a complication of bone marrow transplantation**  
Ilhan O., Koc H., Akan H., GÜRMAN G., Arslan O., Ozcan M., Arıkan N., Sencer H., Konuk N., Uysal A., et al.  
JOURNAL OF CHEMOTHERAPY, vol.9, no.1, pp.56-61, 1997 (SCI-Expanded)
- CCLXXI. **Use of high-dose chemotherapy plus granulocyte colony-stimulating factor for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support**  
Koc H., Arslan O., Akan H., Ozcan M., Ilhan O., Aydogdu I., Arat M., BEKSAÇ M., Konuk N., Uysal A.  
ACTA HAEMATOLOGICA, vol.98, no.3, pp.136-139, 1997 (SCI-Expanded)
- CCLXXII. **Hepatic complications of allogeneic bone marrow transplantation.**  
Ustun C., Koc H., Karayalcin S., Akyol G., GÜRMAN G., Ilhan O., Akan H., Ozcan M., Arslan O., Konuk N., et al.  
BLOOD, vol.88, no.10, pp.3815, 1996 (SCI-Expanded)
- CCLXXIII. **Comparison of peripheral blood, lymph node and bone marrow lymphocyte surface antigens, adhesion molecules in B-cell and low grade non-Hodgkin's lymphoma (NHL).**  
BEKSAÇ M., Arat M., Ozcan M., Arslan O., Koc H., Akan H., Ilhan O., GÜRMAN G., Konuk N., Uysal A.  
BLOOD, vol.88, no.10, pp.958, 1996 (SCI-Expanded)
- CCLXXIV. **Donor mononuclear cells infusion and alfa interferon administration in relapsed chronic myeloid leukemia patients after allogeneic bone marrow transplantation**  
GÜRMAN G., Koc H., Akan H., Ilhan O., Ozcan M., Arslan O., SUNGUROĞLU A., Konuk N., BEKSAÇ M., Uysal A.  
BLOOD, vol.88, no.10, pp.3800, 1996 (SCI-Expanded)
- CCLXXV. **The prognostic relevance of HLA phenotype in allogeneic bone marrow transplantation in Turkish patients with chronic myelogenous leukemia (CML).**  
Ilhan O., Ozcan M., BEKSAÇ M., Koc H., Akan H., Kutlay S., Dalva K., GÜRMAN G., Arslan O., Arat M., et al.  
BLOOD, vol.88, no.10, pp.3825, 1996 (SCI-Expanded)
- CCLXXVI. **CD34 cell dose influences hematological recovery after peripheral blood stem cell transplantation.**  
Ilhan O., BEKSAÇ M., Arslan O., Akan H., Koc H., Dilek I., Arat M., Ozcan M., GÜRMAN G., Konuk N., et al.  
BLOOD, vol.88, no.10, pp.3751, 1996 (SCI-Expanded)



- CCLXXVII. **Hemorrhagic cystitis after bone marrow transplantation: The role of electron microscopy in differential diagnosis.**  
GÜRMAN G., Sencer H., Uysal A., Cinar K., Arslan O., Ozcan M., Koc H., Akan H., BEKSAÇ M., Ilhan O., et al.  
BLOOD, vol.88, no.10, pp.3747, 1996 (SCI-Expanded)
- :CLXXVIII. **Lack of prognostic value of CD34 in adult AML**  
Arslan O., Akan H., BEKSAÇ M., Ozcan M., Koc H., Ilhan O., Konuk N., Uysal A.  
LEUKEMIA & LYMPHOMA, vol.23, no.1-2, pp.185-186, 1996 (SCI-Expanded)
- CCLXXIX. **Is there an increased risk of graft-versus-host disease after allogeneic peripheral blood stem cell transplantation?**  
Koc H., GÜRMAN G., Arslan O., Ozcan M., Akan H., Ilhan O., Konuk N., BEKSAÇ M., Uysal A.  
BLOOD, vol.88, no.6, pp.2362-2364, 1996 (SCI-Expanded)
- CCLXXX. **Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen**  
Arslan O., Akan H., Koc H., BEKSAÇ M., Ilhan O., Ozcan M., Yalcin S., GÜRMAN G., Konuk N., Uysal A.  
BONE MARROW TRANSPLANTATION, vol.18, no.1, pp.261, 1996 (SCI-Expanded)
- CCLXXXI. **Febrile neutropenia in a bone marrow transplantation unit**  
Akan H., Koc H., Arslan O., BEKSAÇ M., Ilhan O., GÜRMAN G., Ozcan M., Ustun C., Konuk N., Uysal A.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.93, pp.982, 1996 (SCI-Expanded)
- CCLXXXII. **HLA DR2; A prognostic factor in response to immunosuppressive therapy in aplastic anemia**  
Ilhan O., BEKSAÇ M., Koc H., Akan H., Arslan O., GÜRMAN G., Ozcan M., Konuk N., Uysal A.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.93, pp.473, 1996 (SCI-Expanded)
- :CLXXXIII. **High dose epirubicin containing CEOP regimen in intermediate or high grade nonHodgkin's lymphoma**  
Ilhan O., Arslan O., Koc H., BEKSAÇ M., Akan H., GÜRMAN G., Ozcan M., Konuk N., Uysal A.  
BLOOD, vol.86, no.10, pp.3245, 1995 (SCI-Expanded)
- :CLXXXIV. **Soluble adhesion molecules during progenitor cell engraftment**  
Akan H., Senqul S., BEKSAÇ M., Koc H., Ilhan O., GÜRMAN G., Ozcan M.  
BLOOD, vol.86, no.10, pp.3887, 1995 (SCI-Expanded)
- CCLXXXV. **Multidrug resistance and p-glycoprotein analysis in Candida species obtained from patients with hematological malignancies**  
BEKSAÇ M., Arman D., Ozcan M., Ferhat S., Cakar N.  
BLOOD, vol.86, no.10, pp.2986, 1995 (SCI-Expanded)
- :CLXXXVI. **Relationship between serum cytokine levels and aplasia period following high dose chemotherapy supported by granulocyte-colony stimulating factor as a salvage chemotherapy without stem cell rescue in malignant lymphomas.**  
Koc H., Akan H., Ilhan O., GÜRMAN G., Ozcan M., Arslan O., BEKSAÇ M., Konuk N., Uysal A.  
BLOOD, vol.86, no.10, pp.2779, 1995 (SCI-Expanded)
- CLXXXVII. **CIRCULATING SOLUBLE CD44 AND ICAM-1 LEVELS IN LOW-GRADE NON-HODGKINS-LYMPHOMA PATIENTS DURING INTERFERON-ALPHA TREATMENT**  
BEKSAÇ M., AKAN H., KOC H., LIHAN O., OZCAN M.  
BLOOD, vol.84, no.10, 1994 (SCI-Expanded)
- :LXXXVIII. **CORRELATION OF STEM-CELL FACTOR AND SOLUBLE ADHESION MOLECULES WITH BLAST COUNTS IN PATIENTS UNDERGOING CHEMOTHERAPY**  
AKAN H., BEKSAÇ M., ILHAN O., KOC H., GÜRMAN G., OZCAN M.  
BLOOD, vol.84, no.10, 1994 (SCI-Expanded)
- :CLXXXIX. **PERIPHERAL T-CELL RECEPTORS ALPHA-BETA AND GAMMA-DELTA IN PATIENTS WITH HODGKINS LYMPHOMA**  
AKAN H., BEKSAÇ M., AYDOGDU I., KOC H., ILHAN O., OZCAN M.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.87, no.3, pp.544-547, 1994 (SCI-Expanded)
- CCXC. **RELEVANCE OF SERUM G-CSF LEVELS IN BONE-MARROW TRANSPLANTATION PATIENTS**  
BEKSAÇ M., OZCAN M., KOC H., AKAN H., ILHAN O.

EXPERIMENTAL HEMATOLOGY, vol.22, no.6, pp.480-481, 1994 (SCI-Expanded)

**CCXCI. CIRCULATING ENDOGENOUS GRANULOCYTE COLONY-STIMULATING FACTOR LEVELS AFTER BONE-MARROW TRANSPLANTATION**

BEKSAÇ M., OZCAN M., KOC H., AKAN H., ILHAN O., SARDAS O.

BLOOD, vol.80, no.11, pp.2946-2947, 1992 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Lenfoplazmasitik Lenfomada Yeni Nesil Dizileme Yöntemiyle Mutasyon İncelemesinin Tanı ve Tedavi Planında Yeri**  
KOYUN D., YÜKSEL S., Cengiz Seval G., CİVRİZ BOZDAĞ S., Toprak S. K., Topcuoglu P., Arslan Ö., BEKSAÇ M., İLHAN O., KUZU I., et al.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.8, no.1, pp.39-45, 2024 (Peer-Reviewed Journal)
- II. **Vitamin D Gene Polymorphism in Patients with Aseptic Necrosis after Allogeneic Hematopoietic Stem Cell Transplantation**  
Soydan E., Sahin U., Ceylaner S., gökmen a., Dogan H., Kurdal Okcu M., ilhan o., Arslan Ö., Ozcan M.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.7, no.2, pp.51-56, 2023 (Peer-Reviewed Journal)
- III. **Kazanılmış Faktör VIII ve IX İnhibitörü Olan Hastalarda İmmünoşüpresif Tedavi Etkinlik ve Güvenilirliğinin Değerlendirilmesi**  
KOYUN D., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., ÖZCAN M., TOPÇUOĞLU P.  
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.76, pp.24-29, 2023 (Peer-Reviewed Journal)
- IV. **P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS**  
Seval G. C., Kircali E., Koyun D., Karakaya B., Yilmaz H., Yavuz G., Akbulut H., Toprak S. K., Topcuoglu P., Arslan O., et al.  
HemaSphere, vol.6, pp.26, 2022 (Scopus)
- V. **Low Dose TBI in Addition to Low Dose Melphalan and Fludarabine As a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients with High Risk Hematologic Malignancies**  
Gokmen A., Şahin U., Soydan E., Okcu M. K., Arslan O., Özcan M.  
Transplantation and Cellular Therapy, vol.28, no.3, pp.245, 2022 (Scopus)
- VI. **Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients**  
Kircali E., Seval G. C., Bozdog S. C., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Ilhan O., Gurman G., et al.  
Transplantation and Cellular Therapy, vol.27, no.3, pp.271, 2021 (Scopus)
- VII. **Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University**  
Seval G. C., Bozdog S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Ilhan O., Tuncali T., et al.  
Transplantation and Cellular Therapy, vol.27, no.3, pp.401, 2021 (Scopus)
- VIII. **The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis**  
NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., DEMİRER T., BEKSAÇ M., et al.  
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.74, 2021 (Peer-Reviewed Journal)
- IX. **The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation**  
CENGİZ SEVAL G., KIRCALI E., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., GÜRMAN G., BEKSAÇ M., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.74, 2021 (Peer-Reviewed Journal)

- X. **Allojeneik kök hücre naklinde Primer ve sekonder graft yetmezliği**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., BEKSAÇ M., ÖZCAN M., GÜRMAN G., TOPÇUOĞLU P.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.5, 2021 (Peer-Reviewed Journal)
- XI. **Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome**  
ATACA ATILLA P., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., BEKSAÇ M., ARSLAN Ö., İLHAN O., ÖZCAN M., et al.  
Journal of Ankara University Faculty of Medicine, vol.73, no.2, pp.113-117, 2020 (Peer-Reviewed Journal)
- XII. **Myelodisplastik Sendromda Allojeneik Kök Hücre Nakli**  
ATACA ATILLA P., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., BEKSAÇ M., ARSLAN Ö., İLHAN O., ÖZCAN M., et al.  
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.73, no.2, pp.113-117, 2020 (Peer-Reviewed Journal)
- XIII. **Miyelodisplastik Sendrom HastalarınınAkan Hücre Ölçer ile Yapılan OgataSkorlaması Yoluyla Değerlendirilmesi:Pilot Çalışma**  
ATILLA E., Kırçalı E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., BEKSAÇ M., ARSLAN Ö., TOPÇUOĞLU P., ÖZCAN M., et al.  
LLM Dergi, vol.4, no.3, pp.45-49, 2020 (Peer-Reviewed Journal)
- XIV. **Evaluation of Patients With Myelodysplastic Syndromeby Ogata Scoring in Flow Cytometry: Pilot Study**  
ATILLA E., Kırçalı E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., BEKSAÇ M., ARSLAN Ö., TOPÇUOĞLU P., ÖZCAN M., et al.  
LLM Dergi, vol.4, no.3, pp.45-49, 2020 (Peer-Reviewed Journal)
- XV. **Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis**  
CENGİZ SEVAL G., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAY B. N., ŞANLI H., ARSLAN Ö., GÜRMAN G., et al.  
LLM Dergi, vol.4, no.2, pp.23-27, 2020 (Peer-Reviewed Journal)
- XVI. **Our Treatment Approach to Hairy Cell Leukemia**  
ATACA ATILLA P., ATILLA E., KIRCALI E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., AKAN H., BEKSAÇ M., et al.  
Journal of Ankara University Faculty of Medicine, vol.73, no.1, pp.5-8, 2020 (Peer-Reviewed Journal)
- XVII. **Tüylü Hücreli Lösemide Tedavi Yaklaşımımız**  
ATACA ATILLA P., ATILLA E., Kırçalı E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., AKAN H., BEKSAÇ M., et al.  
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.73, no.1, pp.5-8, 2020 (Peer-Reviewed Journal)
- XVIII. **The Outcomes of Splenectomy and Drug Therapy in Patients with Splenic Marginal Zone Lymphoma**  
CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., ARSLAN Ö., GÜRMAN G., KUZU I.  
LLM Dergi, vol.4, no.1, pp.10-13, 2020 (Peer-Reviewed Journal)
- XIX. **MİKOZİS FUNGOİDES VE SEZARY SENDROMU TANILI HASTALARIN TEDAVİSİNDE HEMATOPOİETİK KÖK HÜCRE NAKLİ SONUÇLARI:7 YILLIK MERKEZ DENEYİMİ**  
CENGİZ SEVAL G., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAY B. N., ŞANLI H., ARSLAN Ö., GÜRMAN G., et al.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.4, no.2, pp.23-27, 2020 (Peer-Reviewed Journal)
- XX. **Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma**  
Cengiz Seval G., Karaman Z., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Demirer T., Gürman G., İlhan O., et al.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.3, no.3, pp.55-59, 2019 (Peer-Reviewed Journal)
- XXI. **İmatinib Tedavisi Alan Hastalarda T Lenfosit Aktivasyonunun Akım Sitometrik Analizi**  
GÖREN ŞAHİN D., DALVA K., meriç s., GÜRMAN G., ÖZCAN M., ARSLAN Ö., ARAT M.

Osmangazi Tıp Dergisi, 2019 (Peer-Reviewed Journal)

- XXII. **Evaluation of Consultation Results for Histopathological Diagnosis in Hematological Malignancies**  
CANSIZ ERSÖZ C., KAYGUSUZ G., ÖZCAN M., KUZU I.  
LLM Dergi, pp.31-37, 2019 (Peer-Reviewed Journal)
- XXIII. **The Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Transplantation for Acute Leukemia**  
ŞAHİN U., ERDAL H., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.  
LLM Dergi, vol.3, no.1, pp.9-13, 2019 (Peer-Reviewed Journal)
- XXIV. **Akut Lösemide Allojeneik Nakil Öncesi Serum Ferritin Düzeyinin Nakil Sonuçlarına Etkisi**  
ŞAHİN U., HASAN E., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.  
Lösemi Lenfoma Miyelom Hastaları ve Araştırma Eğitimi Birliği Dergisi, vol.3, no.1, pp.1-3, 2019 (Peer-Reviewed Journal)
- XXV. **Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center**  
ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.2, no.4, pp.93-97, 2018 (Peer-Reviewed Journal)
- XXVI. **Primer Mediastinal Büyük BHücreli Lenfoma Hastalarımızın Tedavi Sonuçlarının Geriye Dönük Değerlendirilmesi**  
ATILLA E., ATACA ATILLA P., Cengiz Seval G., TOPRAK S. K., İLHAN O., ARSLAN Ö., GÜRMAN G., DEMİRER T., ÖZCAN M.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.2, no.3, pp.60-64, 2018 (Peer-Reviewed Journal)
- XXVII. **Allogeneic Stem Cell Transplantation Experience in Chronic Lymphocytic Leukemia**  
ATILLA E., Pekca G., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., İLHAN O., GÜRMAN G., et al.  
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.71, no.1, pp.43-46, 2018 (Peer-Reviewed Journal)
- XXVIII. **Kronik Lenfositik Lösemi'de Allojeneik Kök Hücre Nakli Deneyimi**  
ATILLA E., PEKCAN G., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., İLHAN O., GÜRMAN G., et al.  
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.71, no.1, pp.43-46, 2018 (Peer-Reviewed Journal)
- XXIX. **Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience**  
ATACA ATILLA P., ATILLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., İLHAN O., ARSLAN Ö., GÜRMAN G., et al.  
Hematology Oncology and Stem Cell Therapy, vol.11, no.1, pp.13-17, 2018 (Scopus)
- XXX. **Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.**  
Atilla P. A., Atilla E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., İLHAN O., ARSLAN Ö., GÜRMAN G., et al.  
Hematology/oncology and stem cell therapy, vol.11, no.1, pp.13-17, 2018 (Scopus)
- XXXI. **KRONİK LENFOSİTİK LÖSEMİ'DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?**  
ATILLA E., Özel F., ATACA ATILLA P., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., İLHAN O., ÖZCAN M., ARSLAN Ö., GÜRMAN G., et al.  
Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, vol.20, no.3, pp.294-299, 2018 (Peer-Reviewed Journal)
- XXXII. **Primary Pulmonary Extranodal Marginal Zone Lymphoma: An Atypical Radiological Pattern**  
AKIN KABALAK P., ÖZ M., KANKAYA D., ÇİLEDAĞ A., ATASOY Ç., ÖZCAN M., ÖZDEMİR KUMBASAR Ö.  
Respiratory Case Reports, vol.6, no.3, pp.166-169, 2017 (Peer-Reviewed Journal)
- XXXIII. **Primary Pulmonary Extranodal Marginal Zone Lymphoma: An Atypical Radiological Pattern**

AKIN KABALAK P., ÖZ M., KANKAYA D., ÇİLEDAĞ A., ATASOY K. Ç., ÖZCAN M., ÖZDEMİR KUMBASAR Ö.  
Respiratory Case Reports, 2017 (Peer-Reviewed Journal)

XXXIV. **The End of a Long Debate: Methylenetetrahydrofolate Reductase Gene Polymorphisms do not Increase Thrombosis Risk**

Sahin U, ÖZCAN M.

EURASIAN JOURNAL OF MEDICINE, vol.49, no.1, pp.76-77, 2017 (ESCI)

XXXV. **Yoğun Kemoterapi Almış Refrakter Hematolojik Hastalıklarda Haploidentik Kök Hücre Naklinin Sağkalıma Etkisi**

YÜKSEL M., DALVA K., ŞAHİN U., KURDALOKCU M., KÖKSAL Ö., GÖKMEN A., KILIÇ G., SOYDAN E., ARSLAN Ö., İLHAN O., et al.

LLM DERGİ, 2017 (Peer-Reviewed Journal)

XXXVI. **Successful Desensitization of a Patient with Rituximab Hypersensitivity**

Ataca P., Atilla E., Kendir R., BAVBEK S., ÖZCAN M.

CASE REPORTS IN IMMUNOLOGY, vol.2015, 2015 (ESCI)

XXXVII. **The autologous hematopoietic stem cell transplantation in adult patients with lymphoma: Turkish Bone Marrow Transplantation Registry results**

Arpaci F., Ataergin S., GÜRMAN G., Çağırğan S., Arat M., Özet A., Ayli M., ÖZCAN M., ÜNAL A., Soysal T., et al.

Turkish Journal of Cancer, vol.37, no.2, pp.45-53, 2007 (Scopus)

XXXVIII. **Acute hepatic failure in a case of acute lymphoblastic leukemia**

Cesur S., TOPÇUOĞLU P., Aşık O., Birengel S., ÖZCAN M.

Turkish Journal of Medical Sciences, vol.34, no.4, pp.275-279, 2004 (Scopus)

XXXIX. **The Role of ABO Incompatibility in Allogeneic Peripheral Blood Stem Cell Transplant.**

Arslan Ö., Coşkun H. Ş., Arat M., Soydan E., Özcan M., Gürman G., Çelebi H., Demirer T., Akan H., İlhan O., et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.19, no.3, pp.401-9, 2002 (Scopus)

## Books & Book Chapters

I. **Managing Patients with Aggressive Non-Hodgkin Lymphoma in the Time of COVID-19 Pandemic**

Cengiz Seval G., Özcan M.

in: HEMATOLOJİ VE COVID-19, Osman İlhan, Selami Koçak Toprak, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.1-4, 2020

II. **HEPATİK SİNÜZOİDAL TIKANIKLIK SENDROMU**

GÖKGÖZ Z., ÖZCAN M.

in: HEMATOLOG HEMATOPOETİK KÖK HÜCRE NAKLİ, Güner Hayri Özsan, Muhit Özcan, Editor, GALENOS YAYINEVİ, Ankara, pp.139-148, 2019

III. **HAPLOİDENTİK KÖK HÜCRE NAKLİ**

CENGİZ SEVAL G., ÖZCAN M.

in: Hematolog-Hematopoetik Kök Hücre Nakli, , Editor, Türk Hematoloji Derneği, pp.94-115, 2019

## Refereed Congress / Symposium Publications in Proceedings

I. **Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience**

Koyun D., Şahin U., Cengiz Seval G., Gören D., Gökmen A., Civriz Bozdağ S., Toprak S. K., Kurt Yüksel M., Topçuoğlu P., Arslan Ö., et al.

65th ASH® Annual Meeting and Exposition, California, United States Of America, 9 - 12 December 2023, pp.3617-3619

II. **ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE**

Koyun D., Cengiz Seval G., Bozdog S. C., Toprak S. K., Topçuoğlu P., Özcan M., Arslan Ö., Demirer T., Gurman G., Beksac M., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.301-302

- III. **KRONİK LENFOSİTİK LÖSEMİLERDE İMMUNGLOBULİN GENLERİ VARYANT ALT TİPLERİ, ALT KLONLAR İLE SOMATİK HİPERMUTASYON İLE HASTALIK BİYOLOJİSİNİN İLİŞKİSİ**  
Aygün R. Ş., Yüksel S., Özüncü M. B., Yüksel M., Cengiz Seval G., Arslan Ö., Özcan M., Kuzu I.  
49. Ulusal Hematoloji Kongresi , Antalya, Turkey, 1 - 05 November 2023, pp.148-149
- IV. **İdiopatik multisentrik Castleman hastalığının nadir bir varyantı : Tafro sendromu olgu sunumu**  
Yılmaz H., Yüksel S., Kuzu I., Özcan M.  
49. Ulusal Hematoloji Kongresi , Antalya, Turkey, 1 - 04 November 2023, pp.309
- V. **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE**  
Karakaya B., Yılmaz H., Ermis G. Y., Cengiz Seval G., Bozdog S. C., Toprak S. K., Yuksel M. K., Arslan Ö., Özcan M., Demirer T., et al.  
49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.457-458
- VI. **EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES**  
Beksac M., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Demirer T., İlhan O., et al.  
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, France, 23 April 2023, vol.58, pp.107
- VII. **Akut B Lenfoblastik Lösemi Tanılı Bir Olguda Merkaptopürin Tedavisi Sırasında Kazanılmış Faktör V Eksikliği**  
Koyun D., Özcan M.  
3. Lösemi Lenfoma Miyelom Kongresi, Ankara, Turkey, 25 - 27 May 2023, pp.25
- VIII. **ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND/OR REFRACTORY HODGKIN LYMPHOMA:A MULTICENTER REAL WORLD EXPERIENCE**  
Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Civriz Bozdağ S., Koçak Toprak S., Kurt Yüksel M., Topçuoğlu P., Arslan Ö., Beksac M., et al.  
9th International Congress on Leukemia Lymphoma Myeloma, Antalya, Turkey, 12 - 13 May 2023, pp.40-41
- IX. **EVALUATION OF THE EFFICACY AND SAFETY RITUXIMAB, LENALIDOMIDE,AND IBRUTINIB IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA**  
Koyun D., Şahin U., Gökmen A., Özcan M.  
9th International Congress on Leukemia Lymphoma Myeloma, Antalya, Turkey, 12 - 13 May 2023, pp.47-48
- X. **COVID-19 ENFEKSİYONUNUN OTOLOG KÖK HÜCRE NAKLİ UYGULANAN MULTİPLE MYELOM TANILI BİR OLGUDA ETKİSİ**  
Koyun D., Cengiz Seval G., Civriz Bozdağ S., Özcan M., Beksac M., Koçak Toprak S.  
15. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi , Antalya, Turkey, 16 - 19 March 2023, pp.101
- XI. **NÜKS VEYA DİRENÇLİ PRİMER MEDİASTİNAL BÜYÜK B HÜCRELİ LENFOMA TANILI HASTALARDA KÖK HÜCRE NAKİL DENEYİMİ**  
Koyun D., Özcan M.  
15. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 16 - 19 March 2023, pp.91-92
- XII. **INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE**  
YILMAZ H., Şahin Y. I., Mammadli H., YILDIZ B., Duran O. F., AYDIN R. F., CENGİZ SEVAL G., TOPRAK S. K., ERTEN Ş., TOPÇUOĞLU P., et al.  
9th International Congress on Leukemia Lymphoma Myeloma, Turkey, 12 May 2023

- XIII. **EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR**  
Koyun D., Cengiz Seval G., Civriz Bozdağ S., Özcan M., Topçuoğlu P.  
2023 Highlights of ASH, İstanbul, Turkey, 17 - 18 February 2023, pp.24-26
- XIV. **Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis**  
Yılmaz H., Cengiz Seval G., Karakaya B., Yavuz G., Aydoğan M., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., Arslan Ö., et al.  
64th ASH Annual Meeting & Exposition, Louisiana, United States Of America, 09 December 2022
- XV. **NÜKS VE DİRENÇLİ HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: ÇOK MERKEZLİ GERÇEK YAŞAM VERİSİ**  
Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Gökmen A., Civriz Bozdağ S., Koçak Toprak S., Kurt Yüksel M., Topçuoğlu P., Arslan Ö., et al.  
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 November 2022, pp.130-132
- XVI. **LENFOPLAZMASİTİK LENFOMADA YENİ NESİL DİZİLEME YÖNTEMİYLE MUTASYON İNCELEMESİNİN TANI VE TEDAVİ PLANINDA YERİ**  
Koyun D., Kıvrak H., Cengiz Seval G., Yüksel S., Civriz Bozdağ S., Koçak Toprak S., Topçuoğlu P., Arslan Ö., Bektaş M., İlhan O., et al.  
48. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 05 November 2022, pp.165-166
- XVII. **AKUT MİYELOİD LÖSEMİ HASTALARINDA FLT3 VE NPM1 MUTASYONLARININ KÜTLE SPEKTROMETRİSİYLE BELİRLENMİŞ METABOLİT ŞABLONLARLA İLİŞKİSİ**  
Gerekçi Yeşilyurt S., Koyun D., Özcan M., Koçak Toprak S., Özen C.  
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 November 2022, pp.167-168
- XVIII. **The Impact of CD34+Cell and Immefector Cell Dose on Transplant Outcomes**  
Koyun D., Cengiz Seval G., Bozdağ S. C., Toprak S. K., Topçuoğlu P., Özcan M., Arslan Ö., Demirel T., İlhan O., Gurman G., et al.  
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, vol.140, pp.12673-12674
- XIX. **Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib**  
Zinzani P. L., ÖZCAN M., Capra M., Santoro A., Panayiotidis P., Bouabdallah K., Jurczak W., Phelps C., Hiemeyer F. J. R., Soler L. M., et al.  
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, pp.6470-6473
- XX. **Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data**  
Ferhanoglu B., Gulbas Z., Uzay A., ÖZCAN M., ÖZKALEMKAŞ F., Dal M. S., Kalyon H., Akay O. M., Devci B., Bekoz H., et al.  
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, vol.140, pp.6704-6705
- XXI. **Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study**  
Sehn L. H., Hertzberg M., Opat S., Herrera A. F., Assouline S., Flowers C. R., Kim T. M., McMillan A. K., ÖZCAN M., Safar V., et al.  
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, pp.9464-9467
- XXII. **Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis**  
Yılmaz H., Cengiz Seval G., Karakaya B., Yavuz G., Aydoğan M., Bozdağ S. C., Toprak S. K., Yüksel M. K., Topçuoğlu P., Arslan Ö., et al.  
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of

America, 10 - 13 December 2022, vol.140, pp.4369-4370

- XXIII. **Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study**  
Advani R. H., Avigdor A., Sureda A., Lavie D., Hohaus S., Zaucha J. M., Vu Minh Hua V. M. H., Zilioli V. R., Gazitua R., ÖZCAN M., et al.  
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, pp.1759-1760
- XXIV. **MUTATION PROFILING BY TARGETTED NGS PANELS ARE USEFUL FOR EITHER DIFFERENTIAL DIAGNOSIS OF IG SECRETING B CELL LYMPHOMAS BUT ALSO HELPFUL FOR GUIDING THE TREATMENT**  
Gahramanlı Z., Kıvrak H., Yüksel S., Koyun D., Toprak S. K., Özcan M., Kuzu I.  
21st Meeting of the European association for Haematopathology, Florence, Italy, 17 - 22 September 2022, pp.159
- XXV. **Relaps/Refrakter Mikozis Fungoides ve Sezary Sendromu Vakalarında Brentiksumab Vedotin'in Etkinliği: Tek Merkez Deneyimi**  
CENGİZ SEVAL G., ŞANLI H., GÜNDÜZ K., CİVRİZ BOZDAĞ S., AKAY B. N., YILDIZHAN İ., ÖZCAN M., TOPRAK S. K.  
30. Ulusal Dermatoloji Kongresi, Girne, Cyprus (Kktc), 18 - 22 October 2022
- XXVI. **Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable**  
CENGİZ SEVAL G., KUZU I., Yüksel S., YILMAZ H., Yavuz G., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.  
19th International Myeloma Society Annual Meeting, 25 August 2022
- XXVII. **Ibrutinib As A Promising Treatment For Waldenström Macroglobulinemia**  
İLHAN O., CENGİZ SEVAL G., AVCU F., Ferhanoglu B., ÖZCAN M., ÇETİN G., KURTOĞLU E., YILMAZ H., ATALAY F., GÜLTÜRK E., et al.  
HemaSphere 2022, United States Of America, 05 June 2022
- XXVIII. **The efficacy and safety of second allogeneic hematopoietic stem cell transplantation**  
TOPRAK S. K., KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
2022 ASCO Annual Meeting, United States Of America, 01 June 2022
- XXIX. **Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).**  
Wang M., Jurczak W., Jerkeman M., Trotman J., Zinzani P. L., Walewski J. A., Zhu J., Spurgeon S., Goy A., Hamlin P. A., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022
- XXX. **The Effects of Plerixafor on Hemostatic System in Patients Undergoing Stem Cell Mobilization**  
KOÇ Ö., DOĞAN Ö., ŞAHİN U., KIRCALI E., KOYUN D., ÖZCAN M.  
Tandem Meetings ASTCT and CIBMTR, United States Of America, 23 April 2022
- XXXI. **Response And Vaccination Status Or Lack Of Immunoparesis Are Associated With Better Outcome Following Covid-19 Infection Among Patients Diagnosed With Multiple Myeloma: A Single Center Experience On 110 Patients**  
CENGİZ SEVAL G., KIRCALI E., KOYUN D., KARAKAYA B., YILMAZ H., AKBULUT H., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
3rd European Myeloma Network Meeting Virtual, United States Of America, 06 April 2022
- XXXII. **Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience**  
İLHAN O., YAVUZ G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), United States Of America, 19 - 22 March 2022
- XXXIII. **Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome**



KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., BEKSAÇ M., et al.

48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), United States Of America, 19 - 22 March 2022

**XXXIV. OKHN SONRASI İLK 12 AYDA NÜKSÜ BELİRLEMEDE GIMEMA VE CIBMTR SKORLAMA YAKLAŞIMLARININ BAĞIMSIZ HASTA GRUBUNDA VALİDASYONU**

Beksaç M., Cengiz Seval G., Koyun D., Yilmaz H., Karakaya B., Akbulut H., Aydoğan M., Özcan M., Gürman G., İlhan O. 14. Ulusal Kemik İliği Transplantasyonu ve Hücresele Tedaviler Kongresi, Antalya, Turkey, 10 - 12 March 2022, no.165, pp.82-83

**XXXV. İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ**

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., YAVUZ G., KARAKAYA B., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

14. Ulusal kemik iliği Transplantasyonu ve Hücresele Tedaviler Kongresi, 10 March 2022

**XXXVI. GRAFT VERSUS HOST HASTALIĞI PROFİLAKSİSİNDE ATG VE POST CY KULLANIMININ NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ**

Karakaya B., ŞAHİN Y. İ., MAMMADLI H., YAVUZ G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

14. Ulusal kemik iliği Transplantasyonu ve Hücresele Tedaviler Kongresi, 10 March 2022

**XXXVII. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI NÜKS ETMİŞ AML HASTALARINDA HİPOMETİLE EDİCİ İLAÇLARLA KOMBİNE VENETOKLAX TEDAVİSİ**

ÖZTÜRK C., URAL A. U., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., GÜRMAN G., İLHAN O., et al.

14. Ulusal kemik iliği Transplantasyonu ve Hücresele Tedaviler Kongresi, 10 March 2022

**XXXVIII. THE OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN LYPHOMA**

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.

63TH ASH CONGRESS, ATLANTA, United States Of America, 8 - 11 December 2021

**XXXIX. CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)**

Zinzani P. L., Capra M., ÖZCAN M., Lv F., Li W., Yañez E., Sapunarova K., Lin T., Jin J., Jurczak W., et al. EHA 2021, 12 December 2021

**XL. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma**

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.

63rd ASH Annual Meeting and Exposition, 11 December 2021

**XLI. Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma**

Zinzani, P. L., Thieblemont C., Melnichenko V., Bouabdallah K., Waleswski J., Majlis A., Fogliatto L., Garcia-Sancho A. M., Christian B., Gulbas Z., et al.

Ash Annual Meeting 2021, ATLANTA, United States Of America, 11 December 2021

**XLII. KAZANILMIŞ FAKTÖR 8 VE 9 İNHİBİTÖRÜ OLAN HASTALARDA İMMUNSUPRESİF TEDAVİ ETKİNLİK VE GÜVENİLİRLİĞİ**

Koyun D., Cengiz Seval G., Yazgan S. C., Civriz Bozdağ S., Özcan M., Topçuoğlu P.

47. Ulusal Hematoloji Kongresi, Antalya, Turkey, 4 - 07 November 2021, no.256, pp.221-222

**XLIII. NÜKS VEYA DİRENÇLİ HODGKİN DIŞI LENFOMADA RİTUXİMAB, LENALİDOMİD, İBRUTİNİB BİRLİKTE KULLANIM ETKİNLİK VE GÜVENİLİRLİĞİ**

Koyun D., Şahin U., Gökmen A., Özcan M.

47. Ulusal Hematoloji Kongresi, Antalya, Turkey, 4 - 07 November 2021, vol.14, no.227, pp.170-171

**XLIV. PRİMER AMİLOİDOZ TEDAVİSİNE ANTİ-CD38 MONOKLONAL ANTİKOR İLAVESİYLE EN AZ OTOLOG**

## NAKİLE EŞ DEĞER YANITLAR ALINABİLİR

Yılmaz H., Cengiz Seval G., Karakaya B., Kırçalı E., Koyun D., Yüksel M., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Özcan M., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Turkey, 4 - 07 November 2021, pp.224

### XLV. HODGKİN LENFOMA TANILI HASTALARDA EKSTRANODAL TUTULUM VE YENİ TEDAVİLER

Yavuz Ermiş G., Yılmaz H., Özütemiz S., Selvi N., Öztürk C., Kırçalı E., Koyun D., Karakaya B., Cengiz Seval G., Civriz Bozdağ S., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Turkey, 4 - 07 November 2021, pp.346-347

### XLVI. T/B LENFOLASTİK LENFOMA TANILI HASTALARIN YENİ TEDAVİLER İŞİĞİNDE RETROSPEKTİF DEĞERLENDİRİLMESİ

Karakaya B., Akbulut H., Öztürk C., Koyun D., Kırçalı E., Yılmaz H., Yavuz Ermiş G., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Turkey, 4 - 07 November 2021, pp.178-179

### XLVII. AKUT PROMİYELOSİTİK LÖSEMİ TANILI HASTALARIN KLİNİK ÖZELLİKLERİ VE TEDAVİ SONUÇLARI: TEK MERKEZ DENEYİMİ

Yavuz Ermiş G., Yılmaz H., Özütemiz S., Selvi N., Öztürk C., Kırçalı E., Karakaya B., Koyun D., Cengiz Seval G., Civriz Bozdağ S., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Turkey, 4 - 07 November 2021, pp.202-204

### XLVIII. PROFİLAKTİK DEFİBROTİD SOS DIŞINDA AKUT GRAFT VS HOST HASTALIĞINDA DA ETKİN

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., YAVUZ G., KARAKAYA B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

47. Ulusal Hematoloji Kongresi, 04 November 2021

### XLIX. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study

Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski, R., Johnson N. A., Oliveira J. S. R. d., Buccheri V., Perini G. F., Dickinson M., et al.

2021 Blood Meeting, Adelaide, Australia, 19 September 2021

### L. Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial

ÖZCAN M., JİN J., Szomor Á., Panayiotis P., Yoon D. H., Tyczyńska A., Soler L. M., Cao A., Hiemeyer F., Childs B. H., et al.

ESMO 2021, 16 September 2021

### LI. Molecular Alterations Obtained by High Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targetted Therapies

KUZU I., SEVAL G. C., YÜKSEL S., Kaygusuz G., DALVA K., ÖZCAN M., BEKSAÇ M.

Multiple myelom AMP kongre 2021, 30 April - 01 May 2021

### LII. RELAPS/ REFRAKTER HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: TEK MERKEZ DENEYİMİ

Koyun D., Şahin U., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., Arslan Ö., Demirel T., Beksaç M., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Antalya, Turkey, 2 - 03 April 2021, no.52, pp.104-105

### LIII. Solid Organ Nakli Ve Allojenik Kök Hücre Nakli Sonrası Gelişen Post-Transplant Lenfoproliferatif Hastalık- Tek Merkez Deneyimi

Öztürk C., KIRCALI E., KOYUN D., YILMAZ H., YAVUZ G., KARAKAYA B., TOPRAK S. K., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 2 - 03 April 2021

### LIV. MULTİPL MİYELOMDA OTOLOG PRİFERİK KÖK HÜCRE NAKLİ SONRASI ERKEN NÜKSÜ BELİRLEMEDE CIBMTR, ISS VE R-ISS SKORLAMA SİSTEMLERİNİN KARŞILAŞTIRILMASI

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİREL T.,

İLHAN O., TUNCALI T., et al.

13. Ulusal kemik iliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021

- LVI. **Allojenik Kök Hücre Nakli Hastalarında Peritransplant Metronidazol Kullanımıyla Akut GVHD Riskinin İlişkisi**  
KIRCALI E., SEVAL G. C., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 April 2021
- LVI. **KAN GRUBU UYUŞUMSUZLUĞUNUN HAPLOİDENTİK TRANSPLANT SONUÇLARINA ETKİSİ VE KAN GRUBU DÖNÜŞÜM SÜRECİ**  
GÖKGÖZ M., ŞAHİN U., GÖKMEN A., SOYDAN E., CENGİZ SEVAL G., ARSLAN Ö., ÖZCAN M., TOPÇUOĞLU P.  
13. Ulusal kemik iliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021
- LVII. **ALLOJENİK KÖK HÜCRE NAKLİ HASTALARINDA PERİTRANSPLANT METRONİDAZOL KULLANIMIYLA AKUT GVHD RİSKİNİN İLİŞKİ**  
KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
13. Ulusal kemik iliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021
- LVIII. **PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION**  
KIRCALI E., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., BEKSAÇ M.  
8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.38, pp.50
- LIX. **THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION**  
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., KARAKAYA B., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., et al.  
8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.38, no.71, pp.1-81
- LX. **PRIMARY GASTRIC NK/T CELL LYMPHOMA WITH T CELL PHENOTYPE: A RARE EBV RELATED LOCALLY INVOLVED AGGRESSIVE LYMPHOMA CASE.**  
KOYUN D., YÜKSEL S., CENGİZ SEVAL G., KUZU I., ÖZCAN M., CİVRİZ BOZDAĞ S.  
8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.28, pp.60-61
- LXI. **Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis**  
AKBULUT D., YÜKSEL S., KIRCALI E., AKTAŞ B. Y., KAYGUSUZ G., Sağlam A., SÖYLEMEZOĞLU A. F., ÜNER A., ÖZCAN M., TÜRKER F. A., et al.  
UNITED STATES CANADIAN ACADEMY OF PATHOLOGY 110th ANNUAL MEETING, 05 March 2021, vol.34, pp.796-797
- LXII. **The impact of pretransplant immunomodulatory drugs on cmv reactivation**  
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., KARAKAYA B., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., et al.  
8th International congress on leukemia lymphoma myeloma, 2021, 21 May 2021
- LXIII. **Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University**  
SEVAL G. C., BOZDAĞ S., TOPRAK S. K., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., TUNCALI T., et al.  
Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 08 February 2021
- LXIV. **Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients**  
KIRCALI E., SEVAL G. C., ÖZTÜRK C., BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 8 - 12 February 2021
- LXV. **Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our**

**Retrospective Bendamustine Combination Experience with Melflufen As Single Agent**

KIRCALI E., CENGİZ SEVAL G., ÇOLAK S., GÜNDÜZ M., ATACA ATILLA P., ATILLA E., ÖZEN M., ÖZCAN M., BEKSAÇ M.  
62nd ASH Annual Meeting and Exposition, 05 December 2020

- LXVI. **Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study**  
ÖZCAN M., Ramchandren R., Zinzani P. L., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., Oliveira J. S., Buccheri V., Perini G. F., et al.  
62th ASH Meeting, Turkey, 5 December - 08 February 2020, vol.136, pp.19-20
- LXVII. **MYELOPROLİFERATİF NEOPLAZİDE PEG-IFN- $\alpha$ -2A ETKİNLİK VE GÜVENİLİRLİĞİ: TEK MERKEZ RETROSPEKTİF GERÇEK YAŞAM ÇALIŞMASI**  
Koyun D., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Arslan Ö., İlhan O., Beksaç M., Özcan M.  
46. Ulusal Hematoloji Kongresi , Antalya, Turkey, 28 - 31 October 2020, no.197, pp.112
- LXVIII. **FOLİKÜLER LENFOMADA BAZAL PET' TE TOPLAM METABOLİK TÜMÖR HACMİ VE TOPLAM LEZYON GLİKOLİZİNİN PROGNOSTİK ÖNEMİ**  
Kırcalı E., Cengiz Seval G., Araz M., Uslu A., Öztürk C., Koyun D., Yılmaz H., Özkan E., Toprak S. K., Yüksel M., et al.  
46. Ulusal Hematoloji Kongresi, Antalya, Turkey, 28 - 31 October 2020, no.278, pp.105
- LXIX. **GRAFT VS HOST HASTALIĞINDA ALFA- 1 ANTİTRİPSİN DENEYİMİMİZ**  
Koyun D., Cengiz Seval G., Kırcalı E., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Özcan M., Arslan Ö., Demirer T., Beksaç M., et al.  
46. Ulusal Hematoloji Kongresi , Antalya, Turkey, 28 - 31 October 2020, no.283, pp.117-118
- LXX. **R/ R MULTİPL MYELOM HASTALARINDA BENDAMUSTİN ETKİSİNİN GERİYE YÖNELİK DEĞERLENDİRİLMESİ VE MELFLUFENLE KIYASI**  
CENGİZ SEVAL G., ÖZCAN M., BEKSAÇ M., ATILLA E., ATACA ATILLA P.  
42.Ulusal Hematoloji Kongresi, Turkey, 28 - 30 October 2020
- LXXI. **AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİDİR**  
CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., DALVA K., GÜRMAN G., et al.  
42.Ulusal Hematoloji Kongresi, Turkey, 28 - 30 October 2020
- LXXII. **Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)**  
Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., de Oliveira J. S. R., Buccheri V., Perini G. F., Dickinson M., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- LXXIII. **The Influence Of Anti-Thymocyte Globulin (Atg) On The Outcomes Of Patients With Aml W/Wo Measurable Residual Disease (Mrd) At The Time Of Unrelated Donor Transplantation**  
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., KIRCALI E., BALTACI M. A., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020
- LXXIV. **Treatment Of Thrombocytopenia After Allogeneic Stem Cell Transplantationwith Eltrombopag**  
KIRCALI E., CENGİZ SEVAL G., KOYUN D., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020
- LXXV. **Role Of Chimerism And Flow-Cytometric Monitoring Of Measurable Residualdisease (Mrd) After Allogeneic Hematopoietic Stem Cell Transplantation (Allohsct) In Predicting Relapse In Acute Myeloid Leukemia (AML)**  
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M.,

DEMİRER T., İLHAN O., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020

- LXXVI. Flamsa-Based High-Dose Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Stem Cell Transplantation (Allo-Hsct): Is It Effective in Patients With Primary Refractory Or Relapsed Acute Leukemia?**

CENGİZ SEVAL G., EKİN K., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020

- LXXVII. Rapid drug desensitization with rituximab in 24 cases: A single-center experience**

PÜR L., SOYUER O., ÖZTÜRK A. B., BAVBEK S.

EAACI Meeting 2020, 6 - 08 June 2020, vol.75, pp.5-99

- LXXVIII. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies**

KUZU I., CENGİZ SEVAL G., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, Milan, Italy, 11 May - 13 February 2020, vol.22, pp.35

- LXXIX. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm**

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kircali E., Öztürk C., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Arslan Ö., et al.

ASCO 2020, 29 May - 02 June 2020, vol.38, no.15

- LXXX. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies**

KUZU I., CENGİZ SEVAL G., YÜKSEL M., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, 11 - 13 May 2020

- LXXXI. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in epatients with myeloproliferative neoplasm.**

Ozcan M., Koyun D., Seval G. C., Uslu A., Kircali E., Ozturk C., Bozdag S. C., Toprak S. K., Topcuoglu P., Arslan O., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38

- LXXXII. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.**

Demirer T., Seval G. C., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Gurman G., Ilhan O., Beksac M., Ozcan M.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38

- LXXXIII. Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.**

Toprak S. K., Seval G. C., Atilla E., Bozdag S. C., Yuksel M., Topcuoglu P., Akay B. N., Sanli H., Gurman G., Ozcan M.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38

- LXXXIV. HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM**

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., GÜRMAN G., İLHAN O., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Turkey, 5 - 07 March 2020

- LXXXV. CD34 VE İMMUNEFKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ**

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., USLU A., DALVA K., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Turkey, 5 - 07 March 2020

- LXXXVI. AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ**

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., GÜRMAN G., YÜKSEL M.

12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Turkey, 5 - 07 March 2020

LXXXVII. **YÜKSEK DOZ MELFALAN SONRASI YANIT DERİNLİĞİ ARTIŞI NÖTROPENİ DERİNLİĞİ İLEDEĞİL AMA TROMBOSİTOPENİ DERİNLİĞİ İLE İLŞKİLİ**

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., GÜRMAN G., İLHAN O., YÜKSEL M.

12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Turkey, 5 - 07 March 2020

LXXXVIII. **CD34+ VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ**

Koyun D., Cengiz Seval G., Dalva K., Uslu A., Öztürk C., Kırçalı E., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Arslan Ö., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Muğla, Turkey, 5 - 07 March 2020, no.159, pp.60-61

LXXXIX. **Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**

CENGİZ SEVAL G., ÖZTÜRK N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2020, 19 - 23 February 2020

XC. **Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow**

CENGİZ SEVAL G., USLU A., KIRCALI E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, 19 - 23 February 2020

XCI. **Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?**

KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

61st ASH Annual Meeting and Exposition, 7 - 10 December 2019

XCII. **RELAPS VE REFRAKTER HODGKİN LENFOMADA BRENTUXİMAB VEDOTİN UZUN DÖNEM SONUÇLARI: ÇOKMERKEZLİ GERÇEK YAŞAM DENEYİMİ**

ÖZBALAK M. M., SALİHOĞLU A., SOYSAL T., karadoğan i., PAYDAŞ S., ÖZDEMİR E., yıldız b., KARADURMUŞ N., KAYNAR L., yağcı m., et al.

45. Ulusal Hematoloji Kongresi, Antalya, Turkey, 30 October - 02 November 2019, pp.159-160

XCIII. **Relaps/Refrakter Hodgkin Lenfomada Nivolumab: Çok Merkezli Türkiye Deneyimi Uzun Dönem Sonuçları**

BEKÖZ H. S., ÖZBALAK M. M., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., TOPTAŞ T., TUĞLULAR A. T., ALTUNTAŞ F., kızıl çakar m., SÖNMEZ M., et al.

45. Ulusal Hematoloji Kongresi, Antalya, Turkey, 30 October - 02 November 2019

XCIV. **Relaps ve Refrakter Hodgkin Lenfomada Brentuximab Vedotin Uzun Dönem Sonuçları: Çok Merkezli Gerçek Yaşam Deneyimi**

ÖZBALAK M. M., Salihoğlu A., SOYSAL T., Karadogan İ., PAYDAŞ S., Özdemir E., Yıldız B., KARADURMUŞ N., KAYNAR L., YAĞCI A. M., et al.

45. Ulusal Hematoloji Kongresi, Turkey, 30 October - 02 November 2019

XCV. **Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?**

Kırçalı E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

XCVI. **Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R-2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with**

**Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-**

**Related Quality of Life (HRQoL) Analysis of the International Robust Study**

Chiappella A., Witzig T. E., Cocks K., Greenwood M., Williams A., Scott D. W., Gascoyne R. D., Yamamoto K., Jurczak W., ÖZCAN M., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**XCVII. Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs**

CENGİZ SEVAL G., KUZU I., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., BEKSAÇ M.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**XCVIII. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**

CENGİZ SEVAL G., Ozturk N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**XCIX. Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma**

Dreyling M., Panayiotidis P., Follows G. A., Mollica L., Nagler A., ÖZCAN M., Santoro A., Stevens D., Trevarthen D., Hiemeyer F., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**C. Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study**

Sehn L. H., Matasar M. J., Flowers C. R., Kamdar M., McMillan A. K., Hertzberg M., Assouline S., Kim T. M., Kim W. S., ÖZCAN M., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**CI. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data**

CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., Yuksel M. K., TOPÇUOĞLU P., KUZU I., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**CII. YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ**

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., Aral D., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019

**CIII. NGS TUM SECENEKLERİ TUKETMİŞ NUKS VE DİRENCLİ MMHASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADAREHBERLİK EDEBİLİR Mİ?**

CENGİZ SEVAL G., KUZU I., YÜKSEL S., DALVA K., ÖZCAN M., BEKSAÇ M.

45. Ulusal Hematoloji Kongresi, Turkey, 31 October - 02 November 2019

**CIV. HANGİSİ, ORJİNAL İMATİNİB Mİ JENERİK Mİ KRONİK MYELOİD LÖSEMİDE DAHA ETKİN?**

KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

45. Ulusal Hematoloji Kongresi, 31 October 2019

**CV. KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL'DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?**

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., Aral D., CİVRİZ BOZDAĞ S., YÜKSEL M.,

TOPÇUOĞLU P., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019

- CVI. **Nivolumab for relapsed or refractory Hodgkin lymphoma: long term results of multi-center experience in Turkey**  
FERHANOĞLU A. B., BEKÖZ H. S., ÖZBALAK M. M., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., TOPTAŞ T., TUĞLULAR A. T., ALTUNTAŞ F., Kızıl Çakar M., et al.  
6th Aegean Hematology Oncology Symposium, 3 - 06 October 2019
- CVII. **Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation**  
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.  
17th International Myeloma Workshop, 12 - 15 September 2019
- CVIII. **Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased OS in myeloma patients after ASCT?**  
YÜKSEL M., CENGİZ SEVAL G., Uslu A., Kircili E., KOYUN D., Ozturk C., Ozdemir Z. N., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.  
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.505-506
- CIX. **Is mobilization with chemotherapy effect response in the multiple myeloma?**  
CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., Akan H., et al.  
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.500
- CX. **Phase 1/2a LYM1002 study of ibrutinib (ibr) plus nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder status**  
Hodkinson B., Schaffer M., Brody J., Jurczak W., Carpio C., Ben-Yehuda D., Avivi I., Saleem R., ÖZCAN M., Alvarez J., et al.  
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, United States Of America, 29 March - 03 April 2019, vol.79
- CXI. **Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions**  
İLHAN O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.382
- CXII. **Results of a single center experience: An attempt to augment conditioning regimen in first autologous stem cell transplantation**  
CENGİZ SEVAL G., KOYUN D., Kircali E., TOPRAK S. K., ÖZCAN M., BEKSAÇ M.  
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.500-501
- CXIII. **Can Nelarabine Rescue The Graft After Allogeneic Hematopoietic Stem Cell Transplantation In T-ALL ?**  
YÜKSEL M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., BEKSAÇ M., et al.  
24 Congress of the European Hematology Association, 13 - 16 June 2019
- CXIV. **Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Long-Term Results of Multi-Center Experience in Turkey.**  
FERHANOĞLU A. B., ÖZBALAK M. M., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., TUĞLULAR A. T., TOPTAŞ T., SÖNMEZ M., GÜLBAŞ Z., et al.  
The 24th Congress of European Hematology Association, Amsterdam, Netherlands, 13 - 16 June 2019
- CXV. **Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Real-Life Experience.**  
FERHANOĞLU A. B., ÖZBALAK M. M., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., TOPTAŞ T.,



TUĞLULAR A. T., SÖNMEZ M., Gülbaş Z., et al.

EHA24, 24th International Congress of European Hematology Association, Amsterdam, Netherlands, 13 - 16 June 2019

- CXVI. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?**  
Cengiz Seval G., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Gürman G., Demirer T., İlhan O., Akan H., et al.  
7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.45
- CXVII. CAN THE DRUGS USED BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) HAVE IMPACT ON CMV REACTIVATION THAT RESULTS IN DECREASED OS IN MYELOMA PATIENTS AFTER ASCT?**  
Yüksel M., Cengiz Seval G., Uslu A., Kırçalı E., Koyun D., Öztürk C., Çınar G., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., et al.  
7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.59
- CXVIII. IS AGE AN IMPORTANT FACTOR FOR AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH NONHODGKIN LYMPHOMA?**  
Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Gürman G., Demirer T., et al.  
7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.47-48
- CXIX. HAPLOIDENTICAL STEM CELL TRANSPLANTATION MAY BE A GOOD ALTERNATIVE AS SALVAGE TREATMENT FOR HEAVILY PRETREATED PATIENTS WITH LEUKEMIA**  
Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Gürman G., Demirer T., et al.  
7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.56-57
- CXX. SUCCESSFUL TREATMENT OF GRAFT FAILURE WITH SECOND ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT CONDITIONING REGIMEN**  
Cengiz Seval G., Uslu A., Öztürk C., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Gürman G., Demirer T., et al.  
8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.75
- CXXI. COMPARISON OF AUTOLOGOUS CONDITIONING REGIMENS AMONG LYMPHOMA PATIENTS**  
Gokgöz Z., Uğur Bilgin A., Arslan Ö., Özcan M., İlhan O.  
7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.52
- CXXII. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER**  
Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Gürman G., Demirer T., et al.  
7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.37
- CXXIII. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?**  
İlhan O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- CXXIV. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.**  
DEMİRER T., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., AKAN H., İLHAN O., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- CXXV. RETROSPECTIVE ANALYSIS OF 149 UNSELECTED PATIENTSWITH MANTLE CELL LYMPHOMA CONFIRMS PROGNOSTICRELEVANCE OF MIPI: SINGLE CENTER EXPERIENCE**

SEVAL G. C., ULAŞ B. B., bolat b., Taşçı O., karatepe f., KUZU I., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019

**CXXVI. retrospective analysis of 149 unselected patients with mantle cell lymphoma confirms prognostic relevance of mipi: single center experience**

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.

ICLLM 2019, 02 May 2019

**CXXVII. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?**

SEVAL G. C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019

**CXXVIII. Nodüler Lenfosit Baskın Hodgkin Lymphoma (NLBHL)'da Kombine İnflamasyon İndeksinin Prognostik Önemi**

PAYDAŞ S., ÇAKAR M. K., BARIŞTA İ., SEYDAOĞLU G., PEHLİVAN M., DOĞAN M., ALTUNTAŞ F., CİVRİZ BOZDAĞ S., ÜNAL A., YILDIZ B., et al.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019

**CXXIX. CAN ELTROMBOPAG TREAT THE THROMBOCYTOPENIA AFTER STEM CELL TRANSPLANTATION**

Yüksel M., Kırçalı E., Cengiz Seval G., Koyun D., Uslu A., Öztürk C., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Beksaç M., et al.

7th International Congress on Leukemia Lymphoma, İstanbul, Turkey, 2 - 04 May 2019

**CXXX. MULTİPLE MYELOM HASTALARINDA OTOLOG PERİFERİK KÖK HÜCRE NAKLİ ESNASINDA GELİŞEN NÖTROPENİK ATEŞ**

Uslu A., Cengiz Seval G., Öztürk C., Narlı Özdemir Z., Kırçalı E., Koyun D., Topçuoğlu P., Toprak S. K., Civriz Bozdağ S., İlhan O., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Antalya, Turkey, 1 - 02 March 2019, no.142, pp.130

**CXXXI. Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimimiz**

Kırçalı E., Cengiz Seval G., Koyun D., Civriz Bozdağ S., Topçuoğlu P., Özcan M., Beksaç M., İlhan O., Arslan Ö., Gürman G., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Antalya, Turkey, 1 - 03 March 2019

**CXXXII. Posttransplant Lenfositöz Önemli Bir Parametre midir?**

CENGİZ SEVAL G., USLU A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., AKAN H., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019

**CXXXIII. Akut Miyeloid Lösemide Nakil Öncesi Minimal Kalıntı Hastalık Diğer Risk Faktörlerinden Daha Önemli midir**

NARLI ÖZDEMİR Z., ŞAHİN U., BALTACI M. A., USLU A., ÖZTÜRK C., CENGİZ SEVAL G., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019

**CXXXIV. Miyelom Hastalarında Ohkhn Öncesi Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi?**

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 1 - 03 March 2019

**CXXXV. Multipl Miyelom Olgularında Ototolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları**

Cengiz Seval G., Koyun D., Kırçalı E., Şahin U., Toprak S. K., Özcan M., Beksaç M.

11. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Antalya, Turkey, 1 - 03 March 2019

**CXXXVI. Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür**

## **Sağlayabilir mi?**

CENGİZ SEVAL G., KIRCALI E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., AKAN H., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019

### **CXXXVII. Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmede Kimerizm İle Mrd Karşılaştırılması**

CENGİZ SEVAL G., ULAŞ B. B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019

### **CXXXVIII. İyi Riskli Aml'de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi**

PEKCAN G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019

### **CXXXIX. T-All Hastalarında Allojeneik Hematopoietik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi?**

CENGİZ SEVAL G., USLU A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019

### **CXL. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?**

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019

### **CXLI. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)**

CENGİZ SEVAL G., Atilla E., Ulas B., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, United States Of America, 13 - 24 February 2019, vol.25

### **CXLII. Does Level of Vitamin D Prior to Allogeneic Stem Cell Transplantation Affect the Transplant Outcomes?**

Soydan E., Gokmen A., Gokgoz Z., Sen S., Ozkumur K. O., Okcu M. K., ARSLAN Ö., ÖZCAN M.

Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, United States Of America, 13 - 24 February 2019, vol.25

### **CXLIII. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTEMYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER**

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019

### **CXLIV. MİYELOM HASTALARINDA OHKHN ÖNCESİ KULLANILAN İLAÇLARIN CMV REAKTİVASYONU ÜZERİNE SAĞKALIMIAZALTICI ETKİSİ OLABİLİR Mİ?**

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019

### **CXLV. İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi**

AKKUŞ E., FİDAN Ç., KUŞTAŞ A. A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Turkey, 5 - 07 April 2018, vol.16, pp.44

**CXLVI. PEMBROLIZUMAB İN PATIENTS WITH RELAPSED OR REFRACTORY PMBCL DATA FROM THE KEYNOTE-013 AND KEYTONE-170 STUDIES**

ÖZCAN M.

ASH 2018, 4 - 08 December 2018

**CXLVII. Comparison of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience**

TOPÇUOĞLU P., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

60th ASH Annual Meeting, san diego, United States Of America, 29 November - 05 December 2018, vol.132, pp.4673

**CXLVIII. Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience**

CENGİZ SEVAL G., Ulas B., TAŞCI O., Ozel F., Bulat B., KUZU I., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132

**CXLIX. Evaluation of Elderly Patients with Hematological Malignancies By Two Different Geriatric Risk Scoring Systems: G8 and Flemish Version of the Triage Risk Screening Tool (fTRST)**

Atilla E., Yalciner M., Kilic O., Muftuoglu N., Atilla P. A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ÖZCAN M., GÜRMAN G., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132

**CL. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience**

GÜRMAN G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132

**CLI. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients**

Atilla E., TOPÇUOĞLU P., AKKUŞ E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ÖZCAN M., BEKSAÇ M., İLHAN O., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132

**CLII. Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies**

Armand P., Rodig S. J., Melnichenko V., Thieblemont C., Bouabdallah K., Tumyan G., ÖZCAN M., Portino S., Fogliatto L., Caballero D., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132

**CLIII. Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma**

Dreyling M., Santoro A., Mollica L., Leppa S., Follows G. A., Lenz G., Kim W. S., Nagler A., Panayiotidis P., Demeter J., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132

**CLIV. Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoietic Stem Cell Transplantation?**

İLHAN O., CENGİZ SEVAL G., ÖZKURT Z. N., Ural A. U., Ayli M., Sevindik O. G., CİVRİZ BOZDAĞ S., YÜKSEL M., Gulbas

Z., ÖZCAN M.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132

- CLV. **Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study**  
Sehn L. H., Herrera A. F., Matasar M. J., Kamdar M., Assouline S., Hertzberg M., Kim T. M., Kim W., McMillan A., ÖZCAN M., et al.  
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132
- CLVI. **BLASTİK PLAZMASİTOİD DENDRİTİK HÜCRELİ NEOPLAZİ: NADİR GÖRÜLEN BİR HEMATOLOJİK MALİGNİTEDE TEK MERKEZ DENEYİMİ**  
NARLI ÖZDEMİR Z., CENGİZ SEVAL G., USLU A., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., KUZU I., ÖZCAN M., GÜRMAN G., et al.  
44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October 2018
- CLVII. **Akut Miyeloid Lösemide Nakil Öncesi ve Nakil Sonrası +28. Gün Değerlendirilen Minimal Kalıntı Hastalığın Hastalık Seyrine Etkisi**  
DALVA K., NARLI ÖZDEMİR Z., ŞAHİN U., USLU A., MURADOVA B., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.  
44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October - 03 November 2018, pp.245-246
- CLVIII. **ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ**  
KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., TOPÇUOĞLU P., GÜRMAN G., et al.  
44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018
- CLIX. **ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ**  
KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., TOPÇUOĞLU P., GÜRMAN G., et al.  
44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018
- CLX. **AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNUN NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ**  
CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., et al.  
44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018
- CLXI. **Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients**  
CENGİZ SEVAL G., GÖREN ŞAHİN D., SOYDAN E., ÖZÇELİK E. T., GÖKMEN A., GÖKGÖZ Z., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., ARAT M.  
2018 Society of Hematologic Oncology (SOHO) Annual Conference, 12 - 15 September 2018
- CLXII. **Is post-transplant albumin a predictor of early transplant complications?**  
TOPÇUOĞLU P., CENGİZ SEVAL G., AKKUŞ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., Akan H., et al.  
44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.344-345
- CLXIII. **BCNU-EAM vs non-BCNU alternative alkylator -EAM conditioning regimens for autologous stem cell transplantation in lymphoma patients**  
Sahin D. G., Cengiz G. S., Soydan E., Ozcelik E. T., Gokmen A., Gokgoz Z., TOPÇUOĞLU P., ARSLAN Ö., GÜRMAN G., ÖZCAN M., et al.  
44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.256-257
- CLXIV. **Haploidentical transplantation does not have survival advantage over unrelated donor**

**transplantation in haematological diseases**

Soydan E., Gokmen A., Gokgoz Z., İLHAN O., ARSLAN Ö., ÖZCAN M.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.747

- CLXV. **Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen**  
Ilhan O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Topcuoglu P., Arslan O., Ozcan M., Demirer T., et al.  
44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.272-273
- CLXVI. **Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation with Different Doses of Antithymocyte Globulin Containing Conditioning in Hematological Malignancies**  
Gokgoz Z., Soydan E., Gokmen A., ARSLAN Ö., İLHAN O., ÖZCAN M.  
44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.284-285
- CLXVII. **Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma**  
CENGİZ SEVAL G., Serteselen E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., Aslan O., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.  
44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.338
- CLXVIII. **The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4 (+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect**  
YÜKSEL M., Ozdemir Z. N., Sahin U., ÇAĞDAŞ AYVAZ D. N., Atikcan D. T., Serteselen E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., Aslan O., et al.  
44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.533-534
- CLXIX. **Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation**  
Uslu A., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., GÜRMAN G., Demirer T., Arslan O., Ozcan M., TOPRAK S. K., Topcuoglu P., Ilhan O.  
44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.161-162
- CLXX. **adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbc result of a phase 2 clinical trial**  
ÖZCAN M.  
23TH EHA, 11 - 15 June 2018
- CLXXI. **Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience**  
Cengiz Seval G., BULAT B., Ozel F., Tasci O., Kuzu I., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.  
ASCO Annual Meeting 2018, 1 - 05 June 2018, vol.36, pp.19525
- CLXXII. **Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy**  
NARLI ÖZDEMİR Z., SEVAL G. C., USLU A., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., KUZU I., ÖZCAN M., GÜRMAN G., et al.  
5th Aegean Hematology Oncology Symposium, Greece, 20 - 23 March 2018
- CLXXIII. **Akciğer Yerleşimli Ekstranodal Marjinal Zon Lenfoma Olgusu**  
yıldız c., eroğlu z., özcan a., CANBAKAN S., DEMİRRAĞ F., ÖZCAN M.  
ASYOD UASK 2018, Antalya, Turkey, 14 - 18 March 2018
- CLXXIV. **Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu**

- ŞAHİN U., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., ÖZEN M., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., et al.  
10. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018
- CLXXV. **ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR**  
GÜNDÜZ M., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., AKAN H., et al.  
10. ULUSAL KEMİK İLİĞİTRANSPLANTASYONU VEHÜCRESEL TEDAVİLER KONGRESİ, Antalya, Turkey, 1 - 03 March 2018
- CLXXVI. **ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASI AKUT MYELOİD LÖSEMİ NÜKSÜNÜN YÖNETİMİ VE PROGNOZU**  
ŞAHİN U., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., ÖZEN M., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., et al.  
10. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018, pp.126-127
- CLXXVII. **AKUT GRAFT VERSUS HOST HASTALIĞI KLİNİK SONUÇLARI: TEK MERKEZ DENEYİMİ**  
NARLI ÖZDEMİR Z., CENGİZ SEVAL G., USLU A., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
10. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Antalya, Turkey, 01 March 2018
- CLXXVIII. **Ph Negatif ALL'de 1. Tam Remisyonda Yapılan Pekiştirme Tedavileri Nakil Sonrası Başarıyı Arttırır**  
NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., AKAN H., İLHAN O., et al.  
10. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018
- CLXXIX. **Retrospective Analysis Learn Conditioning for Autologous Stem Cell Transplantation**  
Soydan E., Gokmen A., Gokgoz Z., İLHAN O., ARSLAN Ö., ÖZCAN M.  
Blood and Marrow Transplantation Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, United States Of America, 21 - 25 February 2018, vol.24
- CLXXX. **Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma**  
İLHAN O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., et al.  
Blood and Marrow Transplantation Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, United States Of America, 21 - 25 February 2018, vol.24
- CLXXXI. **MYELOFİBROZİSTE ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONUÇLARI: TEK MERKEZ DENEYİMİ**  
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., GÜRMAN G., İLHAN O., AKAN H., et al.  
10. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 01 March 2018
- CLXXXII. **KEMOTERAPİ İLE MOBİLİZASYON MULTİPL MİYELOMDA YANITLARI ETKİLİYOR MU?**  
CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., AKAN H., et al.  
10. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 01 March 2018
- CLXXXIII. **ITK Gen Defektine Bağlı CD4+ T Hücre Yetmezliği Olan Erişkinde Allojeneik Hematopoietik Kök Hücre Naklinin Sonuçları**  
YÜKSEL M., NARLI ÖZDEMİR Z., ŞAHİN U., CENGİZ SEVAL G., ÇAĞDAŞ AYVAZ D., ATIKCAN D. T., SERTESEN E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.  
10. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Antalya, Turkey, 01 March 2018, pp.138
- CLXXXIV. **Real-world data in relapsed refractory myelopoma patients treated with carfilzomib, a multicenter Turkish experience**

- SEVİNDİK Ö. G., PEHLİVAN M., TUĞLULAR A. T., solmaz ş. m., DOĞU M. H., YALNIZ F. F., URAL A. U., yeğen z. s., ARAT M., ÖZKOCAMAN V., et al.  
AMERİKAN HEMATOLOJİ DERNEĞİ KONGRESİ, United States Of America, 9 - 12 December 2017, vol.130, pp.5405
- CLXXXV. **REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH CARFILZOMIB, A MULTICENTER TURKISH EXPERIENCE**  
SEVİNDİK Ö. G., PEHLİVAN M., TUĞLULAR A. T., SOLMAZ Ş. M., DOĞU M. H., YALNIZ F. F., URAL A. U., YEĞEN Z. S., ARAT M., ÖZKOCAMAN V., et al.  
American Society of Hematology Congress, Atlanta, United States Of America, 9 - 12 December 2017, vol.130, pp.5405
- CLXXXVI. **PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities**  
dreyling m., santoro a., mollica l., leppa s., fallows g., lenz g., kim w. s., nagler a., panayiotidis p., demeter j., et al.  
ASH, 6 - 14 December 2017
- CLXXXVII. **Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia**  
YOUNES A., BRODY J., CECİLİA C., LOPEZ A., YEHUDA D. B., FERHANOĞLU A. B., NAGLER A., ÖZCAN M., ALBEREDA F. B., MASOOD A., et al.  
ASH 2017, 6 - 14 December 2017
- :LXXXVIII. **MS12 Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study**  
SEHN L., HERRERA A. F., MATASAR M. J., KAMDAR M., MCMİLLAN A., KİM T. M., KİM W. S., HERTZBERG M., ÖZCAN M., PENUEL E., et al.  
ASH 2017, 6 - 14 December 2017
- CLXXXIX. **Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1**  
DREYLİNG M., PANAYİOTİDİS P., MİKLOS E., GEORGE F., MİLLOCA L., NAGLER A., ÖZCAN M., SANTORO A., İSHİDA T., LU C., et al.  
ASH 2017, 6 - 14 December 2017
- CXC. **Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience**  
Ferhanoglu A. B., ÖZBALAK M. M., SALİHOĞLU A., Soysal T., Karadogan I., Paydas S., Ozdemir E., Yildiz B., Karadurmus N., Kaynar L., et al.  
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130
- CXCI. **Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma**  
Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., Topcuoglu P., Ozel F., CİVRİZ BOZDAĞ S., YÜKSEL M., Arslan O., Ozcan M., Demirer T., et al.  
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130
- CXCII. **Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma**  
Atilla E., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., Akan H., Arslan O., Demirer T., Beksac M., Ilhan O., et al.  
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130
- CXCIII. **NÜKS/REFRAKTER HODGKİN LENFOMA VAKALARINDA BRENTUXİMAB VEDOTİN'İN UZUN DÖNEM SONUÇLARI:ÇOK MERKEZLİ TÜRKİYE DENEYİMİ**  
FERHANOĞLU A. B., salihoglu a., ÖZBALAK M., SOYSAL T., KARADOĞAN İ., PAYDAŞ S., ÖZDEMİR E., YILDIZ B., KARADURMUŞ N., KAYNAR L., et al.



43. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 1 - 04 November 2017
- CXCIV. **NÜKS VEYA REFRAKTER HODGKİN LENFOMAHASTALARINDA NİVOLUMAB KULLANIMI TÜRKİYE VERİLERİ**  
FERHANOĞLU A. B., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., TOPTAŞ T., TUĞLULAR A. T., SÖNMEZ M., Gülbaş Z., Tekgündüz E., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017
- CXCV. **Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler**  
Aydın T., MERTER M., ŞAHİN U., Pekcan G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.53
- CXCVI. **Kronik Myeloproliferatif Neoplazilerde Kalretikulin (CALR) mutasyonu**  
Öztekin Ş., ÖCAL E., Boyacıgil Ş., ÖZCAN M., BEKSAÇ M., ARSLAN Ö., TOPÇUOĞLU P., koçak toprak s., GÜRMAN G., KUZU I.  
Ulusal Hematoloji Kongresi, Turkey, 31 October - 04 November 2017
- CXCVII. **OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ?**  
MERTER M., Güleç B., Özcan G., Zehra Özdemir Z., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., ÖZCAN M., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.220
- CXCVIII. **İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi**  
AKKUŞ E., KUŞTAŞ A. A., Pekcan G., MERTER M., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.98-99
- CXCIX. **Nüks veya Refrakter Hodgkin Lenfoma Hastalarında Nivolumab Kullanımı Türkiye Verileri**  
FERHANOĞLU B., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER A., TOPTAŞ T., TUĞLULAR A. T., SÖNMEZ M., GÜLBAŞ Z., TEKGÜNDÜZ E., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017
- CC. **Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation**  
MERTER M., Köken K., YÜKSEL M., Demir E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France, 26 - 29 March 2017, vol.52, pp.141-142
- CCI. **peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma:A single center experience**  
seval G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., AKAN H., et al.  
ebmt 2017, 26 - 29 March 2017
- CCII. **The outcome of haploidentical stem cell transplantation**  
ATILLA E., bilgiç e., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., ÖZCAN M., GÜRMAN G.  
ebmt 2017, 22 - 25 June 2017
- CCIII. **ALLOGENEİC HEMATOPOİETİC STEM CELL TRANSPLANTATION IN ADVANCED AGE ADULTS:İS İT POSSİBLE TO TRANSPLANT SAFELY?**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., AKAN H., GÜRMAN G., ÖZCAN M., BEKSAÇ M., ARSLAN Ö., et al.  
ebmt2017, 26 - 29 March 2017
- CCIV. **Nivolumab for Relapsed or refractory Hodgkin Lymphoma: Exprience in Turkey**  
FERHANOĞLU A. B., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., GÜLBAŞ Z., TÜRKER A., TOPTAŞ T., TEKGÜNDÜZ E., KAYA A., TAŞDEMİR N., et al.

22nd Congress of the European Hematology Association, 22 - 25 June 2017

- CCV. **Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: A Single Center Experience**  
TOPRAK S. K., ATILLA E., ATACA ATILLA P., CIVRIZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., ARAT M., et al.  
Experience 22nd Congress of the European Hematology Association, 22 June - 25 May 2017
- CCVI. **Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantation for acute myeloid leukemia**  
GÜRMAN G., AYDEMİR GÜLOKSUZ G., ATILLA E., ATACA ATILLA P., CIVRIZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., et al.  
leukemia 53rd Annual Meeting, 2 - 06 June 2017
- CCVII. **Allojeneik stem cell transplantation results in our myelodysplastic syndrome (MDS) patients**  
GÜRMAN G., ATACA ATILLA P., AYDIN T., ATILLA E., CIVRIZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., DEMİRER T., et al.  
patients 53rd Annual Meeting Jun 2-6, 2017, 2 - 06 June 2017
- CCVIII. **REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH CARFILZOMIB, A MULTICENTER EXPERIENCE**  
SEVİNDİK Ö. G., SOLMAZ Ş. M., PEHLİVAN M., KABUKLU S. H., YALNIZ F. F., ÖZKOCAMAN V., ARAT M., TURGUT M., ÖZCAN M., ARSLAN Ö., et al.  
6. INTERNATIONAL CONGRESS OF LEUKEMIA LYMPHOMA MYELOMA, Antalya, Turkey, 11 - 13 May 2017
- CCIX. **REAL-WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH CARFILZOMIB, A MULTICENTER TURKISH EXPERIENCE**  
SEVİNDİK Ö. G., SOLMAZ Ş., PEHLİVAN M., KAVUKÇU S., YALNIZ F. F., ÖZKOCAMAN V., ARAT M., TURGUT M., ÖZCAN M., ÖZSAN G. H., et al.  
6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 May 2017
- CCX. **A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be**  
PEKCAN G., YÜKSEL M., ŞAHİN U., CIVRIZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
6th International Congress on Leukemia Lymphoma Myeloma, Antalya, Turkey, 11 - 13 May 2017, pp.112
- CCXI. **Real-world data in relapsed refractory myeloma patients with carfilzomib, a multicenter Turkish experience**  
SEVİNDİK Ö. G., medeni solmaz ş., PEHLİVAN M., HACIOĞLU S., YALNIZ F. F., ÖZKOCAMAN V., ARAT M., TURGUT M., ÖZCAN M., ARSLAN Ö., et al.  
6th International Congress on Leukemia-Lymphoma-Myeloma, 11 - 13 May 2017
- CCXII. **Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization**  
MERTER M., KÖKEN K., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CIVRIZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 May 2017
- CCXIII. **Intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) as salvage in patients with AML relapsing after hematopoietic stem cell transplantation.**  
Gokmen A., Soydan E., Gokgoz Z., Ozkumur K. O., Arslan O., Ilhan O., Ozcan M.  
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- CCXIV. **A single center experience with two decades of follow-up on patients with hairy cell leukemia.**  
İLHAN O., Atilla E., Atilla P. A., CIVRIZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., et al.  
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- CCXV. **Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.**  
GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CIVRIZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., Topcuoglu P., Ozcan

M., Arslan O., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35

- CCXVI. **Herpes SimplexVirus infection in patients after allogeneic hematopoetic stem cell transplantation**  
ATİLLA E., ÖZEL F., YILMAZ V., ATACA ATİLLA P., ATEŞAĞAOĞLU B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., et al.  
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CCXVII. **Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease**  
MERTER M., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
43rdAnnual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017
- CCXVIII. **Peripheral blood stem cell mobilization and collection from elderly patients (265 years) with multiple myeloma: A single center experience**  
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., AKAN H., et al.  
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 March 2017
- CCXIX. **Large Unsaturated Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation**  
MERTER M., KÖKEN K., YÜKSEL M., DEMİR N., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017
- CCXX. **Peripheral Blood Stem Cell Mobilization and collection from elderly patients 65 years with multipl myeloma: A , single center exprience**  
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., ÖZCAN M., GÜRMAN G., BEKSAÇ M., et al.  
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CCXXI. **Acute GVHD and untreated/haploidentical Trnasplants increses the incidence of hemorrhagic cystitis in Allo- HSCT Recipients**  
TOPÇUOĞLU P., ATİLLA E., ATACA ATİLLA P., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., DEMİRER T., ARSLAN Ö., ÖZCAN M., et al.  
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CCXXII. **The outcome of Haploidentical Hematopoietic Celll Trnasplantations (Haplo HSCT)**  
ATİLLA E., ECE B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., ÖZCAN M., GÜRMAN G.  
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CCXXIII. **Allogeneic Hematopoetic Stem Cell Trnasplantation (Allo-HSCT) in advanced age adults:Is it possible to transplant safely?**  
ATİLLA E., BAŞ Ö., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., AKAN H., GÜRMAN G., ÖZCAN M., TOPÇUOĞLU P., et al.  
43rd Annual Meeting Of EBMT, 26 - 29 March 2017
- CCXXIV. **Allogeneic stem cell transplantation for chonic lymphocytic Leukemai**  
ATİLLA E., ATACA ATİLLA P., pekcan g., İLHAN O., GÜRMAN G., ÖZCAN M., ARSLAN Ö.  
BMT TANDEM MEETINGS, 22 - 26 February 2017
- CCXXV. **Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients**  
GÜRMAN G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
BMT Tandem Meetings, 22 - 26 February 2017
- CCXXVI. **Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL)**  
ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., BEKSAÇ M., İLHAN O., GÜRMAN G., et al.

BMT Tandem Meetings, 22 - 26 February 2017

- CCXXVII. **Does Hypogammaglobulinemia at Diagosis Effects Survival and Infection Risk in Chronic Lymphocytic Leukemia (CLL)?**  
Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., İLHAN O., ÖZCAN M., ARSLAN Ö.  
58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 3 - 06 December 2016, vol.128
- CCXXVIII. **Comparison of Reduced Intensity Conditioning (RIC) Regimen and Myeloablative Conditioning (MAC) Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Adult Patients with Acute Leukemia**  
GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 3 - 06 December 2016, vol.128
- CCXXIX. **Akut Myeloid Lösemide Flow Sitometriile İndüksiyon Sonrası Tespit Edilen CD34 Hücre Sayısı Sağlık ve Relapsı Etkileri**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., BEKSAÇ M., ÖZCAN M., İLHAN O., AKAN H., et al.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016
- CCXXX. **Akut Lenfositik Lösemide ALL Santral Sinir Sistemi SSS Tutulumuna Yaklaşım**  
ATACA ATILLA P., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., BEKSAÇ M., İLHAN O., GÜRMAN G., et al.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016
- CCXXXI. **ALLOJENEİK KÖK HÜCRE NAKLİ OLAN AKUT LÖSEMİLERDE HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASI**  
GÜLÖKSÜZ G. A., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXXXII. **Allojeneik Kök Hücre Nakli Olan Akut Lösemilerde Hazırlık Rejimlerinin Karşılaştırılması**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016
- CCXXXIII. **Seyrek bir Malignite Primer Mediastinal Büyük B**  
ATACA ATILLA P., ATILLA E., CENGİZ SEVAL G., PEKCAN G., İLHAN O., ARSLAN Ö., GÜRMAN G., ÖZCAN M.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016
- CCXXXIV. **ALLOJENEİK KÖK HÜCRE NAKLİ HASTALARIMIZDAGELİŞEN KATATER TROMBOZLARI**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., TOPRAK S. K., YÜKSEL M., YALÇINER M., SEVAL CENGİZ G., ARSLAN Ö., ÖZCAN M., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXXXV. **PERİFERİK T HÜCRELİ LENFOMALARDA OTOLOGHEMATOPOETİK KÖK HÜCRE TRANSPLANTASYONU TEK MERKEZ DENEYİMİ**  
ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXXXVI. **AKUT LENFOSİTİK LÖSEMİDE ALL SANTRAL SİNİR SİSTEMİ SSS TUTULUMUNA YAKLAŞIM**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., İLHAN O., GÜRMAN G., ÖZCAN M.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXXXVII. **Allojeneik Kök Hücre Nakli Hastalarımızda Gelişen Katater Trombozları**  
ATILLA E., YALÇINER M., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016

- :CXXXVIII. **KRONİK LENFOSİTİK LÖSEMİ DE TANI ANINDA HİPOGAMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR**  
ATACA ATILLA P., ATILLA E., PEKCAN G., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., İLHAN O., ÖZCAN M., ARSLAN Ö., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXXXIX. **ALLOJENEİK KÖK HÜCRE NAKİL ÖNCESİ FAZLA KİLOLU OBEZ OLMANIN SAĞKALIM VE NÜKS İLE İLİŞKİSİ**  
ATILLA E., ATACA ATILLA P., CEYLAN A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., ARSLAN Ö., et al.  
42. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 19 - 22 October 2016
- CCXL. **ANTİ HLA ANTİKOR VARLIĞININ ALLOJENEİK KÖKHÜCRE NAKLİ YAPILAN HASTALARDA ENGRAFMAN ÜZERİNE ETKİSİ TEK MERKEZ DENEYİMİ**  
MERTER M., AYDOĞAN M., TEKEŞ M. A., ŞAHİN U., AYYILDIZ Ö. M., KOCABAY H. E., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXLI. **MYELODİPLASTİK SENDROM HASTALARININ OGATA SKORLAMASI İLE FLOW SİTOMETRİK OLARAK DEĞERLENDİRİLMESİ**  
ATILLA E., ATACA ATILLA P., TÜREDİ Ö., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., ARSLAN Ö., ÖZCAN M., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXLII. **Kronik Lenfositik Lösemi de Tanı Anında Hipogamaglobulinemi Sağkalım ve Enfeksiyon Riski Üzerinde Etkili Midir**  
ATILLA E., ATACA ATILLA P., TOPRAK S. K., AKAN H., BEKSAÇ M., İLHAN O., ÖZCAN M., ARSLAN Ö., GÜRMAN G., TOPÇUOĞLU P.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016
- CCXLIII. **AKUT MYELOİD LÖSEMİDE FLOW SİTOMETRİ İLE İNDÜKSİYON SONRASI TESPİT EDİLEN CD34 HÜCRE SAYISI SAĞKALIM VE RELAPSI ETKİLER**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., TOPRAK S. K., ARSLAN Ö., BEKSAÇ M., ÖZCAN M., İLHAN O., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXLIV. **Myelodisplastik Sendrom Hastalarının Ogata Skorlaması ile Flow Sitometrik Olarak Değerlendirilmesi**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., BEKSAÇ M., ARSLAN Ö., TOPÇUOĞLU P., ÖZCAN M., İLHAN O., et al.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016
- CCXLV. **PRİMER MYELOFİBROZİS TE ALLOJENEİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ**  
CENGİZ G. S., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., İLHAN O., ÖZCAN M.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXLVI. **ALLOJENEİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA PERİTRANSPLANT ALBUMİN DÜŞÜŞÜ İLE GVHD İLİŞKİSİ**  
MERTER M., ŞAH F. T., ŞAHİN U., YALÇINER M., KOCABAY H. E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., TOPRAK S. K., ARSLAN Ö., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CCXLVII. **TROMBOTİK MİKROANJİOPATİDE TERAPÖTİK PLAZMA DEĞİŞİMİ**  
ATILLA E., ATACA ATILLA P., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., ARSLAN Ö., DEMİRER T., AKAN H., BEKSAÇ M., et al.  
42. Ulusal Hematoloji, Turkey, 19 - 22 October 2016
- CCXLVIII. **SEYREK BİR MALİGNİTE: PRİMER MEDİASTİNAL BÜYÜK B HÜCRELİ LENFOMA**  
ATACA ATILLA P., ATILLA E., CENGİZ SEVAL G., PEKCAN G., İLHAN O., ARSLAN Ö., GÜRMAN G., ÖZCAN M.  
42. Ulusal Hematoloji Kongresi, Turkey, 18 - 22 October 2016
- CCXLIX. **BEING OVERWEIGHT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IS RELATED TO BETTER SURVIVAL**

ATILLA E., ATACA ATILLA P., CIVRIZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., ARSLAN Ö., İLHAN O., ÖZCAN M., et al.

JSH 2016, 13 - 15 October 2016

- CCL. **MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM CNS INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA ALL PRE AND POST TRANSPLANT** Conference 21st Congress of the European Hematology Association Location Copenhagen DENMARK  
ATACA ATILLA P., ATILLA E., CIVRIZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., BEKSAÇ M., İLHAN O., GÜRMAN G., et al.  
21st Congress of the European-Hematology-Association Location: Copenhagen, DENMARK, 9 - 12 June 2016, vol.101
- CCLI. **Extracorporeal Photopheresis Safe and Effective for the Treatment of Mycosis Fungoides**  
ATILLA E., ATACA ATILLA P., CIVRIZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., AKAY B. N., ŞANLI H., TOPÇUOĞLU P., ÖZCAN M., GÜRMAN G., et al.  
EHA 2016, 9 - 12 June 2016
- CCLII. **Approach to Hairy Cell Leukemia HCL 31 years of Experience**  
KIRCALI E., ATACA ATILLA P., ATILLA E., CIVRIZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., DEMİRER T., et al.  
EHA 2016, 9 - 12 June 2016
- CCLIII. **MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRE AND POST TRANSPLANT**  
ATACA ATILLA P., ATILLA E., CIVRIZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., AKAN H., BEKSAÇ M., İLHAN O., GÜRMAN G., et al.  
EHA 2016, 9 - 12 June 2016
- CCLIV. **Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma** ASCO Annual Meeting J Clin Oncol 34 2016 suppl abstr e 19001  
İLHAN O., ATILLA E., ATACA ATILLA P., CIVRIZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
ASCO, 3 - 07 June 2016
- CCLV. **Age is not a Significant Factor in Decision of Doing Autologous Stem Cell Transplantation in Fit Patients with Myeloma and Lymphoma!**  
ATILLA E., ATACA ATILLA P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., GÜRMAN G., İLHAN O.  
ASCO 2016, 3 - 07 June 2016
- CCLVI. **Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma Subcategory**  
İLHAN O., ATILLA E., ATACA ATILLA P., CIVRIZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
ASCO 2016, ABD, 3 - 07 June 2016
- CCLVII. **THE EFFICACY OF TYROSINE KINASE INHIBITORS WITH STEROID IN Ph ACUTE LYMPHOBLASTIC LEUKEMIA**  
GÜRMAN G., MERTER M., ATILLA E., ŞAHİN U., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O.  
ASCO 2016, ABD, 3 - 07 June 2016
- CCLVIII. **9 THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS SINGLE CENTER EXPERIENCE**  
MERTER M., ŞAHİN U., gündüz m., NARLI ÖZDEMİR Z., CIVRIZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., et al.  
24th Biennial International Congress on Thrombosis / EMLTD Congress Location: Istanbul, 4 - 07 May 2016
- CCLIX. **Are Age and JAK2V617F Mutation Related to Trombosis in Chronic Myeloproliferative Diseases**  
ATILLA E., ATACA ATILLA P., TOPRAK S. K., KAYGUSUZ G., KUZU I., CIVRIZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., et al.  
24th Biennial International Congress on Thrombosis, 4 - 07 May 2016

- CCLX. A rare manifestation: Primary mediastinal large-b cell lymphoma.**  
Atilla E, Ataca P, İLHAN O, ARSLAN Ö, GÜRMAN G, ÖZCAN M.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- CCLXI. Successful treatment in primary central nervous system lymphoma.**  
Atilla E, Ataca P, TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., İLHAN O, GÜRMAN G, ÖZCAN M.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- CCLXII. The efficacy of tyrosine kinase inhibitors with steroid in phi- acute lymphoblastic leukemia.**  
GÜRMAN G, Merter M, Atilla E, Sahin U, TOPÇUOĞLU P., ARSLAN Ö, ÖZCAN M., İLHAN O.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- CCLXIII. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.**  
Ilhan O, Atilla E, Ataca P, CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Topcuoglu P., Arslan O, Ozcan M., Demirer T., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- CCLXIV. PRACTICAL APPROACH IN DIFFERENTIAL DIAGNOSIS WITH INTERACTIVE DISCUSSION OF REPRESENTATIVE CASES**  
ÖZCAN M.  
UPTADES IN WHO LYMPHOMA CLASSIFICATION:2008-2016 PRACTICAL DIAGNOSTIC APPROACH WITH CLINICAL ASPECTS, 16 - 17 April 2016
- CCLXV. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma**  
İLHAN O, ATILLA E, ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., ARSLAN Ö, ÖZCAN M., DEMİRER T., et al.  
ASCO, 3 - 07 June 2016
- CCLXVI. 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation**  
TOPÇUOĞLU P., ATILLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., BEKSAÇ M., ÖZCAN M., GÜRMAN G.  
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 3 - 06 April 2016
- CCLXVII. Successful treatment in primary central nervous system lymphoma**  
ATILLA E., ATACA ATILLA P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., İLHAN O., GÜRMAN G., ÖZCAN M.  
ASCO, 3 - 07 June 2016
- CCLXVIII. prognosis of acute leukemia patients in active disease undergoing allogeneic hematopoietic stem cell transplantation**  
ŞAHİN U., MERTER M., ateşoğlu b., erdal h., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M.  
41.ebmt meeting, 22 - 25 March 2015
- CCLXIX. PAROKSİSMAL NOKTÜRNAL HEMOGLOBİNÜRİHASTALARINDA ALLOJENEİK HEMATOPOETİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ**  
NARLI ÖZDEMİR Z., TOPRAK S. K., TOPÇUOĞLU P., ŞAHİN U., GÜNDÜZ M., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., et al.  
9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016
- CCLXX. AKTİF HASTALIKLI AKUT LÖSEMİDE ATG VEHAZIRLIK REJİMİ İLE ALLOJENİK NAKİL SONRASICMV REAKTİVASYONUNUN PROGNOZA ETKİSİ**  
GÜNDÜZ M., ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., et al.  
9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016
- CCLXXI. HAİRY CELL LÖSEMİ HCL VAKALARIMIZ TEKMERKEZ DENEYİMİ**  
Kırcalı E., ATACA P., ATILLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O.,

- DEMİRER T., et al.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CCLXXII. **Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides** 5 8 December 2015 ASH Annual Meeting Abstracts Blood 2015 126 5062 published ahead of print December 5 2015  
ATILLA E., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., KURT YÜKSEL M., AKAY B. N., ŞANLI H., TOPÇUOĞLU P., ÖZCAN M., GÜRMAN G., et al.  
57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL, USA, 5 - 08 December 2015
- CCLXXIII. **The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph Acute Lymphoblastic Leukemia**  
GÜRMAN G., MERTER M., ATACA P., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., İLHAN O., ATILLA E.  
The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph+ Acute Lymphoblastic Leukemia, 5 - 07 December 2014
- CCLXXIV. **Clinical Allogeneic Transplantation Acute and Chronic GVHD Immune Reconstitution**  
GÜRMAN G., ATACA P., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., AKAN H., ARSLAN Ö., TOPÇUOĞLU P., et al.  
57th ASH Annual Meeting & Exposition, 5 - 08 December 2015
- CCLXXV. **Upper and Lower Respiratory Tract Infections By Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)**  
Atilla E., Ataca P., ŞAHİN EROĞLU D., TOPÇUOĞLU P., DOLAPÇI G. İ., TEKELİ F. A., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., ÖZCAN M., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CCLXXVI. **Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients**  
GÜRMAN G., Ataca P., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., Akan H., ARSLAN Ö., TOPÇUOĞLU P., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CCLXXVII. **Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides**  
Atilla E., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., AKAY B. N., ŞANLI H., TOPÇUOĞLU P., ÖZCAN M., GÜRMAN G., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- :CLXXVIII. **Seroprevalence for Toxoplasma Gondii in Allogeneic Hematopoietic Stem Cell Transplantation Recipients**  
Atilla E., Ataca P., BALLI S., Isikoglu B., TOPÇUOĞLU P., ÖZCAN M., Akan H.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CCLXXIX. **First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)**  
O'Connor O. A., ÖZCAN M., Jacobsen E. D., Vidal J. M. R., Trotman J., Demeter J., Masszi T., Pereira J., Ramchandren R., d'Amore F. A., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CCLXXX. **Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?**  
Atilla E., Ataca P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., BEKSAÇ M., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126



- CCLXXXI. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation**  
Merter M., Atilla E., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CCLXXXII. Allojeneik Hematopoietik Kök Hücre Nakli AHKHN Hastalarında Gelişen Üst ve Alt Solunum Yolları Viral Enfeksiyonları**  
ATİLLA E., ATACA P., ŞAHİN D., DOLAPÇI G. İ., TEKELİ F. A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
Febril Nötropeni Simpozyumu, Turkey, 28 - 30 November 2015
- CLXXXIII. Hairy Cell Lösemi HCL vakalarımız Tek Merkez Deneyimi**  
KIRCALI E., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., AKAN H., et al.  
41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CLXXXIV. Ph Negatif ALL Hastalarında Allojenik Kök Hücre Nakli Öncesi Tedavilerin Klinik Seyir ile İlişkisi**  
NARLI ÖZDEMİR Z., EKİN K., ATACA P., ATİLLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., BEKSAÇ M., İLHAN O., et al.  
41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CCLXXXV. PH NEGATİF ALL HASTALARINDA ALLOJENİK KÖKHÜCRE NAKLİ ÖNCESİ TEDAVİLERİN KLİNİK SEYİRİLE İLİŞKİSİ**  
Özdemir Z. N., Kircalı E., ATACA P., ATİLLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., BEKSAÇ M., İLHAN O., et al.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CLXXXVI. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA ANTİ HLA ANTİKORLARI İLE ENGRAFMAN YETMEZLİĞİ İLİŞKİSİ TEK MERKEZ**  
ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., KAYGUSUZ G., KUZU I., ÖZCAN M., İLHAN O., TOPRAK S. K.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 23 October 2015
- CLXXXVII. ALLOJENEİK KÖK HÜCRE TRANSPLANTASYONHASTASINDA KRONİK GRAFT VERSUS HOSTHASTALIĞININ GENEL SAĞKALIM ÜZERİNE ETKİSİ**  
ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., AKAN H., ARSLAN Ö., TOPÇUOĞLU P., BEKSAÇ M., et al.  
41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- LXXXVIII. WALDENSTRÖM MAKROGLOBULİNEMİSİNDE TEKMERKEZ DENEYİMİ**  
ŞAHİN U., MERTER M., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., BEKSAÇ M., İLHAN O., ARSLAN Ö., ÖZCAN M., et al.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CLXXXIX. MİKOZİS FUNGOİDES TEDAVİSİNDE EKSTRAKORPOREAL FOTOFEREZ ECP**  
ATİLLA E., ATACA P., ŞAHİN D., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ŞANLI H., ÖZCAN M., GÜRMAN G., et al.  
) 41.Ulusal Hematoloji Kongresi, Turkey, 21 - 23 October 2015
- CCXC. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA ANTİ HLA ANTİKORLARI İLE ENGRAFMAN YETMEZLİĞİ İLİŞKİSİ TEK MERKEZ DENEYİMİ**  
MERTER M., ŞAHİN U., Ateşagaoglu b., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 23 October 2015
- CCXCI. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRENAKLİNDE İKİ FARKLI ANTİTİMOSİTGLOBULİN PREMEDİKASYON PROTOKOLÜNÜN KARŞILAŞTIRILMASI**  
MERTER M., ŞAHİN U., Ateşagaoglu B., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

- CCXCII. **MİKOZİS FUNGOİDES TEDAVİSİNDEEKSTRAKORPÖREAL FOTOFEREZ ECP**  
ATİLLA E., ATACA P., ŞAHİN D., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., AKAY B. N., ŞANLI H., ÖZCAN M., GÜRMAN G., et al.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CCXCIII. **MYELODİPLASTİK SENDROMDA MDS ALLOJENEİKHEMATOPOİETİK KÖK HÜCRE NAKLİ**  
ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., GÜRMAN G., TOPÇUOĞLU P.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CCXCIV. **Chronic Myeloproliferative Disease in Geriatric Patients Single Center Experience**  
TOPRAK S. K., ATİLLA E., ATACA P., BEKSAÇ M., konuk n., TOPÇUOĞLU P., ARSLAN Ö., GÜRMAN G., ÖZCAN M., İLHAN O.  
77th Annual Meeting of the Japanese Society of Hematology, 16 - 18 October 2015
- CCXCV. **Is Allogeneic Stem Cell Transplantation Safe in MDS**  
TOPÇUOĞLU P., ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., GÜRMAN G.  
77th Annual Meeting of Japanese Society of Hematology, 16 - 18 October 2015
- CCXCVI. **Allogeneic Stem Cell Transplant Safe in MDS**  
TOPÇUOĞLU P., ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., GÜRMAN G.  
77th Annual Meeting of the Japanese Society of Hematology, October 16-18, 2015, Kanazawa, Japan., 1 - 03 October 2015
- CCXCVII. **Is Allogeneic Stem Cell Transplant Safe in MDS**  
TOPÇUOĞLU P., ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., GÜRMAN G.  
77th Annual Meeting of the Japanese Society of Hematology, Oral Presentation, 16 - 18 October 2015
- CCXCVIII. **Myeloproliferative Disease in Geriatric Patients Single Center Experience**  
TOPRAK S. K., ATİLLA E., ATACA P., BEKSAÇ M., Konuk N., TOPÇUOĞLU P., ARSLAN Ö., GÜRMAN G., ÖZCAN M., İLHAN O.  
77th Annual Meeting of the Japanese Society of Hematology, 16 - 19 October 2015
- CCXCIX. **Autologous Stem Cell Transplantation and Primary Systemic Light Chain AL Amyloidosis**  
TOPRAK S. K., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., AKAN H., et al.  
15th International Myeloma Workshop, Auditorium Parco della Musica, Rome, Italy, September 23-26, 2015., 23 - 26 September 2015
- CCC. **Follow up of del 5 q MDS patients with or without other chromosomal abnormalities**  
TÜREDİ Ö., ATACA P., TUNCALI T., ATİLLA E., VİCDAN N. A., DURMAZ C. D., DALVA K., KUTLAY N., KARABULUT H. G., ILGIN RUHİ H., et al.  
10th European Cytogenetics Conference, 4 - 07 July 2015, pp.102
- CCCI. **posttransplant erythrocytosisin eleven cases**  
TOPRAK S. K., pekcan g., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., GÜRMAN G.  
ehameeting 2015, 11 - 14 June 2015
- CCCII. **Does chronic lymphocytic leukemia occur in younger adults in Turkey**  
PEKCAN G., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., KURT YÜKSEL M., AKAN H., İLHAN O., GÜRMAN G., ÖZCAN M.  
ASCO 2015, 29 May - 02 June 2015
- CCCIII. **CML leukemic stem cell CML LCS Its existence in patients who achieved cytogenetic molecular response under treatment of TKI**  
İLHAN O., USLU A., TOPRAK S. K., TOPÇUOĞLU P., ATİLLA E., ATACA P., ÖZTÜRK A., DALVA K., ARSLAN Ö., ÖZCAN M.  
ASCO 2015, 29 - 02 May 2015
- CCCIV. **Allagenic stemcell transplantation results in our myelodysplastic syndrome MDS patient**  
GÜRMAN G., ATACA P., AYDIN T., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., KURT YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., DEMİRER T.  
ASCO -2015, 29 - 02 May 2015
- CCCV. **Azatitidine in combination with ATRA valproic acid in elderly AML patient**

ÖZCAN M., CİVRİZ BOZDAĞ S., BERNA A., ATİLLA E., ATACA P., TOPRAK S. K., KURT YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O.

ASCO 2015, 29 May - 02 June 2015

- CCCVI. **Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT A Single Center Experience 41st Annual Meeting of the European Society for Blood and**  
MERTER M., uğur ş., gündüz m., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

(Allo-HSCT): A Single Center Experience. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 22-25 Mayıs 2015., 22 - 25 May 2015

- CCCVII. **AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS 60 YEARS WITH MYELOMA OR LYMPHOMA**

ATİLLA E., GÜNDÜZ M., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., MELTEM K. Y., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21 - 23 May 2015

- CCCVIII. **Allogeneic Stem Cell Transplantation for Hodgkin and non Hodgkin Lymphoma**

ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., BEKSAÇ M., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21-23 May 2015. Turkish Society of Hematology, Proceedings & Abstract Book, abstract # 0109, poster # PS-101 pp 175., 21 - 23 May 2015

- CCCIX. **CML leukemic stem cell (CML LSC): Its existence in patients who achieved cytogenetic/molecular response under treatment of TKI.**

İlhan O., Uslu A., TOPRAK S. K., Topcuoglu P., Atilla E., Ataca P., Ozturk A., Dalva K., Arslan O., Ozcan M.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- CCCX. **Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.**

GÜRMAN G., Ataca P., Aydin T., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Topcuoglu P., Ozcan M., Demirer T., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- CCCXI. **Does chronic lymphocytic leukemia occur in younger adults in Turkey?**

Pekcan G., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., Akan H., İLHAN O., GÜRMAN G., ÖZCAN M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- CCCXII. **Azacitidine in combination with ATRA, valproic acid in elderly AML patients.**

ÖZCAN M., CİVRİZ BOZDAĞ S., Atesagaoglu B., Atilla E., Ataca P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., İLHAN O., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- CCCXIII. **allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Single Centre Experienc**

ŞAHİN U., MERTER M., ATİLLA E., TOPÇUOĞLU P., TOPRAK S. K., İLHAN O., YÜKSEL M., ÖZCAN M., CİVRİZ BOZDAĞ S., DALVA K.

BONE MARROW TRANSPLANTATION, 22 - 25 March 2015

- CCCXIV. **Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or Lymphoma**

ATİLLA E., MEHMET G., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

Best of ASBMT Tandem Meetings, Poster Presentation, Turkey, 27 - 28 March 2015

- CCCXV. **DIFFERENT DOSES OF ATG IN THE CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**  
PEKCAN G., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ATEŞ O., ÖZCAN M., DEMİRER T.  
41.EBMT MEETING, 24 - 26 March 2015
- CCCXVI. **ALOGENEİC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SINGLE CENTER EXPERIENCE**  
MERTER M., ŞAHİN U., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M.  
41.EBMT MEETING, 24 - 26 March 2015
- CCCXVII. **Autologus stem cell transplantation in elderly patients with myeloma and lymphoma single center experience**  
GÜNDÜZ M., ATILLA E., ATACA P., PEKCAN G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
41.EBMT KONGRESİ, 24 - 26 March 2015
- CCCXVIII. **THE RELAPSE IN ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION NO APPROACHES HAVE BEEN SUPERIOR YET**  
TOPÇUOĞLU P., GÜNDÜZ M., ÖZEN M., ATILLA E., ATACA P., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
41.EBMT MEETING, 24 - 26 March 2015
- CCCXIX. **EXTRAMEDULLARY RELAPSE OF ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A SINGLE CENTER EXPERIENCE**  
MERTER M., ŞAHİN U., GÜNDÜZ M., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M.  
41.EBMT MEETING, 24 - 26 March 2015
- CCCXX. **impact of pretransplant serum ferritin on outcomes of allogeneic hematopoietic stem cell transplantation for acute leukemia**  
ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O.  
41.ebmt meeting, 22 - 25 March 2015
- CCCXXI. **Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S483**  
UĞUR Ş., MERTER M., ATEŞAĞAOĞLU B., ERDAL H., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015
- CCCXXII. **Different Doses of Anti Thymocyte Globulin ATG in the Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S228**  
GÜLTEKİN P., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015
- CCCXXIII. **Is it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation HSCT using Plasma Exchange PE A Single Center s Experience**  
YÜKSEL M., Gultekin G., Edipoglu E., Bay M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., BEKSAÇ M., et al.  
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 22 - 25 March 2015
- CCCXXIV. **Upper and Lower Respiratory Tract Infections by Respiratory Viruses by Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Single Center Experience**

ŞAHİN D., ATILLA E., CİVRİZ BOZDAĞ S., ATACA P., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

41th EBMT Meeting, 22 - 25 March 2015

- CCCXXV. **Chronic Myeloproliferative Disease in Geriatric Patients**  
TOPRAK S. K., ATILLA E., ATACA P., BEKSAÇ M., konuk n., TOPÇUOĞLU P., ARSLAN Ö., GÜRMAN G., ÖZCAN M.  
77th Annual Meeting of the Japanese Society of Hematology, 16 - 18 October 2015
- CCCXXVI. **Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation**  
TOPÇUOĞLU P., Gunduz M., Ozen M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., Akan H., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CCCXXVII. **Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside**  
Ataca P., TOPRAK S. K., Atilla E., TOPÇUOĞLU P., YÜKSEL M., KAYGUSUZ G., KUZU I., ARSLAN Ö., ÖZCAN M., İLHAN O., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- :CCXXVIII. **Do FMS-like Tyrosine Kinase 3 and Nucleophosmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?**  
Gunduz M., Ataca P., Ozen M., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., DEMİRER T., BEKSAÇ M., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CCCXXIX. **Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center**  
Sahin U., Merter M., Ataca P., Atilla E., Atesagaoglu B., Pekcan G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CCCXXX. **Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy**  
YÜKSEL M., Gokmen A., ÖZCAN M., ARSLAN Ö., İLHAN O., Ozbek D., Kurdal M., Koktas O.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CCCXXXI. **The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model**  
CENGİZ SEVAL G., ÖZKAVUKCU İ. S., SEVAL M. M., Ayli M., ÖZCAN M.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CCCXXXII. **Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Autologous, Non-Purged Peripheral Stem Cell Transplantation for High Risk Neuroblastoma Patients**  
ÜNAL E., TAÇYILDIZ N., Yavuz G., DİNÇASLAN H., Tanyildiz G., Ayyildiz E., ÖZCAN M.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- :CCXXXIII. **Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience**  
Atilla E., Sahin U., Ataca P., Uslu A., Kircali E., Atesagaoglu B., Pekcan G., Merter M., Gunduz M., Ozen M., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- :CCXXXIV. **The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph plus Acute Lymphoblastic Leukemia**  
GÜRMAN G., Merter M., Ataca P., Ozen M., Atesagaoglu B., Gunduz M., Pekcan G., Sahin U., TOPRAK S. K., TOPÇUOĞLU

P., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124

CCCXXXV. **Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients**

TOPÇUOĞLU P., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., Konuk N., Akan H., İLHAN O., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124

CCCXXXVI. **Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?**

İLHAN O., Ataca P., Atilla E., TOPRAK S. K., KAYGUSUZ G., KUZU I., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124

CCCXXXVII. **RİTUKSİMAB'A KARŞI HİPERSENSİTİVİTEGELİŞEN HASTADA ETKİN SEÇENEK: RİTUKSİMABDESENSİTİZASYONU**

ATACA ATILLA P., ATILLA E., Kendir R., BAVBEK S., ÖZCAN M.

40. Ulusal Hematoloji Kongresi, Turkey, 22 - 25 October 2014

CCCXXXVIII. **PRİMER SANTRAL SİNİR SİSTEMİ LENFOMA TEDAVİSİNDE ETKİN SEÇENEK YÜKSEK DOZ METOTREKSAT RİTUKSİMAB VE SİTOZİNARABİNOZİD İN BİRLİKTE KULLANIMI**

ATACA P., ATILLA E., TOPRAK S. K., YÜKSEL M., ÖZCAN M., KONUK N., İLHAN O.

40.Ulusal Hematoloji Kongresi, Turkey, 22 - 24 October 2014

CCCXXXIX. **STEM CELL MOBILIZATION IN ELDERLY MULTIPLE MYELOMA PATIENTS: SINGLE CENTER EXPERIENCE**

TOPRAK S. K., CENGİZ SEVAL G., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., AKAN H., BEKSAÇ M., et al.

19th Congress of the European Hematology Association, 12 June 2014

CCCXL. **Splenectomy-only approach for the first-line treatment of splenic marginal zone lymphoma**

Ozcan M., Sevel G. C., Topcuoglu P., Arslan O., GÜRMAN G., KUZU I.

50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 30 May - 03 June 2014, vol.32

CCCXLI. **Hazırlama rejimi ile ilişkili çok nadir bir komplikasyon Akut Yaygın Damar içi Pıhtılaşması**

YÜKSEL M., gökmen a., tek i., özbek ., kurdal okçu m., köktaş ö., öztürk n., soydan e., ARSLAN Ö., ÖZCAN M., et al.

8.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 6 - 08 March 2014

CCCXLII. **AKRABA DIŞI ALLOJENEİK HEMATOPOETİK HÜCRE NAKLİNDE HLA UYUŞUMUNUN ETKİSİ-TEK MERKEZ DENEYİMİ**

CENGİZ SEVAL G., TOPÇUOĞLU P., ÖZEN M., GÜNDÜZ M., ATILLA E., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

8. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, 06 March 2014

CCCXLIII. **Refrakter Akut Lösemide FLAMSA tedavisinin ardından T hücrelerinden arındırılmamış Haploidentik Allojeneik Kök Hücre Transplantasyonu**

YÜKSEL M., gökmen a., tek i., özbek d., kurdal okçu m., köktaş ö., öztürk n., soydan e., ARSLAN Ö., ÖZCAN M., et al.

8.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 6 - 08 March 2014

CCCXLIV. **Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation**

GÜRMAN G., Atilla E., Ozen M., Kubilay P., Yilmaz G., Gunduz M., ARSLAN Ö., ÖZCAN M., DEMİRER T., Akan H., et al. BMT Tandem Meetings, Texas, United States Of America, 26 February - 02 March 2014, vol.20

CCCXLV. **Chemosensitivity to Induction or High Dose Therapy, Pre/Post Transplant PET Negativity and Absence of Minimal Residual Disease within Mobilized Stem Cell Graft Predict Long Term Disease Free Survival in Multiple Myeloma**

Bakanay S. M., DALVA K., KÖKSOY E. B., Civit D., Ayyildiz E., ÖZCAN M., İLHAN O., BEKSAÇ M.

BMT Tandem Meetings, Texas, United States Of America, 26 February - 02 March 2014, vol.20

CCCXLVI. **Comparison Of Flow Cytometric and Clinical Findings In Patients With Paroxysmal Nocturnal**

## **Hemoglobinuria**

Demirer T., Baslar S., Uysal V. A., Beksac M., Ozen M., Konuk N., Ilhan O., Arslan O., Ozcan M., Topcuoglu P., et al.  
55th Annual Meeting of the American-Society-of-Hematology, Louisiana, United States Of America, 7 - 10 December 2013, vol.122

CCCXLVII. **Hepa systems in hematology clinic to ameliorate the increased fungal infection risk owing to environmental changing.**

GÜRMAN G., Ozen M., Yilmaz G., Coskun B., Topcuoglu P., Ozturk B., Ozcan M., Arslan O., Ilhan O., Beksac M., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

:CCXLVIII. **Comparison of allogeneic stem cell transplantations in chronic myeloid leukemia before and after the era of tyrosine kinase inhibitors.**

Ozcan M., Ozturk B., Ozen M., Topcuoglu P., Arat M., Arslan O., Ilhan O., Akan H., Beksac M., Konuk N., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

CCCXLIX. **Minimal Residual Plasma Cell Content of Autologous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.**

Bakanay S. M., Dalva K., Koksoy B. E., Ayyildiz E., ÖZCAN M., İLHAN O., BEKSAÇ M.  
54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 8 - 11 December 2012, vol.120

CCCL. **HBsAg POZİTİF OLAN ALICILARDA ALLOJENİK HEMATOPOETİK HÜCRE TRANSPLANTASYONU**

TOPÇUOĞLU P., SOYDAN E., İDİLMAN R., CENGİZ SEVAL G., ÜSTÜN C., ARSLAN Ö., ÖZCAN M., KONUK N., İLHAN O., BEKSAÇ M., et al.

35. Ulusal Hematoloji Kongresi, 07 October 2009

CCCLI. **Hematopoetik periferik kök hücre ürünü mikrobiyolojik kontrol verileri Ankara Onkoloji Hastanesi Kemik İliği Nakli ve Hemaferез Ünitesi Deneyimi**

karasu özgür f., YÜKSEL M., kurdal m., kaşkaval b., batı s., dirim e., YENİGÜN A., ŞAHİN BALÇIK Ö., ALBAYRAK M., ÖZCAN M., et al.

4.Ulusal Hemaferез Kongresi, Turkey, 24 - 26 September 2009

CCCLII. **Otolog ve Allogeneik Kök Hücre Aferezi Ankara Onkoloji Hastanesi Deneyimi**

YÜKSEL M., BARIŞ K., ÖZGÜR F., KURDAL M., MURAT A., ŞAHİN BALÇIK Ö., ÖZCAN M., ALTUNTAŞ F.

4.Ulusal Hemaferез Kongresi, Turkey, 24 - 26 September 2009

CCCLIII. **Flow Cytometric Analysis of T Cell Functions in CML Patients Under Imatinib Therapy.**

Sahin D. G., DALVA K., Meric S., GÜRMAN G., ÖZCAN M., ARSLAN Ö., Arat M.

50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2008, vol.112, pp.911

CCCLIV. **Ankara üniversitesi tip fakültesi hastaneleri'xxnde kemoterapi uygulamalarında yer alan hemşirelerde siklofosamid ve metotreksat maruziyet düzeyleri ve kromozom kırıkları ile ilişkilerinin incelenmesi**

Serttaş Matrak M., Türkbey E., Karabulut H., Sürmeli E., Parlak L., KUTLAY N., Erkuşlu D., BURGAZ S., KARAHALİL B., Elmalı E., et al.

10. Ulusal İç Hastalıkları Kongresi, Turkey, 15 - 19 October 2008

CCCLV. **The methylation analysis of DAP kinase gene in imatinib resistant chronic myeloid leukemia**

VAROL N., ÖZKAN T., ÇELİK S., GÜMÜŞ AKAY G., AKÇORA D., RÜSTEMOĞLU A., TAŞPINAR M., BAYDIN P., ÖZTUNA D., İLHAN O., et al.

XX International Congress of Genetics, Berlin, Germany, 12 - 17 July 2008

CCCLVI. **THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR) BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) OUTCOME**

Serbest E., Topcuoglu P., Dalva K., Bilgin A. U., Soydan E. A., Ozcan M., Arslan O., Ilhan O., BEKSAÇ M., GÜRMAN G., et al.

Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, California, United States Of

America, 13 - 17 February 2008, vol.14, pp.111-112

- CCCLVII. **THE RELATION BETWEEN THE FREQUENCY OF PRESENCE OF THROMBOPHILIA AND THROMBOEMBOLIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT)**  
Topcuoglu P., Gunaltay S., Dalva K., Bilgin A. U., Arat M., Ozcan M.  
Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, California, United States Of America, 13 - 17 February 2008, vol.14, pp.111
- CCCLVIII. **Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma**  
BEKSAÇ M., Soydan E., ÖZKOCAMAN V., TOPÇUOĞLU P., Evranos B., Kizil M., Bilgin A. U., Arat M., ÖZCAN M., ARSLAN Ö., et al.  
49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 8 - 11 December 2007, vol.110
- CCCLIX. **Detection of ABL tyrosine kinase domain mutations in Turkish chronic myeloid leukemia CML patients treated with imatinib mesylate**  
AKÇORA D., GÜMÜŞ AKAY G., RÜSTEMOĞLU A., AYDOS O. S., ALTINOK B., SUNGUROĞLU A., ÖZCAN M., BEKSAÇ M., GÜRMAN G.  
European Society of Human Genetics (ESHG) Congress, Nice, France, 16 - 19 June 2007
- CCCLX. **The impact of histopathological subtype of cutaneous chronic GvHD on alloHSCT outcome: lichenoid versus sclerodermoid**  
SOYDAN E., CENGİZ SEVAL G., ŞANLI H., TOPÇUOĞLU P., UĞUR BİLGİN A., BAKANAY ÖZTÜRK Ş. M., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., et al.  
33rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 25 March 2007
- CCCLXI. **The conditioning regimen intensity of allogeneic hematopoietic cell transplantation (Allo-HCT) in chronic myeloid leukemia (CML): The historical case matched comparison of ablative versus reduced intensity regimen**  
GÜRMAN G., Arat M., Topcuoglu P., Caglayan E. A., Arslan O., Ozcan M., Akan H., BEKSAÇ M., Konuk N., Uysal A., et al.  
Tandem BMT Meeting 2007, Colorado, United States Of America, 8 - 12 February 2007, vol.13, pp.81-82
- CCCLXII. **MULTİPL MİYELOMA VE MALİN LENFOMALI HASTALARDA OTOLOG PERİFERİK KÖK HÜCRE TOPLANMASINDA AFEREZ GÜN SAYISI ÖNGÖRÜLEBİLİR Mİ? - ANKARA HESAPLAMA FORMÜLÜ**  
ARAT M., CENGİZ SEVAL G., SOYDAN E., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DALVA K., BEKSAÇ M., et al.  
32. Ulusal Hematoloji Kongresi, 08 November 2006
- CCCLXIII. **Refrakter ve Relaps Akut Myeloblastik Lösemide EMA Kurtarma Rejimi Sonuçlarımız**  
TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., GÜRMAN G., DEMİRER T., AKAN H., KONUK N., UYSAL A., BEKSAÇ M., et al.  
XXXII. Ulusal Hematoloji Kongresi, Turkey, 8 - 10 November 2006
- CCCLXIV. **Follow-up of ADAMTS13 Enzyme and its relationship with clinical events after allogeneic haematopoietic stem cell transplantation**  
CİVRİZ BOZDAĞ S., Gunaltay S., Dalva K., Ozcan M.  
32nd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, Hamburg, Germany, 19 - 22 March 2006, vol.37
- CCCLXV. **The impact of methylenetetrahydrofolate reductase C677T gene polymorphism on engraftment after allogeneic hematopoietic cell transplantation in patients receiving methotrexate in graft versus host disease prophylaxis**  
Arat M., Soydan E., Topcuoglu P., Ozcan M., Arslan O., GÜRMAN G., İlhan O.  
32nd Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, Hawaii, United States Of America, 16 - 20 February 2006, vol.12, pp.5
- CCCLXVI. **A new predictive and prognostic marker for de novo AML: Peripheral blood CD34 (pCD34) count at recovery following remission induction (RI) therapy (Supp. by Ankara university2003-0809114).**



Arat M., Topcuoglu P., YÜKSEL M., Dalva K., Gultekin G., GÜRMAN G., Arslan O., Ozcan M., BEKSAÇ M., Konuk N., et al.  
47th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 10 - 13 December  
2005, vol.106

CCCLXVII. **The impact of methylenetetrahydrofolate reductase C677T gene polymorphism on engraftment after allogeneic hematopoietic cell transplantation.**

Soydan E., Topcuoglu P., Ozcan M., Arslan O., GÜRMAN G., BEKSAÇ M., Arat M., Ilhan O.

47th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 10 - 13 December  
2005, vol.106

:CCLXVIII. **Allogeneic haematopoietic cell transplantation in acute myeloblastic laeukemia: Ibni Sina experience (1989-2004)**

Ilhan O., Topcuoglu P., Arat M., Soydan E., TOPRAK S. K., YÜKSEL M., Ustun C., Celebi H., Dilek I., Arslan O., et al.

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Czech Republic, 20 - 23 March 2005,  
vol.35

CCCLXIX. **The comparison of myeloablative versus reduced intensity conditioning regimen in ABO mismatched allogeneic hematopoietic cell transplantation.**

Topcuoglu P., Arat M., Bolukbasi T., Soydan E., Ozer Y., Ozcan M., Gorman G., Demirer T., Akan H., BEKSAÇ M., et al.

46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December  
2004, vol.104

CCCLXX. **Allogeneic hemapoietic progenitor cell collection using four different cell separators: A retrospective comparative analysis.**

Arat M., Arslan O., Soydan E., Ayyildiz E., Dalva K., Tol M., Ozcan M., GÜRMAN G., Demirer T., Akan H., et al.

46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December  
2004, vol.104

CCCLXXI. **Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.**

TOPRAK S. K., Dalva K., Mizrak D., Arat M., Ozcan M., GÜRMAN G., Ilhan O., BEKSAÇ M.

46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December  
2004, vol.104

CCCLXXII. **190 BCR-ABL ve 210 BCR-ABL Füzyon genlerinin telomeraz aktivitesi ve telomer boyu ile ilişkisi ve hematopoetik hücrelerdeki proliferatif etkileri farklıdır.**

KUTLAY N., ÖZCAN M., TÜKÜN F. A.

XXI. Ulusal Hematoloji Kongresi, Turkey, 23 - 28 September 2004, vol.21, pp.68

:CCLXXIII. **The outcome of patients with an identified HLA identical sibling donor: impact of transplantation rate on early transplant outcome**

Soydan E., Arat M., Bulakbasi T., Topcuoglu P., Arslan O., Ozcan M., GÜRMAN G., BEKSAÇ M., Akan H., Ilhan O.

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, Spain, 28 - 31 March 2004, vol.33

:CCLXXIV. **High-dose thiotepa, melphalan and carboplatin followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - a retrospective evaluation**

Demirer T., Soydan E., Fen T., Ilhan O., Ayli M., Arat M., Ozcan M., Gunel N., Arslan O., Genc Y., et al.

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, Spain, 28 - 31 March 2004, vol.33

CCCLXXV. **The use of low molecular weight heparins (dalteparin) for prophylaxis against thromboembolic complications during allogeneic haematopoietic stem cell transplantation**

Ozcan M., Soydan E., Ustun C., Celebi H., Arslan O., Arat M., GÜRMAN G., Ilhan O., Koc H., Konuk N., et al.

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, Spain, 28 - 31 March 2004, vol.33

:CCLXXVI. **High-dose therapy is given to multiple myeloma patients with similar clinical characteristics to those in conventional chemotherapy and improves survival in multiple myeloma: a retrospective analysis**

**from a single centre**

BEKSAÇ M., Soydan E., Arat M., Topcuoglu P., YÜKSEL M., TOPRAK S. K., Kizil M., Arslan O., Ozcan M., GÜRMAN G., et al.

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, Spain, 28 - 31 March 2004, vol.33

CCLXXVII. **Case-controlled comparative analysis of ablative and reduced-intensity allogeneic haematopoietic stem cell transplantation in standard risk CML**

GÜRMAN G., Arat M., Topcuoglu P., Soydan E., BEKSAÇ M., Ozcan M., Konuk N., Uysal A., Koc H., Arslan O., et al.

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, Spain, 28 - 31 March 2004, vol.33

:CLXXVIII. **Allogeneic Hematopoietic Stem Cell Transplantation in chronic myelogenous leukemia: Comparison of ablative and reduced intensity conditioning regimen.**

GÜRMAN G., Arat M., Topcuoglu P., Soydan E., İlhan O., BEKSAÇ M., Ozcan M., Konuk N., Uysal A., Koc H., et al.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102

:CCLXXIX. **Primer Miyelodysplastik Sendrom Tanısı Alan 86 Hastanın Bournemouth Skorlama Sistemine Göre Retrospektif Analizi Ve Toplam Sağkalımı**

YÜKSEL M., İLHAN O., TOPÇUOĞLU P., soydan e., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., GÜRMAN G., konuk n., uysal a., et al.

XXX. Ulusal Hematoloji Kongresi, Turkey, 10 - 12 October 2003

CCCLXXX. **Multiple Miyelom MM olgularında Kök Hücre Desteğinde Yüksek Doz Kemoterapinin Konvansiyonel Tedavilerle Karşılaştırıldığında Yaşam Süresini Uzattığına Dair Ankara Tıp Fakültesi Hematoloji Bilim Dalı Deneyimi**

BEKSAÇ M., soydan e., ARAT M., TOPÇUOĞLU P., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., GÜRMAN G., İLHAN O., et al.

XXX. Ulusal Hematoloji Kongresi, Turkey, 10 - 12 October 2003

:CCLXXXI. **Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with hematological malignancies**

Idilman R., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., Soydan E., Ozcan M., BEKSAÇ M., Arslan O., Akbulut H., et al.

38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Turkey, 29 March - 01 April 2003, vol.38, pp.146-147

CCLXXXII. **The effect of hepatitis B virus status of the donor on the hepatitis B virus serology of the recipient after allogeneic hematopoietic cell transplantation**

Idilman R., Soydan E., Arat M., TÖRÜNER M., Soykan I., Karayalcin S., Ustun C., Topcuoglu P., Ozcan M., Arslan O., et al.

38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, İstanbul, Turkey, 29 March - 01 April 2003, vol.38, pp.146

:CLXXXIII. **Extracorporeal photoimmunotherapy for treatment of steroid refractory extensive chronic graft versus host disease: Turkish experience**

İlhan O., Kalayoglu S., Unal A., Arat M., Arslan O., Sargin D., Cetin M., Ayyildiz E., Ozcan M., GÜRMAN G., et al.

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31

:CLXXXIV. **A retrospective comparison of oral versus intravenous administration of busulfan**

Arat M., Topcuoglu P., Soydan E., GÜRMAN G., Ozcan M., Arslan O., Koc H., İlhan O., Konuk N., Uysal A., et al.

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31

CCLXXXV. **Comparison of three conditioning regimens used in high-dose therapy of malign lymphomas: CBV-ICE-CTM**

Soydan E., Arat M., Topcuoglu P., Demirer T., Arslan O., Ozcan M., BEKSAÇ M., GÜRMAN G., İlhan O., Konuk N., et al.

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT

- Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CLXXXVI. **The relation between T-helper subsets and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation**  
Ozcan M., Topcuoglu P., BEKSAÇ M., Dalva K.  
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CLXXXVII. **Long-term evaluation of hematopoietic and immune reconstitution following allogeneic peripheral blood hematopoietic cell transplantation during graft-versus-host disease**  
Dilek I., GÜRMAN G., Dalva K., BEKSAÇ M., Ilhan O., Ozcan M., Akan H., Arslan O., Konuk N., Uysal A., et al.  
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- LXXXVIII. **The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-versus-host disease**  
Soydan E., Arat M., Topcuoglu P., Ozcan M., Arslan O., Idilman R., GÜRMAN G., BEKSAÇ M., Akan H., Ilhan O.  
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CLXXXIX. **Comparative analysis of molecular response following interferon-alpha, imatinib mesilate or allogeneic stem cell transplantation (ASCT): best response is obtained with ASCT in chronic myeloid leukemia**  
BEKSAÇ M., Arat M., Dalva K., Ilhan O., TOPRAK S. K., GÜRMAN G., Ozcan M., Arslan O., Konuk N., Uysal A.  
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CCCXC. **The presence of hereditary thrombophilia may increase the risk of thrombotic complications after allogeneic hematopoietic cell transplantation**  
Ozcan M., Topcuoglu P., Arat M., Soydan E., Erkan O., Akan H.  
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CCCXCI. **The effect of hepatitis B virus status of donor on the hepatitis B virus serology of recipient after allogeneic hematopoietic cell transplantation**  
Soydan E., Idilman R., Arat M., Karayalcin S., Ustun C., Ozcan M., Arslan O., BEKSAÇ M., Ilhan O., Akan H.  
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CCCXCII. **Grading oral mucositis using World Health Organization and National Cancer Institute scoring systems**  
Matrak M., Sen R., Yanik A., Ender H., Soydan E., Topcuoglu P., Ozcan M., Akan H.  
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31
- CCCXCIII. **Analysis of high and low risk chronic myeloid leukemia by gene expression profiling.**  
AKYERLİ BOYLU C., BEKSAÇ M., Holko M., Frevel M., Dalva K., GÜRMAN G., Ilhan O., Ozcan M., Akan H., Williams B., et al.  
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100
- CCCXCIV. **Molecular response rates achieved in chronic myelogenous leukemia (CML) patients treated with interferon, imatinib mesylate (STI) or stem cell transplantation. A single institutional experience.**  
BEKSAÇ M., Arat M., Dalva K., Ilhan O., GÜRMAN G., Ozcan M., Arslan O., Konuk N., Uysal A., Akan H.  
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100
- CCCXCV. **Outcome is worse in male compared to female de novo AML patients and can be improved with the use of granulocyte colony stimulating factor(G-CSF) during induction. Results of a randomized multicentric Trial(Turkish leukemia study group (TLG95-002)).**  
BEKSAÇ M., Ozcan M., Tunali A., Dundar S., Bayik M., Paydas S., Ali R., Buyukasik Y., Ilhan O., Ozkalemkas F., et al.

44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100

CCCXCVI. **Akut Lösemilerde hiperlökositöz olgularında lökaferezin sitoredüksiyon etkinliği**  
YÜKSEL M., ARAT M., TOPÇUOĞLU P., ayyıldız e., ARSLAN Ö., ÖZCAN M., BEKSAÇ M., GÜRMAN G.  
XXIX. Ulusal Hematoloji Kongresi, Turkey, 25 October 2002

CCCXCVII. **The long-term ursodeoxycholic acid treatment of chronic graft-versus-host disease of the liver.**  
Idilman R., Arat M., TÖRÜNER M., Soydan E., Soykan I., Erden E., Karayalcin S., Ozcan M., Ustun C., Ozden A., et al.  
53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), BOSTON, MASSACHUSETTS, 1 - 05 November 2002, vol.36

## Supported Projects

ÖZCAN M., KUZU I., Project Supported by Higher Education Institutions, PLAZMA HÜCRE FARKLILAŞMASI BULUNDURAN DÜŞÜK DERECELİ B LENFOPROLİFERATİF HASTALIKLARDA AYIRICI TANI, 2015 - 2015

## Activities in Scientific Journals

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, Editor, 2017 - Continues

## Memberships / Tasks in Scientific Organizations

Lösemi Lenfoma Miyelom Derneği, Chairman, 2020 - Continues, Turkey

## Metrics

Publication: 732

Citation (WoS): 2899

Citation (Scopus): 3017

H-Index (WoS): 24

H-Index (Scopus): 26

## Congress and Symposium Activities

64th Ash Annual Meeting& Exposition, Attendee, Louisiana, United States Of America, 2022

48. Ulusal Hematoloji Kongresi, Session Moderator, Antalya, Turkey, 2022

International Symposium on Hodgkin Lymphoma (ISHL12), Attendee, Koblenz, Germany, 2022

ASCO 2022, Invited Speaker, Illinois, United States Of America, 2022

48th EBMT Annual Meeting, Attendee, Praha, Czech Republic, 2022

14.Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Session Moderator, Antalya, Turkey, 2022

## Awards

Yavuz Ermiş G., Cengiz Seval G., Yılmaz H., Karakaya B., Akbulut M. H., Aydoğan M., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Özcan M., et al., "Köln ve New Orleans Sonrası 2022 Biterken Lösemi Lenfoma Miyelom Güncellemesi" En İyi Poster Bildiri ödülü, Lösemi Lenfoma Miyelom Derneği, December 2022

Beksaç M., Cengiz Seval G., Kuzu I., Yüksel S., Yüksel G., Kaygusuz G., Dalva K., Özcan M., Yeni Nesil Dizilim Analizine Göre

Belirlenen Hedefe Yönelik Tedavilerin Nüks ve Dirençli Multipl Miyelom Hastalarında Etkinliği, Türk Hematoloji Derneği, November 2022

Cengiz Seval G., Şanlı H., Gündüz K., Akay B. N., Civriz Bozdağ S., Yıldızhan İ., Özcan M., Toprak S. K., Relaps/Refrakter Mikozis Fungoides ve Sezary Sendromu Vakalarında Brentuksimab Vedotin Etkinliği: Tek merkez Deneyimi, Türk Dermatoloji Derneği, October 2022

### **Artistic Activity**

ÖZCAN M., Hekimlere Yönelik Bilgilendirme Toplantısı, December 2015

ÖZCAN M., EBMT Kongresi, March 2015